

# THE NATIONAL RHEUMATOID ARTHRITIS SOCIETY

England & Wales · Charity number 1134859

## Details

---

**Other names** NRAS

**Status** Registered

**Legal form** Charitable company

**Company number** [07127101](#)

**Registered** 2010-03-11

**Register** [View on the Charity Commission register](#)

## Contact

---

**Address** National Rheumatoid Arthritis Society  
Suite 3  
Beechwood  
Grove Business Park  
Waltham Road  
White Wa

**Phone** 01628823524

**Email** [enquiries@nras.org.uk](mailto:enquiries@nras.org.uk)

**Website** [www.nras.org.uk](http://www.nras.org.uk)

## Activities

---

**Objects:** THE OBJECTS OF THE CHARITY ('THE OBJECTS') ARE, FOR THE PUBLIC BENEFIT, TO PROMOTE THE RELIEF OF PEOPLE SUFFERING FROM RHEUMATOID ARTHRITIS AND JUVENILE IDIOPATHIC ARTHRITIS BY:1 RAISING AWARENESS AND UNDERSTANDING OF RHEUMATOID ARTHRITIS AND JUVENILE IDIOPATHIC ARTHRITIS, INCLUDING AWARENESS OF THE SEVERITY OF THE DISEASES AND THEIR SOCIAL AND ECONOMIC COSTS;2 PROVIDING INFORMATION ON RHEUMATOID ARTHRITIS AND JUVENILE IDIOPATHIC ARTHRITIS, INCLUDING INFORMATION ON THEIR TREATMENTS AND DRUGS AVAILABLE;3 ADVANCING ALL ASPECTS OF THE CARE AND TREATMENT OF RHEUMATOID ARTHRITIS AND JUVENILE IDIOPATHIC ARTHRITIS AND THE MANAGEMENT OF THESE DISEASES IN THEIR TOTALITY;4 PROVIDING EDUCATION GENERALLY AND TO INDIVIDUALS AND THEIR FAMILIES AND CARERS IN ALL ASPECTS OF RHEUMATOID ARTHRITIS AND JUVENILE IDIOPATHIC ARTHRITIS, INCLUDING THEIR TREATMENT AND MANAGEMENT, AND PROVIDING INFORMATION ABOUT AVAILABLE SUPPORT, INCLUDING FINANCIAL AND SOCIAL SUPPORT;5 SUPPORTING INDIVIDUALS IN RELATION TO RHEUMATOID ARTHRITIS AND JUVENILE IDIOPATHIC ARTHRITIS AND THEIR FAMILIES AND CARERS, INCLUDING BY PUTTING PEOPLE IN TOUCH WITH EACH OTHER TO ENCOURAGE SELF-HELP AND SUPPORT WHERE APPROPRIATE; 6 CARRYING OUT ANY OTHER CHARITABLE ACTIVITY.

**Activities:** Providing information, education, support and advocacy;Raising public awareness of rheumatoid arthritis and JIA;Raising the priority of rheumatoid arthritis and JIA with politicians and policy makers;Campaigning for good care and services for all;Facilitating networking and encouraging self-management.

## Classification

---

- **How:** Provides Services, Provides Advocacy/advice/information
- **What:** General Charitable Purposes, Education/training, The Advancement Of Health Or Saving Of Lives, Disability
- **Who:** Children/young People, People With Disabilities, Other Defined Groups

## Geography

---

- **Area of benefit:** UNDEFINED. IN PRACTICE, LOCAL.
- Scotland
- Throughout England And Wales

## Finances

Period end	Income	Expenditure	Assets	Employees
2024-12-31	£1,541,600	£1,574,100	£2,043,400	30
2023-12-31	£1,868,000	£1,529,900	£2,017,400	30
2022-12-31	£1,647,100	£1,794,100	£1,613,500	27
2021-12-31	£1,497,000	£1,379,900	£1,902,100	24
2020-12-31	£1,242,400	£1,288,300	£1,657,200	23

## Trustees

Name	Role	Appointed
<b>Simon Collins</b>	Chair	2016-06-02
Anna Woolf		2022-06-07
Claire Eleanor Ward		2023-06-23
Helen Ball		2026-03-01
Michelle Ward		2025-10-03
Professor Peter Taylor		2022-06-07
Rachel Anne Ulyett		2025-11-25
Raymanjit Singh Bains		2023-09-22
Richard Flowerdew		2020-06-16
Ruby Catherine Campbell		2026-01-20

**THE NATIONAL RHEUMATOID ARTHRITIS SOCIETY**

England & Wales - Charity number 1134859

---

# Accounts

---

Charity Registration No. 1134859/SC039721

Company Registration No. 07127101 (England and Wales)

**REPORT OF THE TRUSTEES AND  
AUDITED CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2024  
FOR  
NATIONAL RHEUMATOID ARTHRITIS SOCIETY**

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
LEGAL AND ADMINISTRATIVE INFORMATION**

**Trustees**

Mr R Bains  
Mr S Collins  
Mr R Flowerdew  
Mr J Jordan  
Professor P Taylor  
Mrs A Woolf  
Ms C Ward

**CEO**

Mr P Foxton

**Charity number**

1134859/ SC039721

**Company number**

07127101

**Registered office**

Suite 3, Beechwood  
Grove Business Park  
White Waltham  
Maidenhead  
Berks  
SL6 3LW

**Auditors**

Moore Kingston Smith LLP  
The Shipping Building  
The Old Vinyl Factory  
Blyth Road  
Hayes  
UB3 1HA

**Bankers**

HSBC  
35 High Street  
Maidenhead  
SL6 1JQ

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
CONTENTS**

	<b>Page</b>
Trustees' report	1-12
Statement of Trustees' responsibilities	13
Statement as to disclosure to our auditors	14
Independent auditors' report	15-18
Consolidated Statement of financial activities	19
Company Statement of financial activities	20
Consolidated and Company Balance Sheets	21
Consolidated Statement of Cash Flows	22
Notes to the accounts	23-37

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2024**

The Trustees present their report and audited consolidated accounts for the year ended 31 December 2024. The Trustees have adopted the provisions of the Statement of Recommended Practice (SORP) "Accounting and Reporting by Charities" (FRS 102) in preparing the annual report and financial statements of the Charity.

The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the Charity's governing document, the Charities Act 2011, the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015 as updated in 2019)."

### **Chair's Report**


A warm welcome to the NRAS annual report on behalf of the Board of Trustees. I am very pleased to report another successful year with significant progress in several directions. This is entirely due to the dedication and professionalism of our team, both staff and volunteers, whose hard work on behalf of all those living with Rheumatoid Arthritis (RA) and Juvenile Idiopathic Arthritis (JIA) has made a real difference. I thank you all on behalf of the Board.

Firstly, the Board welcomes our new Chief Executive, Peter Foxton, who has taken over from Clare Jacklin following her retirement after many years of service to the charity. Peter joined us in the Summer of 2024 following a rigorous selection process and brings a new perspective on the challenges we and all other charities face thanks to his relevant experience in the sector, latterly in income generation for Phyllis Tuckwell Hospice Care. Peter has 'hit the ground running' and is already making a real impact, not least in the preparation of the new NRAS strategy. This key document, which will guide our direction over the next few years, has been based on extensive consultation across health care professionals, our beneficiaries, volunteers and members, as well as within NRAS itself and will be issued later this year.

Nationally the need for NRAS's services has never been greater. The pressures experienced by the NHS have resulted in challenges across the board and the impacts on rheumatology services, in terms of access and responsiveness, have been significant. Our expertise and patient-focused approach can complement NHS services through the provision of information and support to both the newly diagnosed and those who have been living with RA or JIA for many years. Services such as Right Start, SMILE and the Helpline can make a real difference to people's outcomes.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2024**

Financially, this has been a year of solid performance. As predicted in our budget for the year, income was down on 2023's record level. By tight control of costs however, combined with very welcome increases in legacy and investment income during the second part of the year, we were able to finish 2024 with a small surplus after accounting for investment gains whilst maintaining levels of service throughout. Looking forward to 2025, things look positive due to ongoing efforts to diversify our income streams as well as a significant 3-year grant from the National Lottery recently awarded to help develop some of our services. With an increasingly diversified funding stream and the implementation of our new strategy we are looking to the future with confidence.

A rectangular box containing a handwritten signature in black ink. The signature appears to be 'S. Collins'.

Simon Collins  
Chair of Trustees

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2024**

### **Our purpose and activities**

Guidance from the Charity Commission has been used to review and develop NRAS's aims and objectives so that activities are clearly focused to derive good public benefit.

### **Objectives and activities**

The objects of the Charity (the "Objects") are for the public benefit to promote the relief of people living with Rheumatoid Arthritis (RA) and Juvenile Idiopathic Arthritis (JIA) by:

- Raising awareness and understanding of RA and JIA, including awareness of the severity of the diseases and their social and economic costs;
- Providing information on RA and JIA, including information on their treatments and drugs available;
- Advancing all aspects of the care and treatment of RA and JIA and the management of these diseases in their totality;
- Providing education on the diseases generally and to individuals and their families and carers in all aspects of RA and JIA, including their treatment and management, and providing information about available support;
- Supporting individuals across the UK in relation to RA and JIA and their families and carers, including putting people in touch with each other to encourage self-help and support where appropriate;
- Working alongside NHS rheumatology health professionals across the UK to provide the best care for patients as well as support the clinical staff in their roles.

### **Our vision and purpose**

Our vision is a future where everyone with RA and JIA can thrive.

Our purpose is to inform and support people with RA and JIA and campaign for improvements to care and treatments.

We will achieve our vision by focusing on four main areas of work:

- **Informing and Educating:** To greatly increase understanding of RA and JIA and the number of people accessing our services
- **Supporting and Empowering:** to support more people to safely self-manage their health by improving the relevancy, accessibility, visibility and reach of our services
- **Campaigning and Research:** to support research and campaign to improve access to high quality care and treatments
- **Raising funds and building a resilient organisation:** to build a strong organisation that raises more money from diverse sources to meet the needs of patients

### **Our principal activities**

We are committed to providing support, evidenced-based information, services, education, campaigning and patient advocacy of the highest quality to, and on behalf of all, those affected by RA and JIA across the UK as well as their families. We also support health professionals in the field of rheumatology and primary care through the provision of free Healthcare Professional membership of

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2024**

Our front-line services include:

- A Helpline which operates 30 hours per week and is managed by a team of four colleagues;
- An online peer support community;
- Local and virtual groups;
- A peer-to-peer telephone support programme;
- A supported self-management modular e-learning programme;
- Information booklets;
- Websites packed with information and downloadable resources;
- Patient events (both in person and virtually)
- A membership scheme

Living with RA and JIA is not just about having physical and medical needs. These incurable diseases have a huge impact on emotional wellbeing and quality of life on both the individual and their family. We will continue to strive to help people by supporting **all** their needs in a holistic way whether physical, medical, emotional, mental, social, economic and/or employment related needs as well as those relating to access to benefits.

We are at the table at a national level whenever standards and guidelines, RA/JIA pathways and access to treatment are being discussed. We conduct our own social research and publish key reports on a topic of importance to people with RA/JIA periodically.

Translational scientific and medical research has revolutionised the field of auto-immune conditions such as RA and JIA in the last few decades and whilst we do not fund medical research ourselves, we do support a growing number of academic and clinical research studies throughout the UK on an ongoing basis. We also support recruitment to clinical studies and provide expert volunteers to advise on issues of Patient and Public Involvement. We do on occasion conduct our own funded major social research studies often in partnership with an academic institute.


In 2024, we continued the development of our suite of e-learning self-management programmes, devised and produced by our founder and now National Patient Champion, Ailsa Bosworth MBE. We have a total of seven modules freely available for anyone to access on our website and work has now started on our largest and most complex module to date, Cardiovascular Disease Risk Management. In 2025 we plan to start work on designing a range of short videos to complement the modules already available. These videos will aim to present the key highlights from each of our modules in an informative way and will be accessible on a variety of digital platforms. We also plan to run an awareness campaign to encourage even more health professionals to utilise the SMILE modules for patient education by signposting people living with RA to register for the programme.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2024**

**Achievements, performance and financial review**

*Net income totalled over £1.54m*

**How we raised our money**



It was always going to be a challenge to replicate last year's record-breaking income levels and so it proved to be with overall income down 17.5% on 2023. The year's performance was again dominated by legacy bequests where reported income reached £788.7k, representing over 51% of the Charity's total income. Whilst this reported legacy income was a drop of over 24% on prior year it was still our second-best legacy performance ever and reflects the trend we have seen in recent years for larger individual bequests. We remain immensely grateful to our very generous benefactors whose gifts enable us to continue to invest in our services and deliver new innovations which are so needed especially as we enter a health environment more focussed on delivering services digitally.

Income from donations and gifts was £453.4k, a reduction of 19% on 2023. Work will commence in 2025 to reverse this trend with focus on enhancing our regular giving and corporate packages. These figures also include funds received from pharmaceutical companies who manufacture and market medicines for RA and/or JIA. This income amounted to £121.6k in 2024 (2023: £92.4k), equating to 7.9% of total income. We consider all donations and partnerships with pharmaceutical companies carefully and work within the accepted codes of practice set down by the Association of the British Pharmaceutical Industry (ABPI). As well as helping to fund the core services that we deliver to our beneficiaries, these relationships provide NRAS with access to important information about clinical trial data and help to inform and educate our team members on RA and JIA. As a key expert partner

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2024**

NRAS contributes to advisory boards and employee training, as well as providing support in the development of their own patient-facing support resources.

The Charity also operates a membership scheme for those living with RA or JIA, their families and health care professionals which provides access to a members' forum, monthly newsletters and a bi-annual magazine full of interesting articles and information. Income from the membership scheme totalled £81.3k in 2024 (2023: £85.4k).

Support for NRAS was also received through grants from trusts and foundations and in 2024 this amounted to £105.3k (2023: £72.6k), representing a 45% increase. We would like to express particular thanks to the following organisations who all donated £2,000 or over: National Communities Lotteries Fund Awards for All England, National Lottery Community Fund, The National Lottery – Awards for All Scotland, Edith Florence Spencer Memorial Trust, The Frank Litchfield General Charitable Trust, The Millenium Stadium Charitable Trust, The February Foundation, The Grace Trust, The Vandervell Foundation and The Eveson Trust.

We continue to work with academic partners, pharmaceutical companies or other organisations in the field of social research to help develop and deliver new services to best meet the needs of all those we serve as well as campaign to effect change with government, the NHS and those who commission health and social care services. In 2024 income generated from research activities totalled £16.0k (2023: £29.2k).


All income received through fundraising in 2024 contributed to enabling the Charity to provide a full programme of resources, activities and support which benefits those living with RA and JIA in the UK, their families, schools and the healthcare professionals who care for them. NRAS would like to acknowledge and thank all the individuals, companies, trusts and foundations that have supported our work this year.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2024**

**Total expenditure totalled £1.57m**

Overall expenditure in the year increased by 2.9% to £1.574m. Of this total amount, £304.7k was spent on raising funds compared to £348.0k in 2023. A total of £1.269m (2023: £1.182m) was spent on our charitable activities delivering our full range of services.

**Money spent on charitable activities**



Average full-time equivalent employee numbers totalled 26, unchanged since 2023 with employment costs rising by 3.2% reflecting the annual cost of living increases awarded to all staff.

The Charity reported a consolidated net surplus of £26.0k in 2024, down from £403.9k in 2023.

The Charity's wholly owned trading subsidiary, NRAS Community Services Limited, was largely dormant in 2024. The company reported a nil net profit on its activities in 2024.

**Balance sheet shows net assets of £2.0m**

Net assets in the year increased by £26.0k reflecting:

- Gains on revaluation of investments of £58.5k, representing a 5.8% growth in the fund
- An increase of £212.1k on cash at bank and short term investments
- A reduction of £244.6k on fixed assets and other current assets, primarily reflecting the release of accrued legacy income.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2024**


**Reserves policy**

***Unrestricted, undesignated reserves totalled £1.1m at the end of the year.***

Unrestricted, undesignated reserves at 31 December 2024 totalled £1,098.1k (2023: £1,397.4k) giving rise to an operating cost coverage of 8.37 (2023: 10.96).

The Charity's reserves policy requires that it holds a minimum of six months' operating costs in reserves which at 31 December 2024 amounted to £787.0k (2023: £764.9k). This leaves free reserves as at 31 December 2024 of £311.1k (2023: £632.5k). Free reserves are defined as unrestricted funds which have not been earmarked and may be used generally to further the charity's objectives.

As in previous years, the Charity continues to set aside designated reserves to support the continued delivery of its core services for the upcoming period and also to cover potential investment losses. These designated funds in aggregate amounted to £475.2k as at 31 December 2024. The Board has agreed to set aside additional funds this year which will be designated for service development (£250k), extensive awareness raising campaigns (£100k) and an estate development fund (£100k) bringing total designated funds to £925.2k.



We will work hard to ensure that our funds are used judiciously so that we return the biggest benefit to our beneficiaries for each pound invested. We will continue the expansion of our services to make them more inclusive, broaden our digital offerings as well invest in campaigns to raise awareness of RA and JIA.

**Going concern**

***The charity continues to prepare financial statements on the basis that it is a going concern.***

Our healthy cash balance and investment portfolio means that we have sufficient liquidity to ensure that we can meet our future obligations as they become due for the foreseeable future.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2024**

**Fundraising practices**

The charity complies with the regulatory standards for fundraising. We are registered with the Fundraising Regulator and are committed to the Fundraising Promise and adherence to the Code of Fundraising Practice. This report covers the requirements charities must follow as set out in the Charities Act 2011 and the Charities Social and Protection Act 2016.

Our fundraising effort involves encouraging donations through a variety of events, applying for funds from grant-making bodies and operating a weekly lottery. Our fundraising team comprises paid employees only and we do not use the services of any professional fundraisers. All direct marketing is undertaken by the fundraising department to ensure that it is not unreasonably intrusive nor persistent. All marketing material contains clear instructions on how a person can be removed from mailing lists.

We operate our lottery compliantly under licence from our local authority and all administration is handled by a certified External Lottery Manager with the Gambling Commission.

Our website outlines our complaints policy for the public and clearly explains how an individual can complain. We received no complaints this year in relation to fundraising activities.

We have published our vulnerable persons policy on our website. In addition to our policy we have an agreed operating procedure to protect vulnerable people. Our fundraisers, who are all paid employees, are familiarised with the code of conduct to ensure that it is applied properly.

**Investment Policy and Objectives**

Longer-term assets are invested with the aim of at least maintaining the real value of capital (i.e. against inflation) within an appropriate risk profile. The Charity's investment objectives are to invest for the long-term (five years plus) in a diversified portfolio ensuring that there is sufficient liquidity available to fund any shortfalls or unfunded commitments.

Investments are managed by external professional fund managers as permitted by the relevant acts and the charity commission guidelines. The Charity aims to be a responsible investor and its professional fund managers are expected to take account of Environmental, Social and Governance (ESG) issues in their investment analysis and decision-making process and to engage with trustees when appropriate, including the provision of periodic reports covering ESG issues.

Investment performance reports are received quarterly from the fund managers and the Trustees review performance annually with the fund managers.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2024**

**Future plans**

The Trustees approve and adopt strategic plans for the Charity every three years and detailed budgets are prepared annually to support these initiatives and demonstrate how the objectives will be delivered within the constraints of predicted funding available. The budget is reviewed on a quarterly basis and appropriate management decisions are taken in light of any material forecast variances.

The Charity is currently finalising its strategic plan covering 2025 – 2028 which will set out how the Charity aims to increase its reach and be able to offer support and advice to more diverse communities. Work is already underway to extend and enhance our service provision and to improve awareness of RA and JIA in the wider community.

We expect to continue to work collaboratively to remove barriers to being able to access the right treatment, at the right time in the right place, provided by the right professional. We will continue to work to reduce discrimination within the workplace and the wider society towards people with inflammatory arthritis. We will also champion the best evidence-based healthcare provision no matter where in the UK someone lives and we will support all those who work within the health service to provide the best holistic care without being hampered by a system which prevents them from achieving this.

**Structure, governance and management**

**Governing document**

The Charity is controlled by its governing documents, the memorandum and articles, and constitutes a limited by guarantee company as defined by the Companies Act 2006.

The Charity is a company limited by guarantee and does not have any share capital.

None of the Trustees has any beneficial interest in the company. All of the Trustees are members of the company and guarantee to contribute £1 each in the event of a winding up.

**Trustees**

The Trustees, who are also the directors for the purpose of company law, and who served during the year and to the date of approval of these accounts were:

Mr R Bains  
Mr RA Boucher (resigned 18 March 2025)  
Mr S Collins (Chair)  
Mr R Flowerdew (Deputy Chair)  
Mr J D Jordan (Treasurer)  
Professor P Taylor  
Ms C Ward  
Mrs A Woolf

As set out in the articles (as amended in June 2019), Trustees are required to retire after three years in office. A retiring trustee shall be eligible for re-election. Mr S Collins, Professor P Taylor and Mrs A Woolf will all therefore retire from office at the AGM on 17<sup>th</sup> June 2025 and will seek re-election. Mr S Collins will have served nine years at the time of his retirement this year but has agreed to

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2024**

stand for re-appointment to ensure that there can be an effective handover to a new Chair in due course.

**Trustee induction and training**

New Trustees are briefed on their legal obligations under Charity law, the content of the constitution and decision-making process, the business plan and recent financial performance of the Charity. As part of the process they meet key employees and other Trustees and may attend additional, relevant external training as required.

**Organisation**

The body of Trustees consists of not fewer than four and no more than twenty trustees and administers the Charity through the Senior Executives.

**Related parties and co-operation with other organisations**

None of our trustees receives remuneration or other benefit from their work with the charity. Any connection between a trustee or senior manager of the charity with a supplier or other party with which the Charity transacts must be disclosed to the full board of trustees. In the current year no such related party transactions were reported.

**Pay policy for senior staff**

Remuneration for key management personnel is benchmarked against the voluntary sector and is set by the Trustees. The pay of senior staff is reviewed annually and normally increased in accordance with average earnings.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2024**

**Risk management**

*The trustees have a risk management strategy including a formal risk evaluation which is carried out each year.*

<b>Risk Category</b>	<b>Mitigation and Actions</b>
<p><b>Financial performance and resilience</b> Significant reduction in income streams and cashflow due to economic climate could affect the future viability of the Charity</p>	<ul style="list-style-type: none"> <li>• Fundraising strategy focusing on provision of regular, predictable, unrestricted income streams</li> <li>• Annual budget setting process and quarterly reviews with focus on cash flows and financing of operational plans</li> <li>• Monthly management accounts detailing key performance indicators and reserves coverage</li> </ul>
<p><b>Protecting the Charity's assets</b> Market fluctuations caused by economic instability could negatively impact our investment portfolio and reduce the financial assets available to the Charity.</p>	<ul style="list-style-type: none"> <li>• Investment policy is set so as to maintain an appropriate and prudent risk strategy</li> <li>• Investments are managed by qualified external advisers</li> </ul>
<p><b>Maintaining a stable team</b> Competitive recruitment markets resulting in high levels of vacancies could impact our ability to deliver our full range of core services and lead to over-reliance on key members of the team</p>	<ul style="list-style-type: none"> <li>• Regular benchmarking of remuneration packages to ensure competitive within the charity sector</li> <li>• Continue to prioritise staff wellbeing to maximise retention</li> <li>• Work continues on succession planning</li> </ul>
<p><b>IT Security</b> Failure to ensure integrity and security of data could lead to data loss or theft, potentially resulting in fines, reputational damage and impact delivery of our core services</p>	<ul style="list-style-type: none"> <li>• Engagement of third party IT consultants to manage our IT systems and controls</li> </ul>
<p><b>Data integrity and governance including GDPR</b> Failure to meet our regulatory obligations could lead to fines, reputational damage and impact delivery of our core services</p>	<ul style="list-style-type: none"> <li>• Appointment of third party data protection specialists to identify and monitor risks and ensure compliance with regulations</li> </ul>
<p><b>Attracting and retaining Trustees</b> Failure to attract trustees with a range of skills could affect the future viability of the Charity</p>	<ul style="list-style-type: none"> <li>• Continue to work with our network of partners and colleagues to identify suitable candidates</li> </ul>

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2024**

**Auditors**

In accordance with the company's articles, a resolution proposing that Moore Kingston Smith LLP be re-appointed as auditor of the company will be put at a General Meeting.

**Trustees' responsibilities in relation to the financial statements**

The Trustees, who are also the directors of National Rheumatoid Arthritis Society for the purpose of company law, are responsible for preparing the Trustees' Report and the accounts in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare accounts for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure of the charitable company for that year.

In preparing these accounts the Trustees are required to:

- Select suitable accounting policies and then apply them consistently;
- Observe the methods and principles in the Charities SORP (FRS 102);
- Make judgments and estimates that are reasonable and prudent;
- State whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- Prepare the accounts on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the accounts comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2024**

**Statement as to disclosure to our auditors**


In so far as the trustees are aware at the time of approving our Trustees' annual report:

- There is no relevant information, being information needed by the auditor in connection with preparing their report, of which the group's auditor is unaware, and
- The trustees, having made enquiries of fellow trustees and the group's auditor that they ought to have individually taken, have each taken all steps that he/ she is obliged to take as a trustee, in order to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

S Collins  
Chair of Trustees

J Jordan  
Treasurer/ Trustee

A square box containing a handwritten signature in black ink that reads "S. Collins".A handwritten signature in black ink that reads "J. Jordan".

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2024**

**Opinion**

We have audited the financial statements of National Rheumatoid Arthritis Society (the 'parent charitable company') and its subsidiary (the 'group') for the year ended 31 December 2024 which comprise the Consolidated Statement of Financial Activities, (including the Consolidated Summary Income and Expenditure Account), the Group and Parent Charitable Company Balance Sheets, the Consolidated Statement of Cash Flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the group's and the parent charitable company's affairs as at 31 December 2024 and of the group's incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 (as amended), regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011.

**Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

**Other information**

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained in the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2024**

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

**Opinions on other matters prescribed by the Companies Act 2006**

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' annual report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the trustees' annual report has been prepared in accordance with applicable legal requirements.

**Matters on which we are required to report by exception**

In the light of the knowledge and understanding of the group and parent charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the trustees' annual report.

We have nothing to report in respect of the following matters where the Companies Act 2006, the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011 require us to report to you if, in our opinion:

- the parent charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent charitable company's financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies exemption in preparing the trustees' annual report and from preparing a strategic report.

**Responsibilities of trustees**

As explained more fully in the trustees' responsibilities statement set out on page 13, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the group and parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or parent charitable company or to cease operations, or have no realistic alternative but to do so.

**Auditor's Responsibilities for the audit of the financial statements**

We have been appointed as auditor under Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, the Companies Act 2006 and Section 151 of the Charities Act 2011 and report to you in accordance with regulations made under those Acts.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2024**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the group and parent charitable company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.
- Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the group and parent charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the group or parent charitable company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit report.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

**Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud**

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

The objectives of our audit in respect of fraud, are; to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2024**

regarding the assessed risks of material misstatement due to fraud, through designing and implementing appropriate responses to those assessed risks; and to respond appropriately to instances of fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the charitable company.

Our approach was as follows:

- We obtained an understanding of the legal and regulatory requirements applicable to the charitable company and considered that the most significant are the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 (as amended), regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended), the Charities Act 2011, the Charity SORP, and UK financial reporting standards as issued by the Financial Reporting Council.
- We obtained an understanding of how the charitable company complies with these requirements by discussions with management and those charged with governance.
- We assessed the risk of material misstatement of the financial statements, including the risk of material misstatement due to fraud and how it might occur, by holding discussions with management and those charged with governance.
- We inquired of management and those charged with governance as to any known instances of non-compliance or suspected non-compliance with laws and regulations.
- Based on this understanding, we designed specific appropriate audit procedures to identify instances of non-compliance with laws and regulations. This included making enquiries of management and those charged with governance and obtaining additional corroborative evidence as required.

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

**Use of our report**

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006; and to the charity's trustees, as a body, in accordance with Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, and in respect of the consolidated financial statements, in accordance with Chapter 3 of Part 8 of the Charities Act 2011. Our audit work has been undertaken so that we might state to the charitable company's members and trustees those matters which we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to any party other than the charitable company, the charitable company's members, as a body, and the charity's trustees, as a body for our audit work, for this report, or for the opinion we have formed.

*Moore Kingston Smith LLP*

Luke Holt (Senior Statutory Auditor)

Date: 02/07/2025

for and on behalf of Moore Kingston Smith LLP, Statutory Auditor

The Shipping Building  
The Old Vinyl Factory  
Blyth Road  
Hayes, London  
UB3 1HA

Moore Kingston Smith LLP is eligible to act as auditor in terms of Section 1212 of the Companies Act 2006.

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES (Including Income and Expenditure Account)  
FOR THE YEAR ENDED 31 DECEMBER 2024

		Unrestricted funds 2024	Restricted funds 2024	Total funds 2024	Unrestricted funds 2023	Restricted funds 2023	Total funds 2023
	Notes	£'000	£'000	£'000	£'000	£'000	£'000
<b>Income from:</b>							
Donations and legacies	3	1,241.7	0.4	1,242.1	1,601.9	0.0	1,601.9
Charitable activities	4	191.7	34.2	225.9	162.2	48.7	210.9
Other trading activities	5	14.5	0.0	14.5	20.5	0.0	20.5
Investment income	6	59.1	0.0	59.1	34.7	0.0	34.7
<b>Total income</b>		<b>1,507.0</b>	<b>34.6</b>	<b>1,541.6</b>	<b>1,819.3</b>	<b>48.7</b>	<b>1,868.0</b>
<b>Expenditure on:</b>							
Raising funds	7	304.7	0.0	304.7	348.0	0.0	348.0
Charitable activities	8	1,233.4	36.0	1,269.4	1,132.3	49.6	1,181.9
<b>Total resources expended</b>		<b>1,538.1</b>	<b>36.0</b>	<b>1,574.1</b>	<b>1,480.3</b>	<b>49.6</b>	<b>1,529.9</b>
Net income/(expenditure) before investments		(31.1)	(1.4)	(32.5)	339.0	(0.9)	338.1
Net gains/(losses) on investments	12	58.5	0.0	58.5	65.8	0.0	65.8
Gross transfers between funds		0.0	0.0	0.0	0.0	0.0	0.0
<b>Net movement in funds</b>		<b>27.4</b>	<b>(1.4)</b>	<b>26.0</b>	<b>404.8</b>	<b>(0.9)</b>	<b>403.9</b>
Fund balances at 1 January		1,997.4	20.0	2,017.4	1,594.1	19.4	1,613.5
Transfer between funds		(1.5)	1.5	0.0	(1.5)	1.5	0.0
<b>Fund balances at 31 December</b>		<b>2,023.3</b>	<b>20.1</b>	<b>2,043.4</b>	<b>1,997.4</b>	<b>20.0</b>	<b>2,017.4</b>

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

The notes at pages 23 to 37 form part of these accounts.

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
COMPANY STATEMENT OF FINANCIAL ACTIVITIES (Including Income and Expenditure Account)  
FOR THE YEAR ENDED 31 DECEMBER 2024

		Unrestricted funds 2024	Restricted funds 2024	Total funds 2024	Unrestricted funds 2023	Restricted funds 2023	Total funds 2023
	Notes	£'000	£'000	£'000	£'000	£'000	£'000
<b>Income from:</b>							
Donations and legacies	3	1,241.7	0.4	1,242.1	1,601.9	0.0	1,601.9
Charitable activities	4	191.7	34.2	225.9	162.2	48.7	210.9
Other trading activities	5	14.5	0.0	14.5	20.5	0.0	20.5
Investment income	6	59.1	0.0	59.1	34.7	0.0	34.7
<b>Total income</b>		<b>1,507.0</b>	<b>34.6</b>	<b>1,541.6</b>	<b>1,819.3</b>	<b>48.7</b>	<b>1,868.0</b>
<b>Expenditure on:</b>							
Raising funds	7	304.7	0.0	304.7	348.0	0.0	348.0
Charitable activities	8	1,233.4	36.0	1,269.4	1,132.2	49.6	1,181.8
<b>Total resources expended</b>		<b>1,538.1</b>	<b>36.0</b>	<b>1,574.1</b>	<b>1,480.2</b>	<b>49.6</b>	<b>1,529.8</b>
Net income/(expenditure) before investments		(31.1)	(1.4)	(32.5)	339.1	(0.9)	338.2
Net gains/(losses) on investments	12	58.5	0.0	58.5	65.8	0.0	65.8
Gross transfers between funds		0.0	0.0	0.0	0.0	0.0	0.0
<b>Net movement in funds</b>		<b>27.4</b>	<b>(1.4)</b>	<b>26.0</b>	<b>404.9</b>	<b>(0.9)</b>	<b>404.0</b>
Fund balances at 1 January		2,000.1	20.0	2,020.1	1,596.7	19.4	1,616.1
Transfer between funds		(1.5)	1.5	0.0	(1.5)	1.5	0.0
<b>Fund balances at 31 December</b>		<b>2,026.0</b>	<b>20.1</b>	<b>2,046.1</b>	<b>2,000.1</b>	<b>20.0</b>	<b>2,020.1</b>

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

The notes at pages 23 to 37 form part of these accounts.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
CONSOLIDATED AND CHARITY BALANCE SHEETS  
FOR THE YEAR ENDED 31 DECEMBER 2024**

	Notes	Group		Charity	
		2024 £'000	2023 £'000	2024 £'000	2023 £'000
<b>Fixed assets</b>					
Intangible assets	13	4.2	26.0	4.2	26.0
Tangible assets	13	28.8	36.9	28.8	36.9
Investments	14	1,099.3	1,008.5	1,099.3	1,008.5
		<b>1,132.3</b>	<b>1,071.4</b>	<b>1,132.3</b>	<b>1,071.4</b>
<b>Current assets</b>					
Debtors	16	129.0	403.8	132.1	409.0
Short term investments		261.5	0.0	261.5	0.0
Cash at bank and in hand		618.0	667.4	617.6	664.4
		<b>1,008.5</b>	<b>1,071.2</b>	<b>1,011.2</b>	<b>1,073.4</b>
<b>Liabilities:</b>					
Creditors: amounts falling due within one year	17	(97.4)	(125.2)	(97.4)	(124.7)
		<b>911.1</b>	<b>946.0</b>	<b>913.8</b>	<b>948.7</b>
<b>Net current assets</b>					
		<b>2,043.4</b>	<b>2,017.4</b>	<b>2,046.1</b>	<b>2,020.1</b>
<b>Total assets less current liabilities</b>					
<b>Income funds</b>					
Unrestricted funds	19	2,023.3	1,997.4	2,026.0	2,000.1
Restricted funds	19	20.1	20.0	20.1	20.0
		<b>2,043.4</b>	<b>2,017.4</b>	<b>2,046.1</b>	<b>2,020.1</b>

The Trustees have prepared group accounts in accordance with section 398 of the Companies Act 2006 and section 138 of the Charities Act 2011 and constitute the annual accounts required by the Companies Act 2006 and are for circulation to trustees of the company.

These accounts are prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 and are for circulation to the members of the company.

The notes at pages 23 to 37 form part of these accounts.

The accounts were approved by the Board of Trustees on 17 June 2025



J Jordan  
Treasurer/Trustee

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
CONSOLIDATED STATEMENT OF CASH FLOWS  
FOR THE YEAR ENDED 31 DECEMBER 2024**

	Notes	Group		Charity	
		2024 £'000	2023 £'000	2024 £'000	2023 £'000
<b>Cash flows from operating activities</b>					
Cash used in operations	25	191.5	358.0	194.1	359.6
<b>Investing activities</b>					
Purchase of intangible fixed assets		0.0	0.0	0.0	0.0
Purchase of tangible fixed assets		(6.2)	(4.0)	(6.2)	(4.0)
Purchase of listed investments		(32.3)	(30.2)	(32.3)	(30.2)
Purchase of short term investments		(261.5)	0.0	(261.5)	0.0
Interest received		59.1	34.7	59.1	34.7
<b>Net cash used in investing activities</b>		<u>(240.9)</u>	<u>0.5</u>	<u>(240.9)</u>	<u>0.5</u>
<b>Net decrease in cash and cash equivalents</b>		<u>(49.4)</u>	<u>358.5</u>	<u>(46.8)</u>	<u>360.1</u>
Cash and cash equivalents at beginning of year		667.4	308.9	664.4	304.3
<b>Cash and cash equivalents at end of year</b>		<u>618.0</u>	<u>667.4</u>	<u>617.6</u>	<u>664.4</u>

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2024**

**1 Accounting policies**

**Charity information**

National Rheumatoid Arthritis Society is a private company limited by guarantee incorporated in England and Wales and Scotland. The registered office is Suite 3, Beechwood, Grove Business Park, White Waltham, Berkshire, SL6 3LW

**1.1 Accounting convention**

These accounts have been prepared in accordance with the charity's governing document, the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)". The charity is a Public Benefit Entity as defined by FRS 102.

The accounts are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £'000.

The accounts have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include listed investments and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

**Preparation of consolidated financial statements**

These consolidated financial statements incorporate the financial statements of the Charity and its subsidiary undertaking, NRAS Community Services Limited, made up to 31 December 2024. Intercompany transactions, balances and unrealised gains on transactions between the Charity and its subsidiary are eliminated. Accounting policies of subsidiary undertakings have been changed where necessary to ensure consistency with the policies adopted by the Group. The income of the trading subsidiary is included in the Consolidated Statement of Financial Activities within other trading activities. Expenditure is included in support costs.

**1.2 Going concern**

At the time of approving the accounts, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future and at least for 12 months from approval of these accounts. This expectation is based on the strong investments and cash position, reflecting a significant amount of unrestricted funds and the financial performance of the Charity. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the accounts.

**1.3 Charitable funds**

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The cost of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

**1.4 Incoming resources**

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2024**

**1 Accounting policies**

**(Continued)**

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is probable. If the amount is not known, the legacy is treated as a contingent asset.

The charity receives grants in respect of charitable activities run by the charity. Income from grants are recognised at fair value when the charity has entitlement after any performance conditions have been met, it is probable that the income will be received and the amount can be measured reliably.

Income from trading activities includes income earned from fundraising events and trading activities to raise funds for the charity. Income is received in exchange for supplying goods and services in order to raise funds and is recognised when entitlement has occurred.

Subscription income is recognised on a rolling basis from the date of membership.

Income is measured at the fair value of the consideration received or receivable and represents amounts receivable for services provided in the normal course of business, net of discounts, VAT and other sales related taxes.

**1.5 Resources expended**

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Expenditure is recognised where there is a legal or constructive obligation to make payments to third parties, it is probable that the settlement will be required and the amount of the obligation can be measured reliably. It is categorised under the following headings:

Costs of raising funds includes costs related to fundraising events, merchandising and advertising;

Expenditure on charitable activities includes staff costs and support costs relating to different projects conducted during the year (see note 8).

Irrecoverable VAT is charged as an expense against the activity for which expenditure arose.

**Support costs allocation**

Support costs include both direct expenditure incurred on charitable activities and those costs which assist the work of the charity including office and administrative costs. They are all incurred directly in the furthering of the charity's aims and purposes. Distinction has been made for those costs relating to the raising of funds and to governance, these costs have been analysed separately.

Fundraising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities.

The bases on which support costs have been allocated are set out in Note 9.

Fundraising costs are specified in Note 7.

Governance costs are specified in Note 9.

Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to that category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

**1 Accounting policies**

**1.6 Intangible and tangible fixed assets and depreciation**

Intangible and tangible fixed assets costing over £500 are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Improvements to property	20% straight line or lease period if shorter
Website development	25% straight line
Fixtures, fittings & equipment	25% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in net income/(expenditure) for the year.

**1.7 Impairment of fixed assets**

At each reporting end date, the charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

**1.8 Cash and cash equivalents**

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

**1.9 Short term investments**

Short term investments include short term liquid investments with original maturities of more than three months but less than one year.

**1.10 Financial instruments**

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

**Basic financial assets**

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2024**

**1 Accounting policies**

**(Continued)**

***Basic financial liabilities***

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

***Derecognition of financial liabilities***

Financial liabilities are derecognised when the Charity's contractual obligations expire or are discharged or cancelled.

**1.11 Fixed asset investments**

Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

**1.12 Employee benefits**

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employments of an employee or to provide termination benefits.

**1.13 Leases**

Rentals payable under operating leases, including any lease incentives received, are charged to income on a straight line basis over the term of the relevant lease.

**2 Critical accounting estimates and judgements**

In the application of the charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2024

3 Donations and legacies

	Group and charity	
	2024	2023
	£'000	£'000
Donations and gifts	453.4	561.5
Legacies receivable	788.7	1,040.4
	<u>1,242.1</u>	<u>1,601.9</u>
<i>Analysis by fund</i>		
Restricted funds	0.4	0.0
Unrestricted funds	<u>1,241.7</u>	<u>1,601.9</u>
	<u>1,242.1</u>	<u>1,601.9</u>

4 Income from charitable activities

	Group and charity	
	2024	2023
	£'000	£'000
Subscriptions	81.3	85.4
Lottery income	23.3	23.7
Research studies	16.0	29.2
Grants	105.3	72.6
	<u>225.9</u>	<u>210.9</u>
<i>Analysis by fund</i>		
Restricted funds	34.2	48.7
Unrestricted funds	<u>191.7</u>	<u>162.2</u>
	<u>225.9</u>	<u>210.9</u>

5 Other trading activities

	Group and charity	
	2024	2023
	£'000	£'000
Merchandising and other trading income	<u>14.5</u>	<u>20.5</u>
	14.5	20.5

6 Investments

	Group and charity	
	2024	2023
	£'000	£'000
Income from listed investments	32.3	30.2
Interest income	<u>26.8</u>	<u>4.5</u>
	59.1	34.7

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2024

8 Expenditure on charitable activities

Charity	Provision of info & support	Digital innovations	Raising awareness	Community support	Supporting our young people	Total
	2024 £'000	2024 £'000	2024 £'000	2024 £'000	2024 £'000	2024 £'000
Direct costs	68.1	7.4	42.4	0.0	6.3	124.2
Staff costs	276.4	70.0	208.9	177.3	85.3	817.9
Share of support costs (see note 9)	81.2	0.0	121.8	40.6	40.6	284.2
Share of governance costs (see note 9)	12.3	0.0	12.3	12.3	6.2	43.1
	<b>438.0</b>	<b>77.4</b>	<b>385.4</b>	<b>230.2</b>	<b>138.4</b>	<b>1,269.4</b>
<b>Analysis by fund</b>						
Restricted funds	13.5	20.0	1.1	0.0	1.4	36.0
Unrestricted funds	424.5	57.4	384.3	230.2	137.0	1,233.4
	<b>438.0</b>	<b>77.4</b>	<b>385.4</b>	<b>230.2</b>	<b>138.4</b>	<b>1,269.4</b>

Charity	Provision of info & support	Digital innovations	Raising awareness	Community support	Supporting our young people	Total
	2023 £'000	2023 £'000	2023 £'000	2023 £'000	2023 £'000	2023 £'000
Direct costs	54.8	19.1	28.5	0.0	7.3	109.7
Staff costs	268.0	61.2	138.7	191.9	88.2	748.0
Share of support costs (see note 9)	79.1	0.0	118.9	39.6	39.6	277.2
Share of governance costs (see note 9)	13.4	0.0	13.4	13.4	6.7	46.9
	<b>415.3</b>	<b>80.3</b>	<b>299.5</b>	<b>244.9</b>	<b>141.8</b>	<b>1,181.8</b>
<b>Analysis by fund</b>						
Restricted funds	33.4	5.8	0.0	0.0	10.4	49.6
Unrestricted funds	381.9	74.5	299.5	244.9	131.4	1,132.2
	<b>415.3</b>	<b>80.3</b>	<b>299.5</b>	<b>244.9</b>	<b>141.8</b>	<b>1,181.8</b>

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2024

8 Expenditure on charitable activities

Charity	Provision of info & support	Digital innovations	Raising awareness	Community support	Supporting our young people	Total
	2024 £'000	2024 £'000	2024 £'000	2024 £'000	2024 £'000	2024 £'000
Direct costs	68.1	7.4	42.4	0.0	6.3	124.2
Staff costs	276.4	70.0	208.9	177.3	85.3	817.9
Share of support costs (see note 9)	81.2	0.0	121.8	40.6	40.6	284.2
Share of governance costs (see note 9)	12.3	0.0	12.3	12.3	6.2	43.1
	<b>438.0</b>	<b>77.4</b>	<b>385.4</b>	<b>230.2</b>	<b>138.4</b>	<b>1,269.4</b>
<b>Analysis by fund</b>						
Restricted funds	13.5	20.0	1.1	0.0	1.4	36.0
Unrestricted funds	424.5	57.4	384.3	230.2	137.0	1,233.4
	<b>438.0</b>	<b>77.4</b>	<b>385.4</b>	<b>230.2</b>	<b>138.4</b>	<b>1,269.4</b>

Charity	Provision of info & support	Digital innovations	Raising awareness	Community support	Supporting our young people	Total
	2023 £'000	2023 £'000	2023 £'000	2023 £'000	2023 £'000	2023 £'000
Direct costs	54.8	19.1	28.5	0.0	7.3	109.7
Staff costs	268.0	61.2	138.7	191.9	88.2	748.0
Share of support costs (see note 9)	79.1	0.0	118.9	39.6	39.6	277.2
Share of governance costs (see note 9)	13.4	0.0	13.4	13.4	6.7	46.9
	<b>415.3</b>	<b>80.3</b>	<b>299.5</b>	<b>244.9</b>	<b>141.8</b>	<b>1,181.8</b>
<b>Analysis by fund</b>						
Restricted funds	33.4	5.8	0.0	0.0	10.4	49.6
Unrestricted funds	381.9	74.5	299.5	244.9	131.4	1,132.2
	<b>415.3</b>	<b>80.3</b>	<b>299.5</b>	<b>244.9</b>	<b>141.8</b>	<b>1,181.8</b>

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
 NOTES TO THE ACCOUNTS  
 FOR THE YEAR ENDED 31 DECEMBER 2024

9 Support costs

Group	Support costs	Governance costs	Total	Support costs	Governance costs	Total
	2024	2024	2024	2023	2023	2023
	£'000	£'000	£'000	£'000	£'000	£'000
Staff costs		30.5	30.5		36.5	36.5
IT	97.2		97.2	88.2		88.2
Office	80.0		80.0	86.8		86.8
Professional and consultancy fees	15.8	1.2	17.0	22.1	2.2	24.3
Irrecoverable VAT	24.1		24.1	26.3		26.3
Other overheads	71.6		71.6	41.8		41.8
Depreciation & dilapidations	36.1		36.1	51.7		51.7
Insurance		6.4	6.4		4.6	4.6
Auditors' remuneration:						
- Audit fees		17.3	17.3		17.0	17.0
- Other services			0.0		0.0	0.0
	<b>324.8</b>	<b>55.4</b>	<b>380.2</b>	<b>316.9</b>	<b>60.3</b>	<b>377.2</b>
Analysed between						
Fundraising (note 7)	40.6	12.3	52.9	39.6	13.4	53.0
Charitable activities (note 8)	284.2	43.1	327.3	277.3	46.9	324.2
	<b>324.8</b>	<b>55.4</b>	<b>380.2</b>	<b>316.9</b>	<b>60.3</b>	<b>377.2</b>

The above costs were allocated on a headcount basis.

Charity	Support costs	Governance costs	Total	Support costs	Governance costs	Total
	2024	2024	2024	2023	2023	2023
	£'000	£'000	£'000	£'000	£'000	£'000
Staff costs		30.5	30.5		36.5	36.5
IT	97.2		97.2	88.2		88.2
Office	80.0		80.0	86.7		86.7
Professional and consultancy fees	15.8	1.2	17.0	22.1	2.2	24.3
Irrecoverable VAT	24.1		24.1	26.3		26.3
Other overheads	71.6		71.6	41.8		41.8
Depreciation & dilapidations	36.1		36.1	51.7		51.7
Insurance		6.4	6.4		4.6	4.6
Auditors' remuneration:						
- Audit fees		17.3	17.3		17.0	17.0
- Other services			0.0			0.0
Trustee expenses			0.0			0.0
	<b>324.8</b>	<b>55.4</b>	<b>380.2</b>	<b>316.8</b>	<b>60.3</b>	<b>377.1</b>
Analysed between						
Fundraising (note 7)	40.6	12.3	52.9	39.6	13.4	53.0
Charitable activities (note 8)	284.2	43.1	327.3	277.2	46.9	324.1
	<b>324.8</b>	<b>55.4</b>	<b>380.2</b>	<b>316.8</b>	<b>60.3</b>	<b>377.1</b>

The above costs were allocated on a headcount basis.

10 Trustees

None of the Trustees (nor any persons connected with them) received any remuneration during the year, and 2 trustees were reimbursed a total of £164 travelling and accommodation expenses (2023: £12 to one trustee).

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2024

**11 Employees**

**Number of employees**

	2024 Number	2023 Number
The average monthly number of employees during the year was:		
All employees - Group and Charity	30	30
The average monthly number of full-time equivalent employees during the year was:		
All employees - Group and Charity	26	26

**Employment costs**

	Group		Charity	
	2024 £'000	2023 £'000	2024 £'000	2023 £'000
Wages and salaries	936.1	910.6	936.1	910.6
Social security	46.7	46.8	46.7	46.8
Pension costs	85.9	78.1	85.9	78.1
	<u>1,068.7</u>	<u>1,035.5</u>	<u>1,068.7</u>	<u>1,035.5</u>

The total amount of redundancy payments made by the Company in the year was £1,346 (2023: £5,100).

The number of employees who received total employee benefits (excluding employer pension costs) of more than £60,000 is as follows:

	2024 Number	2023 Number
£70,001 - £80,000	-	1

**Remuneration of key management personnel**

The remuneration of key management personnel is as follows:

	2024 £'000	2023 £'000
Aggregate Compensation	240.4	184.9

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2024

12 Net gains/(losses) on investments

	2024	2023
	£'000	£'000
Revaluation of investments	58.5	65.8

13 Tangible and intangible fixed assets - Group and Charity

	Intangible assets	Tangible assets		Total tangible assets £'000
	Website development £'000	Improvements to property £'000	Fixtures, fittings & equipment £'000	
<b>Cost</b>				
At 31 December 2023	134.8	25.8	58.7	84.5
Additions	0.0	0.0	6.2	6.2
Disposals	0.0	0.0	0.0	0.0
<b>At 31 December 2024</b>	<b>134.8</b>	<b>25.8</b>	<b>64.9</b>	<b>90.7</b>
<b>Depreciation</b>				
At 31 December 2023	108.8	6.4	41.2	47.6
Charge for the year	21.8	5.2	9.1	14.3
Disposals	0.0	0.0	0.0	0.0
<b>At 31 December 2024</b>	<b>130.6</b>	<b>11.6</b>	<b>50.3</b>	<b>61.9</b>
<b>Carrying amount</b>				
At 31 December 2024	4.2	14.2	14.6	28.8
At 31 December 2023	26.0	19.4	17.5	36.9

14 Fixed asset investments - Group and Charity

	2024	2023
	£'000	£'000
Listed investments		
Market value at 1 January	1,008.5	912.5
Additions (including interest reinvested)	32.3	30.2
Revaluation	58.5	65.8
<b>Market value at 31 December</b>	<b>1,099.3</b>	<b>1,008.5</b>

15 Financial instruments

	2024	2023
	£'000	£'000
<b>Carrying amount of financial assets</b>		
Instruments measured at amortised cost	82.4	355.2
Instruments measured at fair value through profit or loss	1,099.3	1,008.5
<b>Carrying amount of financial liabilities</b>		
Measured at amortised cost	84.6	97.5

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2024

16 Debtors

	Group		Charity	
	2024	2023	2024	2023
	£'000	£'000	£'000	£'000
<b>Amounts falling due within one year:</b>				
Trade debtors	7.0	17.7	7.0	17.7
Amounts owed by group undertakings	0	0.0	3.1	5.2
Other debtors	75.4	337.5	75.4	337.5
Prepayments and accrued income	46.6	48.6	46.6	48.6
	<u>129.0</u>	<u>403.8</u>	<u>132.1</u>	<u>409.0</u>

Other debtors include £25.3k relating to long term debtors receivable in greater than one year's time

17 Creditors: amounts falling due within one year

	Group		Charity	
	2024	2023	2024	2023
	£'000	£'000	£'000	£'000
Trade creditors	7.3	15.7	7.3	15.7
Other taxes and social security costs	12.8	27.7	12.8	27.7
Other creditors	44.2	55.7	44.2	55.7
Accruals and deferred income	33.1	26.1	33.1	25.6
	<u>97.4</u>	<u>125.2</u>	<u>97.4</u>	<u>124.7</u>

	2024	2023
	£'000	£'000
Deferred income included in the financial statements as follows:		
At 1 January	13.8	0.0
Movement during the year	(3.8)	13.8
At 31 December	<u>10.0</u>	<u>13.8</u>

18 Retirement benefit schemes

Defined contribution schemes

The Charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the Charity in an independently administered fund.

The charge to profit or loss in respect of defined contribution schemes was £46.7k (2023: £46.8k).

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2024

19 Fund reconciliation

The income funds of the Charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

Unrestricted Funds

	Movement in funds				Balance at 31 December 2024 £'000
	Balance at 1 January 2024	Incoming resources 2024	Resources expended 2024	Transfer of funds 2024	
	£'000	£'000	£'000	£'000	
Unrestricted	1,397.4	1,507.0	(1,479.6)	(326.7)	1,098.1
Designated - to cover predicted operating losses in next year	500.0			(124.8)	375.2
Designated - to cover potential investment losses	100.0				100.0
Designated - service development fund				250.0	250.0
Designated - awareness raising fund				100.0	100.0
Designated - estate development fund				100.0	100.0
	<b>1,997.4</b>	<b>1,507.0</b>	<b>(1,479.6)</b>	<b>(1.5)</b>	<b>2,023.3</b>

	Movement in funds				Balance at 31 December 2023 £'000
	Balance at 1 January 2023	Incoming resources 2023	Resources expended 2023	Transfer of funds 2023	
	£'000	£'000	£'000	£'000	
Unrestricted	1,369.1	1,809.3	(1,362.2)	(418.8)	1,397.4
Designated - Juvenile Idiopathic Arthritis activities	0.0	10.0	(52.3)	42.3	0.0
Designated - to cover predicted operating losses in next year	125.0	0.0		375.0	500.0
Designated - to cover potential investment losses	100.0	0.0		0.0	100.0
	<b>1,594.1</b>	<b>1,819.3</b>	<b>(1,414.5)</b>	<b>(1.5)</b>	<b>1,997.4</b>

Restricted Funds

	Movement in funds				Balance at 31 December 2024 £'000
	Balance at 1 January 2024	Incoming resources 2024	Resources expended 2024	Transfer of funds 2024	
	£'000	£'000	£'000	£'000	
Information video in Hindi	1.1	0.4	(1.1)		0.4
JIA Right Start	1.1		(1.4)	0.3	0.0
Mission RA project	2.8	1.0	(4.9)	1.1	0.0
Q Lab project	15.0		(15.1)	0.1	(0.0)
Welsh lottery funds		20.0	(1.4)		18.6
Translation of video resources into other languages		9.9	(8.8)		1.1
Despatch of booklets to USA		3.3	(3.3)		0.0
	<b>20.0</b>	<b>34.6</b>	<b>(36.0)</b>	<b>1.5</b>	<b>20.1</b>

	Movement in funds				Balance at 31 December 2023 £'000
	Balance at 1 January 2023	Incoming resources 2023	Resources expended 2023	Transfer of funds 2023	
	£'000	£'000	£'000	£'000	
Information video in Hindi	1.1				1.1
Enhanced Right Start	7.8		(8.5)	0.7	0.0
Stress management project	10.5	11.3	(22.6)	0.8	0.0
Blood Monitoring publication	0.0	2.3	(2.3)		0.0
JIA Right Start	0.0	11.5	(10.4)		1.1
Mission RA project	0.0	3.6	(0.8)		2.8
Q Lab project	0.0	20.0	(5.0)		15.0
	<b>19.4</b>	<b>48.7</b>	<b>(49.6)</b>	<b>1.5</b>	<b>20.0</b>

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2024

20 Analysis of net assets between funds - Group

	Restricted £'000	Unrestricted £'000	Total £'000
Fund balances at 31 December 2024 are represented by:			
Tangible fixed assets	0.0	28.8	28.8
Investments	0.0	1,099.3	1,099.3
Current assets/(liabilities)	20.1	895.2	915.3
	<u>20.1</u>	<u>2,023.3</u>	<u>2,043.4</u>

Fund balances at 31 December 2023 are represented by:

	Restricted £'000	Unrestricted £'000	Total £'000
Tangible fixed assets	0.0	36.9	36.9
Investments	0.0	1,008.5	1,008.5
Current assets/(liabilities)	20.0	952.0	972.0
	<u>20.0</u>	<u>1,997.4</u>	<u>2,017.4</u>

Analysis of net assets between funds - Charity

	Restricted £'000	Unrestricted £'000	Total £'000
Fund balances at 31 December 2024 are represented by:			
Tangible fixed assets	0.0	28.8	28.8
Investments	0.0	1,099.3	1,099.3
Current assets/(liabilities)	20.1	897.9	918.0
	<u>20.1</u>	<u>2,026.0</u>	<u>2,046.1</u>

Fund balances at 31 December 2023 are represented by:

	Restricted £'000	Unrestricted £'000	Total £'000
Tangible fixed assets	0.0	36.9	36.9
Investments	0.0	1,008.5	1,008.5
Current assets/(liabilities)	20.0	954.7	974.7
	<u>20.0</u>	<u>2,000.1</u>	<u>2,020.1</u>

21 Commitments under operating leases

At the reporting end date the group and charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	2024 £'000	2023 £'000
Within one year	50.1	47.6
Between two and five years	27.0	77.1
Over five years	<u>77.1</u>	<u>124.7</u>

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY**  
**NOTES TO THE ACCOUNTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

**22 Subsidiary company**

The charity owns the whole of the issued ordinary share capital of NRAS Community Services Ltd (company number: 8953247), a company registered in England. The subsidiary is used for non-primary purpose trading activities. All activities have been consolidated on a line by line basis in the Statement of financial activities. The total net profit is gifted to the charity.

A summary of the results of the subsidiary is shown below:

	<b>2024</b>	<b>2023</b>
	<b>£'000</b>	<b>£'000</b>
Turnover	0.0	0.0
Cost of sales	0.0	0.0
Gross profit	<u>0.0</u>	<u>0.0</u>
Administrative expenses	0.0	(0.1)
Net profit	<u>0.0</u>	<u>(0.1)</u>
Retained earnings brought forward in subsidiary	(2.7)	(2.6)
Gift aid to National Rheumatoid Arthritis Society	0.0	0.0
Retained earnings carried forward in subsidiary	<u>(2.7)</u>	<u>(2.7)</u>
The assets and liabilities were:		
The aggregate of the assets, liabilities and funds was:		
Assets	0.4	3.0
Liabilities	(3.1)	(5.7)
Total net assets	<u>(2.7)</u>	<u>(2.7)</u>
Called up share capital	0.0	0.0
Profit and loss reserve	<u>(2.7)</u>	<u>(2.7)</u>
	<u>(2.7)</u>	<u>(2.7)</u>

**23 Related party transactions**

There were no related party transactions in the year (2023: nil) requiring disclosure.

**24 Capital Commitments**

As at 31 December 2024 the Charity had capital commitments of £nil (2023: £nil).

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY**  
**NOTES TO THE ACCOUNTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2024**

25 Cash generated from/ (used in) operations	Group		Charity	
	2024 £'000	2023 £'000	2024 £'000	2023 £'000
Surplus/ (loss) for the year	26.0	403.9	26.0	404.0
Adjustments for:				
Investment income recognised in profit or loss	(59.1)	(34.7)	(59.1)	(34.7)
Fair value gains and losses on investments	(58.5)	(65.8)	(58.5)	(65.8)
Gift aid donation from subsidiary				0.0
Depreciation and impairment of intangible fixed asset:	21.8	33.6	21.8	33.6
Depreciation and impairment of tangible fixed assets	14.3	18.1	14.3	18.1
Movements in working capital:				
(Increase)/ decrease in debtors	274.8	(6.1)	276.9	(6.1)
Increase/ (decrease) in creditors	(27.8)	9.0	(27.3)	10.5
<b>Cash generated from/(used in) operations</b>	<b>191.5</b>	<b>358.0</b>	<b>194.1</b>	<b>359.6</b>

**26 Analysis of changes in net funds**

	At start of year £'000	Cash flows £'000	At end of year £'000
Cash and cash equivalents	667.4	(49.4)	618.0
<b>Total</b>	<b>667.4</b>	<b>(49.4)</b>	<b>618.0</b>

**THE NATIONAL RHEUMATOID ARTHRITIS SOCIETY**

England & Wales - Charity number 1134859

---

# Accounts

---

Charity Registration No. 1134859/SC039721

Company Registration No. 07127101 (England and Wales)

**REPORT OF THE TRUSTEES AND  
AUDITED CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2023  
FOR  
NATIONAL RHEUMATOID ARTHRITIS SOCIETY**

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
LEGAL AND ADMINISTRATIVE INFORMATION**

**Trustees**

Mr R Bains  
Mr R A Boucher  
Mr S Collins  
Mr R Flowerdew  
Mr J Jordan  
Professor P Taylor  
Mrs A Woolf  
Miss C Ward

**CEO**

Mrs C Jacklin

**Charity number**

1134859/ SC039721

**Company number**

07127101

**Registered office**

Suite 3, Beechwood  
Grove Business Park  
White Waltham  
Maidenhead  
Berks  
SL6 3LW

**Auditors**

Moore Kingston Smith LLP  
The Shipping Building  
The Old Vinyl Factory  
Blyth Road  
Hayes  
UB3 1HA

**Bankers**

HSBC  
35 High Street  
Maidenhead  
SL6 1JQ

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
CONTENTS**

	<b>Page</b>
Trustees' report	1-13
Statement of Trustees' responsibilities	12
Statement as to disclosure to our auditors	13
Independent auditors' report	14-17
Consolidated Statement of financial activities	18
Company Statement of financial activities	19
Consolidated and Company Balance Sheets	20
Consolidated Statement of Cash Flows	21
Notes to the accounts	22-36

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2023**

The Trustees present their report and audited consolidated accounts for the year ended 31 December 2023. The Trustees have adopted the provisions of the Statement of Recommended Practice (SORP) "Accounting and Reporting by Charities" (FRS 102) in preparing the annual report and financial statements of the Charity.

The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the Charity's governing document, the Charities Act 2011, the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015)."

### **Chair's Report**

It's really heartening to be able to report that 2023 was a remarkable year in many ways for NRAS, as we successfully broke many of our own internal records for service delivery. We helped more people than ever before by providing information and support via our Helpline team, in addition to our online communities including Facebook, the Health Unlocked forum and online broadcasts. We also increased the number of publications distributed to health care professionals and individuals alike, with our Benefits and Fatigue booklets being the most requested this year. Seeking to reach and assist people in new ways, we continued to develop our online suite of self-management modules (SMILE RA) and reached over 4,000 registrants by the end of the year.

As well as breaking records for the number of people we serve, we also reported one of our strongest set of financial results to date with record-breaking income of £1.87m. Recognising the very difficult fundraising situation, at the start of the year we had budgeted to record a deficit, planning to use our strong reserves position to enable us to continue to deliver services at existing levels despite anticipated funding reductions. In practice, I am pleased to report that the deficit in the year was turned around and we actually reported a net gain of over £400k, largely due to significantly higher than expected income from legacy bequests. In common with nearly all charities, our experience is that fundraising across all other areas remains challenging and whilst we are always enormously grateful to all those who so generously leave bequests to NRAS, broadening and diversifying our income streams continues to be one of our most important objectives, both to grow funding in absolute terms and to increase its stability and predictability.


Some key successes during 2023 include:

- a highly successful nationwide survey gathering data on the impact of stress on rheumatoid arthritis symptoms. This is now being used in the development of a new resource for patients called 'Stress Matters'
- a substantial increase in our reach during RA Awareness Week via a 'fact or fiction' quiz
- an increase in engagement with monthly NRAS broadcasts on an array of topics with prestigious guest speakers and panel members
- further development of resources for UK South Asians living with RA
- Piloting the JIA Right Start programme

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2023**

After such a successful year on so many counts, it is therefore with sadness that I have to report that in December our CEO, Clare Jacklin, indicated her intention to step down as Chief Executive in 2024 after 5 years at the helm and a total of 17 years with NRAS. We owe a huge debt of gratitude to Clare who took over running the charity in summer of 2019, just ahead of the global COVID pandemic which hit us in early 2020. Clare successfully led the charity through those turbulent pandemic years and implemented many changes to the organisation to meet the evolving needs of our beneficiaries. It is beholden upon me to say on behalf of all the Trustees, Advisors, colleagues and Members, a massive thank you to Clare for her dedication and inspiring leadership before she leaves us in July 2024. Clare will be replaced as CEO by Peter Foxton who joins us after a successful career at Phyllis Tuckwell Hospice Care where he was Director of Income Generation.

Finally, it goes without saying that none of the great achievements I have described above would be possible without the tremendous efforts of our colleagues and volunteers, together with the generosity of our funders. We are fortunate indeed to be able to rely on the efforts and skills of our committed team and I would like to take this opportunity to thank you all on behalf of the Board.

A rectangular box containing a handwritten signature in cursive script that reads "S. Collins".

Simon Collins  
Chair of Trustees

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2023**

## **Our purpose and activities**

Guidance from the Charity Commission has been used to review and develop NRAS's aims and objectives so that activities are clearly focused to derive good public benefit.

## **Objectives and activities**

The objects of the Charity (the "Objects") are for the public benefit to promote the relief of people living with Rheumatoid Arthritis (RA) and Juvenile Idiopathic Arthritis (JIA) by:

- Raising awareness and understanding of RA and JIA, including awareness of the severity of the diseases and their social and economic costs;
- Providing information on RA and JIA, including information on their treatments and drugs available;
- Advancing all aspects of the care and treatment of RA and JIA and the management of these diseases in their totality;
- Providing education on the diseases generally and to individuals and their families and carers in all aspects of RA and JIA, including their treatment and management, and providing information about available support;
- Supporting individuals in relation to RA and JIA and their families and carers, including putting people in touch with each other to encourage self-help and support where appropriate; Working alongside NHS rheumatology health professionals to provide the best care for patients as well as support the clinical staff in their roles.

## **Our vision and mission**

Our vision is life without limits for all those with RA and JIA.

Our mission is to enable the RA and JIA community to thrive by providing access to support, expert knowledge, engagement, campaigning, and research, all of which is informed by those living with these complex, and currently incurable, auto-immune diseases.

Underpinning all of these mission goals is our commitment to:

- Improving the equality and equity of access to the best care across the UK;
- Providing and promoting the best supported self-management resources for those living with RA and JIA;
- Harnessing digital solutions to meet the changing requirements of the individual and the NHS;
- Analysing the impact of our services to better inform our future plans;
- Ensuring the sustainability of the charity and its services by investigating opportunities for longer term engagement with funders and paid-for NRAS services;
- Investing in the continuous development of NRAS colleagues, Volunteers, Ambassadors and Trustees ensuring we maintain the highest level of expertise and knowledge to support our beneficiaries and govern the organisation.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**Our principal activities**

We are committed to providing support, evidenced-based information, services, education, campaigning and patient advocacy of the highest quality to, and on behalf of all, those affected by RA and JIA as well as their families. We also support health professionals in the field of rheumatology and primary care through provision of free health professional membership of NRAS and free patient referral programme and information so that we can help them to help their patients.

Our front-line services include:

- A Helpline which operates 30 hours per week and is managed by a team of four colleagues;
- An online peer support community;
- Local and virtual groups;
- A peer-to-peer telephone support programme;
- A supported self-management modular e-learning programme;
- Information booklets;
- Websites packed with information and downloadable resources;
- Patient events (both in person and virtually)
- A membership scheme

Living with RA and JIA is not just about having physical and medical needs. These incurable diseases have a huge impact on emotional wellbeing and quality of life on both the individual and their family. We will continue to strive to help people by supporting *all* their needs in a holistic way whether physical, medical, emotional, mental, social, economic and/or employment related needs as well as those relating to access to benefits.

We are at the table at a national level whenever standards and guidelines, RA/JIA pathways and access to treatment are being discussed. We conduct our own social research and publish key reports on a topic of importance to people with RA/JIA periodically.

Translational scientific and medical research has revolutionised the field of auto-immune conditions such as RA and JIA in the last few decades and whilst we do not fund medical research ourselves, we do support a growing number of academic and clinical research studies throughout the UK on an ongoing basis. We also support recruitment to clinical studies and provide expert volunteers to advise on issues of Patient and Public Involvement. We do on occasion conduct our own funded major social research studies often in partnership with an academic institute. In 2023, [EXAMPLE].


In 2023, we continued the development of our suite of e-learning self-management programmes, devised and produced by our founder and now National Patient Champion, Ailsa Bosworth MBE. We now have a total of seven modules freely available for anyone to access on our website and work will soon start on our largest and most complex module to date, Cardiovascular Disease Risk Management. In 2024 we plan a strong campaign to encourage even more health professionals to utilise the SMILE modules for patient education by signposting people living with RA to register for the programme.

We also launched a new service in 2023 which aims to support families with a child diagnosed with juvenile idiopathic arthritis (JIA). This new service is modelled on our service for rheumatoid arthritis, New2RA Right Start, and is called New2JIA Right Start

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**Achievements, performance and financial review**

**Net income increased from £1.65m to £1.87m**



The Charity increased overall income by 13% in 2023 to £1.87m making this the Charity's most successful income generation year on record. This performance was dominated by legacy bequests where reported income reached £1.04m, up 35% on 2022. Legacy income represented over 56% of the Charity's total income in 2023 and we remain immensely grateful to our very generous benefactors whose gifts enable us to continue to deliver our much-needed services and which will also provide funds to enable us to invest in enhancements to those services and new innovations especially as we enter a health environment more focussed on delivering services digitally.

Income from donations and gifts was largely unchanged overall from 2022 delivering £561.5k of income, a commendable achievement given the continued pressures on traditional fundraising streams being felt across the sector. These figures also include funds received from pharmaceutical companies who manufacture and market medicines for RA and/or JIA. This income amounted to £92.4k in 2023 (2022: £166.3k). As well as helping to fund the core services that we deliver to our beneficiaries, these relationships provide NRAS with access to important information about clinical trial data and help to inform and educate our team members on RA and JIA. NRAS is now perceived by most pharmaceutical companies working in the area of immunology and rheumatology as a key expert partner in contributing to advisory boards and employee training, as well as providing support in the development of their own patient-facing support resources.

The Charity also operates a variety of membership schemes for those living with RA or JIA, their families and health care professionals. These schemes provide access to a members' forum, monthly newsletters and a bi-annual magazine full of interesting articles and information. Income from the membership schemes totalled £85.4k in 2023 (£2022: £83.1k).


**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2023**

Support for NRAS was also received through grants from trusts and foundations and in 2023 this amounted to £72.6k (2022: £137.0k). We would like to express particular thanks to the following organisations who all donated £2,000 or over each: National Communities Lotteries Fund, The Childwick Trust, The February Foundation, The John Coates Charitable Trust, Stancourt-Dicker Charitable Trust, Vandervell Foundation, The William and Mabel Morris Charitable Trust, The Joseph Strong Frazer Foundation, The Charles Littlewood Hill Trust and D'Oyly Carte Charitable Trust.

A growing area of income generation for the Charity is in the field of social research where we work with academic partners, pharmaceutical companies or other organisations to help develop and deliver new services to best meet the needs of all those we serve as well as campaign to effect change with government, the NHS and those who commission health and social care services. In 2023 income generated from research activities totalled £29.2k (2022: £8.3k).

All income received through fundraising in 2023 contributed to enabling the Charity to provide a full programme of resources, activities and support, which benefits those living with RA and JIA in the UK, their families, schools and the healthcare professionals who care for them. NRAS would like to acknowledge and thank all the individuals, companies, trusts and foundations that have supported our work this year.

**Total expenditure decreased from £1.79m to £1.53m**



Overall expenditure reduced by 14.7% compared with the prior year, thanks partly to the successful office relocation undertaken in late 2022 as a result of which annualised office-related costs reduced by nearly 40%.

Employee numbers remained largely unchanged with the full time equivalent team numbers down from 27 in 2022 to 26 in 2023. This helped keep overall employment costs growth down to just 1.4% in 2023.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2023**

The Charity reported a gain on its investment portfolio of over 7%, equivalent to £65.8k.

The Charity reported a consolidated net surplus of £403.9k in 2023, compared with a net deficit of £288.6k in 2022.

The Charity's wholly owned trading subsidiary, NRAS Community Services Limited, was largely dormant in 2023. The company delivered a small loss of £0.1k on its activities.

***Balance sheet shows net assets of £2.0m***

Net assets in the year increased by £403.9k reflecting:

- Gains on revaluation of investments of £65.8k
- An increase of £358.5k on cash at bank
- A small decrease of £20.4k on fixed assets and other current assets.

**Reserves policy**

***Unrestricted reserves totalled £1,997.4k at the end of the year.***

The Charity continues to set aside designated reserves to support the continued delivery of its core services for the upcoming twelve months and also to cover potential investment losses. These designated funds in aggregate amounted to £600k as at 31 December 2023. The Charity also continues to hold a minimum of six months' operating costs in cash and investments. Investments and cash balances as at 31 December 2023 were valued in aggregate at £1,676k giving rise to an operating cost coverage of 13.15.

Free reserves as at 31 December 2023 were £624.7k (2022: £473.4k). Free reserves are defined as unrestricted funds which have not been earmarked and may be used generally to further the charity's objectives.



**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2023**

We will work hard to ensure that our funds are used judiciously so that we return the biggest benefit to our beneficiaries for each pound invested. We will continue the expansion of our supported self-management suite of modules and broaden our digital offerings as well invest in campaigns to raise awareness of RA and JIA.

**Going concern**

*The charity continues to prepare financial statements on the basis that it is a going concern.*

Our healthy cash balance and investment portfolio means that we have sufficient liquidity to ensure that we can meet our future obligations as they become due for the foreseeable future.

**Fundraising practices**

The charity complies with the regulatory standards for fundraising. We are registered with the Fundraising Regulator and are committed to the Fundraising Promise and adherence to the Code of Fundraising Practice. This report covers the requirements charities must follow as set out in the Charities Act 2011 and the Charities Social and Protection Act 2016.

Our fundraising effort involves encouraging donations through a variety of events, applying for funds from grant-making bodies and operating a weekly lottery. Our fundraising team comprises paid employees only and we do not use the services of any professional fundraisers. All direct marketing is undertaken by the fundraising department to ensure that it is not unreasonably intrusive nor persistent. All marketing material contains clear instructions on how a person can be removed from mailing lists.

We operate our lottery compliantly under licence from our local authority and all administration is handled by a certified External Lottery Manager with the Gambling Commission.

Our website outlines our complaints policy for the public and clearly explains how an individual can complain. We received no complaints this year in relation to fundraising activities. We have published our vulnerable persons policy on our website. In addition to our policy we have an agreed operating procedure to protect vulnerable people. Our fundraisers, who are all paid employees, are familiarised with the code of conduct to ensure that it is applied properly.

**Investment Policy and Objectives**

Longer-term assets are invested with the aim of at least maintaining the real value of capital (i.e. against inflation) within an appropriate risk profile. The Charity's investment objectives are to invest for the long-term (five years plus) in a diversified portfolio ensuring that there is sufficient liquidity available to fund any shortfalls or unfunded commitments.

Investments are managed by external professional fund managers as permitted by the relevant acts and the charity commission guidelines. The Charity aims to be a responsible investor and its professional fund managers are expected to take account of Environmental, Social and Governance (ESG) issues in their investment analysis and decision-making process and to engage with trustees when appropriate, including the provision of periodic reports covering ESG issues.

Investment performance reports are received quarterly from the fund managers and the Trustees review performance annually with the fund managers.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**Future plans**

The Trustees approve and adopt strategic plans for the Charity every three years and detailed budgets are prepared annually to support these initiatives and demonstrate how the objectives will be delivered within the constraints of predicted funding available. The budget is reviewed on a quarterly basis and appropriate management decisions are taken in light of any material forecast variances.

The Charity is now in the final year of its current strategic plan which set out how the Charity would continue to support and stand shoulder-to-shoulder with the entire rheumatology community working towards our vision of life without limits for all living with RA and JIA. Work is already underway to construct an ambitious plan to take the Charity forward over the next three years and to identify how best we can serve our communities in ever more challenging times for the health sector as a whole.

We expect to continue to work collaboratively to remove barriers to being able to access the right treatment, at the right time in the right place, provided by the right professional. We will continue to work to reduce discrimination within the workplace and the wider society towards people with inflammatory arthritis. We will also champion the best evidence-based healthcare provision no matter where in the UK someone lives and we will support all those who work within the health service to provide the best holistic care without being hampered by a system which prevents them from achieving this.

**Structure, governance and management**

**Governing document**

The Charity is controlled by its governing documents, the memorandum and articles, and constitutes a limited by guarantee company as defined by the Companies Act 2006.

The Charity is a company limited by guarantee and does not have any share capital.

None of the Trustees has any beneficial interest in the company. All of the Trustees are members of the company and guarantee to contribute £1 each in the event of a winding up.

**Trustees**

The Trustees, who are also the directors for the purpose of company law, and who served during the year and to the date of approval of these accounts were:

Mr R Bains (appointed 22 September 2023)

Mr RA Boucher

Mr S Collins (Chair)

Ms L Cook (resigned 13 June 2023)

Mr R Flowerdew

Mr D Holloway (appointed 22 September 2023 and resigned 4 January 2024)

Mr J D Jordan (Treasurer)

Ms E Potter (resigned 5 December 2023)

Professor P Taylor

Miss C Ward (appointed 23 June 2023)

Ms S Webb (resigned 5 December 2023)

Mrs A Woolf

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2023**

As set out in the articles (as amended in June 2019), Trustees are required to retire after three years in office. A retiring trustee shall be eligible for re-election. Mr J D Jordan will therefore retire from office at the AGM on 18<sup>th</sup> June 2024 and will seek re-election.

**Trustee induction and training**

New Trustees are briefed on their legal obligations under Charity law, the content of the constitution and decision-making process, the business plan and recent financial performance of the Charity. As part of the process they meet key employees and other Trustees and may attend additional, relevant external training as required.

**Organisation**

The body of Trustees consists of not fewer than four and no more than twenty trustees and administers the Charity through the Senior Executives.

**Related parties and co-operation with other organisations**

None of our trustees receives remuneration or other benefit from their work with the charity. Any connection between a trustee or senior manager of the charity with a supplier or other party with which the Charity transacts must be disclosed to the full board of trustees. In the current year no such related party transactions were reported.

**Pay policy for senior staff**

Remuneration for key management personnel is benchmarked against the voluntary sector and is set by the Trustees. The pay of senior staff is reviewed annually and normally increased in accordance with average earnings.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**Risk management**

*The trustees have a risk management strategy including a formal risk evaluation which is carried out each year.*

<b>Risk Category</b>	<b>Mitigation and Actions</b>
<p><b>Financial performance and resilience</b> Significant reduction in income streams and cashflow due to economic climate could affect the future viability of the Charity</p>	<ul style="list-style-type: none"> <li>• Fundraising strategy focusing on provision of regular, predictable, unrestricted income streams</li> <li>• Annual budget setting process and quarterly reviews with focus on cash flows and financing of operational plans</li> <li>• Monthly management accounts detailing key performance indicators and reserves coverage</li> </ul>
<p><b>Protecting the Charity's assets</b> Market fluctuations caused by economic instability could negatively impact our investment portfolio and reduce the financial assets available to the Charity.</p>	<ul style="list-style-type: none"> <li>• Investment policy is set so as to maintain an appropriate and prudent risk strategy</li> <li>• Investments are managed by qualified external advisers</li> </ul>
<p><b>Maintaining a stable team</b> Competitive recruitment markets resulting in high levels of vacancies could impact our ability to deliver our full range of core services and lead to over-reliance on key members of the team</p>	<ul style="list-style-type: none"> <li>• Regular benchmarking of remuneration packages to ensure competitive within the charity sector</li> <li>• Continue to prioritise staff wellbeing to maximise retention</li> <li>• Work continues on succession planning</li> </ul>
<p><b>IT Security</b> Failure to ensure integrity and security of data could lead to data loss or theft, potentially resulting in fines, reputational damage and impact delivery of our core services</p>	<ul style="list-style-type: none"> <li>• Engagement of third party IT consultants to manage our IT systems and controls</li> </ul>
<p><b>Data integrity and governance including GDPR</b> Failure to meet our regulatory obligations could lead to fines, reputational damage and impact delivery of our core services</p>	<ul style="list-style-type: none"> <li>• Appointment of third party data protection specialists to identify and monitor risks and ensure compliance with regulations</li> </ul>
<p><b>Attracting and retaining Trustees</b> Failure to attract trustees with a range of skills could affect the future viability of the Charity</p>	<ul style="list-style-type: none"> <li>• Continue to work with our network of partners and colleagues to identify suitable candidates</li> </ul>

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**Auditors**

In accordance with the company's articles, a resolution proposing that Moore Kingston Smith LLP be re-appointed as auditor of the company will be put at a General Meeting.

**Trustees' responsibilities in relation to the financial statements**

The Trustees, who are also the directors of National Rheumatoid Arthritis Society for the purpose of company law, are responsible for preparing the Trustees' Report and the accounts in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare accounts for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure of the charitable company for that year.

In preparing these accounts the Trustees are required to:

- Select suitable accounting policies and then apply them consistently;
- Observe the methods and principles in the Charities SORP (FRS 102);
- Make judgments and estimates that are reasonable and prudent;
- State whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- Prepare the accounts on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the accounts comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**Statement as to disclosure to our auditors**


In so far as the trustees are aware at the time of approving our Trustees' annual report:

- There is no relevant information, being information needed by the auditor in connection with preparing their report, of which the group's auditor is unaware, and
- The trustees, having made enquiries of fellow trustees and the group's auditor that they ought to have individually taken, have each taken all steps that he/ she is obliged to take as a trustee, in order to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

S Collins  
Chair of Trustees

J Jordan  
Treasurer/ Trustee

A rectangular box containing a handwritten signature in cursive script that reads "S. Collins".A handwritten signature in cursive script that reads "Jordan".

18 June 2024

## **NATIONAL RHEUMATOID ARTHRITIS SOCIETY**

### **INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF NATIONAL RHEUMATOID ARTHRITIS SOCIETY FOR THE YEAR ENDED 31 DECEMBER 2023**

#### **Opinion**

We have audited the financial statements of National Rheumatoid Arthritis Society (the 'parent charitable company') and its subsidiary (the 'group') for the year ended 31 December 2023 which comprise the Consolidated Statement of Financial Activities, (including the Consolidated Summary Income and Expenditure Account), the Group and Parent Charitable Company Balance Sheets, the Consolidated Statement of Cash Flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the group's and the parent charitable company's affairs as at 31 December 2023 and of the group's incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 (as amended), regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011.

#### **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### **Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

#### **Other information**

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained in the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

## **NATIONAL RHEUMATOID ARTHRITIS SOCIETY**

### **INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF NATIONAL RHEUMATOID ARTHRITIS SOCIETY FOR THE YEAR ENDED 31 DECEMBER 2023**

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

#### **Opinions on other matters prescribed by the Companies Act 2006**

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' annual report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the trustees' annual report has been prepared in accordance with applicable legal requirements.

#### **Matters on which we are required to report by exception**

In the light of the knowledge and understanding of the group and parent charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the trustees' annual report.

We have nothing to report in respect of the following matters where the Companies Act 2006, the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011 require us to report to you if, in our opinion:

- the parent charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent charitable company's financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies exemption in preparing the trustees' annual report and from preparing a strategic report.

#### **Responsibilities of trustees**

As explained more fully in the trustees' responsibilities statement set out on page 12, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the group and parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or parent charitable company or to cease operations, or have no realistic alternative but to do so.

#### **Auditor's Responsibilities for the audit of the financial statements**

We have been appointed as auditor under Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, the Companies Act 2006 and Section 151 of the Charities Act 2011 and report to you in accordance with regulations made under those Acts.

## **NATIONAL RHEUMATOID ARTHRITIS SOCIETY**

### **INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF NATIONAL RHEUMATOID ARTHRITIS SOCIETY FOR THE YEAR ENDED 31 DECEMBER 2023**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the group and parent charitable company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.
- Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the group and parent charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the group or parent charitable company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit report.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

#### **Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud**

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

The objectives of our audit in respect of fraud, are; to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence

## NATIONAL RHEUMATOID ARTHRITIS SOCIETY

### INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF NATIONAL RHEUMATOID ARTHRITIS SOCIETY FOR THE YEAR ENDED 31 DECEMBER 2023

regarding the assessed risks of material misstatement due to fraud, through designing and implementing appropriate responses to those assessed risks; and to respond appropriately to instances of fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the charitable company.

Our approach was as follows:

- We obtained an understanding of the legal and regulatory requirements applicable to the charitable company and considered that the most significant are the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 (as amended), regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended), the Charities Act 2011, the Charity SORP, and UK financial reporting standards as issued by the Financial Reporting Council.
- We obtained an understanding of how the charitable company complies with these requirements by discussions with management and those charged with governance.
- We assessed the risk of material misstatement of the financial statements, including the risk of material misstatement due to fraud and how it might occur, by holding discussions with management and those charged with governance.
- We inquired of management and those charged with governance as to any known instances of non-compliance or suspected non-compliance with laws and regulations.
- Based on this understanding, we designed specific appropriate audit procedures to identify instances of non-compliance with laws and regulations. This included making enquiries of management and those charged with governance and obtaining additional corroborative evidence as required.

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

#### Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006; and to the charity's trustees, as a body, in accordance with Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, and in respect of the consolidated financial statements, in accordance with Chapter 3 of Part 8 of the Charities Act 2011. Our audit work has been undertaken so that we might state to the charitable company's members and trustees those matters which we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to any party other than the charitable company, the charitable company's members, as a body, and the charity's trustees, as a body for our audit work, for this report, or for the opinion we have formed.



Luke Holt (Senior Statutory Auditor)

Date: 26 June 2024

for and on behalf of Moore Kingston Smith LLP, Statutory Auditor

The Shipping Building  
The Old Vinyl Factory  
Blyth Road  
Hayes, London  
UB3 1HA

Moore Kingston Smith LLP is eligible to act as auditor in terms of Section 1212 of the Companies Act 2006.

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES (Including Income and Expenditure Account)  
FOR THE YEAR ENDED 31 DECEMBER 2023

		Unrestricted funds 2023	Restricted funds 2023	Total funds 2023	Unrestricted funds 2022	Restricted funds 2022	Total funds 2022
	Notes	£'000	£'000	£'000	£'000	£'000	£'000
<b>Income from:</b>							
Donations and legacies	3	1,601.9	0.0	1,601.9	1,334.4	0.0	1,334.4
Charitable activities	4	162.2	48.7	210.9	202.9	55.5	258.4
Other trading activities	5	20.5	0.0	20.5	25.7	0.0	25.7
Investment income	6	34.7	0.0	34.7	28.6	0.0	28.6
<b>Total income</b>		<b>1,819.3</b>	<b>48.7</b>	<b>1,868.0</b>	<b>1,591.6</b>	<b>55.5</b>	<b>1,647.1</b>
<b>Expenditure on:</b>							
Raising funds	7	348.0	0.0	348.0	382.0	0.0	382.0
Charitable activities	8	1,132.3	49.6	1,181.9	1,303.5	108.6	1,412.1
<b>Total resources expended</b>		<b>1,480.3</b>	<b>49.6</b>	<b>1,529.9</b>	<b>1,685.5</b>	<b>108.6</b>	<b>1,794.1</b>
Net income/(expenditure) before investments		339.0	(0.9)	338.1	(93.9)	(53.1)	(147.0)
Net gains/(losses) on investments	12	65.8	0.0	65.8	(141.6)	0.0	(141.6)
Gross transfers between funds		0.0	0.0	0.0	0.0	0.0	0.0
<b>Net movement in funds</b>		<b>404.8</b>	<b>(0.9)</b>	<b>403.9</b>	<b>(235.5)</b>	<b>(53.1)</b>	<b>(288.6)</b>
Fund balances at 1 January 2023		1,594.1	19.4	1,613.5	1,871.2	30.9	1,902.1
Transfer between funds		(1.5)	1.5	0.0	(41.6)	41.6	0.0
<b>Fund balances at 31 December 2023</b>		<b>1,997.4</b>	<b>20.0</b>	<b>2,017.4</b>	<b>1,594.1</b>	<b>19.4</b>	<b>1,613.5</b>

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

The notes at pages 22 to 36 form part of these accounts.

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
COMPANY STATEMENT OF FINANCIAL ACTIVITIES (Including Income and Expenditure Account)  
FOR THE YEAR ENDED 31 DECEMBER 2023

		Unrestricted funds 2023	Restricted funds 2023	Total funds 2023	Unrestricted funds 2022	Restricted funds 2022	Total funds 2022
	Notes	£'000	£'000	£'000	£'000	£'000	£'000
<b>Income from:</b>							
Donations and legacies	3	1,601.9	0.0	1,601.9	1,339.2	0.0	1,339.2
Charitable activities	4	162.2	48.7	210.9	202.9	55.5	258.4
Other trading activities	5	20.5	0.0	20.5	25.7	0.0	25.7
Investment income	6	34.7	0.0	34.7	28.6	0.0	28.6
<b>Total income</b>		<b>1,819.3</b>	<b>48.7</b>	<b>1,868.0</b>	<b>1,596.4</b>	<b>55.5</b>	<b>1,651.9</b>
<b>Expenditure on:</b>							
Raising funds	7	348.0	0.0	348.0	382.0	0.0	382.0
Charitable activities	8	1,132.2	49.6	1,181.8	1,300.9	108.6	1,409.5
<b>Total resources expended</b>		<b>1,480.2</b>	<b>49.6</b>	<b>1,529.8</b>	<b>1,682.9</b>	<b>108.6</b>	<b>1,791.5</b>
Net income/(expenditure) before investments		339.1	(0.9)	338.2	(86.5)	(53.1)	(139.6)
Net gains/(losses) on investments	12	65.8	0.0	65.8	(141.6)	0.0	(141.6)
Gross transfers between funds		0.0	0.0	0.0	0.0	0.0	0.0
<b>Net movement in funds</b>		<b>404.9</b>	<b>(0.9)</b>	<b>404.0</b>	<b>(228.1)</b>	<b>(53.1)</b>	<b>(281.2)</b>
Fund balances at 1 January		1,596.7	19.4	1,616.1	1,866.4	30.9	1,897.3
Transfer between funds		(1.5)	1.5	0.0	(41.6)	41.6	0.0
<b>Fund balances at 31 December</b>		<b>2,000.1</b>	<b>20.0</b>	<b>2,020.1</b>	<b>1,596.7</b>	<b>19.4</b>	<b>1,616.1</b>

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

The notes at pages 22 to 36 form part of these accounts.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
CONSOLIDATED AND CHARITY BALANCE SHEETS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

	Notes	Group		Charity	
		2023 £'000	2022 £'000	2023 £'000	2022 £'000
<b>Fixed assets</b>					
Intangible assets	13	26.0	59.6	26.0	59.6
Tangible assets	13	36.9	51.0	36.9	51.0
Investments	14	1,008.5	912.5	1,008.5	912.5
		<b>1,071.4</b>	<b>1,023.1</b>	<b>1,071.4</b>	<b>1,023.1</b>
<b>Current assets</b>					
Debtors	16	403.8	397.7	409.0	402.9
Cash at bank and in hand		667.4	308.9	664.4	304.3
		<b>1,071.2</b>	<b>706.6</b>	<b>1,073.4</b>	<b>707.2</b>
<b>Liabilities:</b>					
Creditors: amounts falling due within one year	17	(125.2)	(116.2)	(124.7)	(114.2)
		<b>946.0</b>	<b>590.4</b>	<b>948.7</b>	<b>593.0</b>
<b>Net current assets</b>					
		<b>2,017.4</b>	<b>1,613.5</b>	<b>2,020.1</b>	<b>1,616.1</b>
<b>Total assets less current liabilities</b>					
<b>Income funds</b>					
Unrestricted funds	19	1,997.4	1,594.1	2,000.1	1,596.7
Restricted funds	19	20.0	19.4	20.0	19.4
		<b>2,017.4</b>	<b>1,613.5</b>	<b>2,020.1</b>	<b>1,616.1</b>

The Trustees have prepared group accounts in accordance with section 398 of the Companies Act 2006 and section 138 of the Charities Act 2011 and constitute the annual accounts required by the Companies Act 2006 and are for circulation to trustees of the company.

These accounts are prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 and are for circulation to the members of the company.

The notes at pages 22 to 36 form part of these accounts.

The accounts were approved by the Board of Trustees on 18 June 2024



J Jordan  
Treasurer/Trustee

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
CONSOLIDATED STATEMENT OF CASH FLOWS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

	Notes	Group		Charity	
		2023 £'000	2022 £'000	2023 £'000	2022 £'000
<b>Cash flows from operating activities</b>					
Cash used in operations	25	358.0	(78.5)	359.6	(73.9)
<b>Investing activities</b>					
Purchase of intangible fixed assets		0.0	0.0	0.0	0.0
Purchase of tangible fixed assets		(4.0)	(42.2)	(4.0)	(42.2)
Purchase of investments		(30.2)	(28.5)	(30.2)	(28.5)
Interest received		34.7	28.6	34.7	28.6
Gift aid donation from subsidiary			0.0		4.8
<b>Net cash used in investing activities</b>		<u>0.5</u>	<u>(42.1)</u>	<u>0.5</u>	<u>(37.3)</u>
<b>Net decrease in cash and cash equivalents</b>		<u>358.5</u>	<u>(120.6)</u>	<u>360.1</u>	<u>(111.2)</u>
Cash and cash equivalents at beginning of year		308.9	429.5	304.3	415.5
<b>Cash and cash equivalents at end of year</b>		<u>667.4</u>	<u>308.9</u>	<u>664.4</u>	<u>304.3</u>

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**1 Accounting policies**

**Charity information**

National Rheumatoid Arthritis Society is a private company limited by guarantee incorporated in England and Wales and Scotland. The registered office is Suite 3, Beechwood, Grove Business Park, White Waltham, Berkshire, SL6 3LW

**1.1 Accounting convention**

These accounts have been prepared in accordance with the charity's governing document, the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)". The charity is a Public Benefit Entity as defined by FRS 102.

The accounts are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £'000.

The accounts have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include listed investments and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

**Preparation of consolidated financial statements**

These consolidated financial statements incorporate the financial statements of the Charity and its subsidiary undertaking, NRAS Community Services Limited, made up to 31 December 2023. Intercompany transactions, balances and unrealised gains on transactions between the Charity and its subsidiary are eliminated. Accounting policies of subsidiary undertakings have been changed where necessary to ensure consistency with the policies adopted by the Group. The income of the trading subsidiary is included in the Consolidated Statement of Financial Activities within other trading activities. Expenditure is included in support costs.

**1.2 Going concern**

At the time of approving the accounts, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future and at least for 12 months from approval of these accounts. This expectation is based on the strong investments and cash position, reflecting a significant amount of unrestricted funds and the financial performance of the Charity. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the accounts.

**1.3 Charitable funds**

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The cost of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

**1.4 Incoming resources**

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

**1 Accounting policies**

**(Continued)**

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is probable. If the amount is not known, the legacy is treated as a contingent asset.

The charity receives grants in respect of charitable activities run by the charity. Income from grants are recognised at fair value when the charity has entitlement after any performance conditions have been met, it is probable that the income will be received and the amount can be measured reliably.

Income from trading activities includes income earned from fundraising events and trading activities to raise funds for the charity. Income is received in exchange for supplying goods and services in order to raise funds and is recognised when entitlement has occurred.

Subscription income is recognised on a rolling basis from the date of membership.

Income is measured at the fair value of the consideration received or receivable and represents amounts receivable for services provided in the normal course of business, net of discounts, VAT and other sales related taxes.

**1.5 Resources expended**

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Expenditure is recognised where there is a legal or constructive obligation to make payments to third parties, it is probable that the settlement will be required and the amount of the obligation can be measured reliably. It is categorised under the following headings:

Costs of raising funds includes costs related to fundraising events, merchandising and advertising;

Expenditure on charitable activities includes staff costs and support costs relating to different projects conducted during the year (see note 8).

Irrecoverable VAT is charged as an expense against the activity for which expenditure arose.

**Support costs allocation**

Support costs include both direct expenditure incurred on charitable activities and those costs which assist the work of the charity including office and administrative costs. They are all incurred directly in the furthering of the charity's aims and purposes. Distinction has been made for those costs relating to the raising of funds and to governance, these costs have been analysed separately.

Fundraising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities.

The bases on which support costs have been allocated are set out in Note 9.

Fundraising costs are specified in Note 7.

Governance costs are specified in Note 9.

Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to that category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

**1 Accounting policies**

(Continued)

**1.6 Intangible and tangible fixed assets and depreciation**

Intangible and tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Improvements to property	20% straight line or lease period if shorter
Website development	25% straight line
Fixtures, fittings & equipment	25% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in net income/(expenditure) for the year.

**1.7 Impairment of fixed assets**

At each reporting end date, the charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

**1.8 Cash and cash equivalents**

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

**1.9 Financial instruments**

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

**Basic financial assets**

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

**1 Accounting policies**

(Continued)

***Basic financial liabilities***

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

***Derecognition of financial liabilities***

Financial liabilities are derecognised when the Charity's contractual obligations expire or are discharged or cancelled.

**1.10 Fixed asset investments**

Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

**1.11 Employee benefits**

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employments of an employee or to provide termination benefits.

**1.12 Leases**

Rentals payable under operating leases, including any lease incentives received, are charged to income on a straight line basis over the term of the relevant lease.

**2 Critical accounting estimates and judgements**

In the application of the charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2023

**3 Donations and legacies**

	Group		Charity	
	2023	2022	2023	2022
	£'000	£'000	£'000	£'000
Donations and gifts	561.5	561.4	561.5	566.2
Legacies receivable	1,040.4	773.0	1,040.4	773.0
	<u>1,601.9</u>	<u>1,334.4</u>	<u>1,601.9</u>	<u>1,339.2</u>
<i>Analysis by fund</i>				
Restricted funds	0.0	0.0	0.0	0.0
Unrestricted funds	<u>1,601.9</u>	<u>1,334.4</u>	<u>1,601.9</u>	<u>1,339.2</u>
	<u>1,601.9</u>	<u>1,334.4</u>	<u>1,601.9</u>	<u>1,339.2</u>

**4 Income from charitable activities**

	Group and charity	
	2023	2022
	£'000	£'000
Subscriptions	85.4	83.1
Lottery income	23.7	30.0
Research studies	29.2	8.3
Grants	72.6	137.0
	<u>210.9</u>	<u>258.4</u>
<i>Analysis by fund</i>		
Restricted funds	48.7	55.5
Unrestricted funds	<u>162.2</u>	<u>202.9</u>
	<u>210.9</u>	<u>258.4</u>

**5 Other trading activities**

	Group and charity	
	2023	2022
	£'000	£'000
Merchandising and other trading income	<u>20.5</u>	<u>25.7</u>
	<u>20.5</u>	<u>25.7</u>

**6 Investments**

	Group and charity	
	2023	2022
	£'000	£'000
Income from listed investments	<u>34.7</u>	<u>28.6</u>
	<u>34.7</u>	<u>28.6</u>

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2023

7 Expenditure on raising funds

	Group and Charity	
	2023	2022
	£'000	£'000
Staging fundraising events	44.0	74.0
Staff costs	251.0	227.6
Support costs	39.6	65.9
Governance costs	13.4	14.5
<b>Expenditure on raising funds</b>	<b>348.0</b>	<b>382.0</b>
<i>Analysis by fund</i>		
Restricted funds	0.0	0.0
Unrestricted funds	348.0	382.0
	<b>348.0</b>	<b>382.0</b>

8 Expenditure on charitable activities

Group	Provision of info & support	Digital innovations	Raising awareness	Community support	Supporting our young people	Total
	2023	2023	2023	2023	2023	2023
	£'000	£'000	£'000	£'000	£'000	£'000
Direct costs	54.8	19.1	28.5	0.0	7.3	109.7
Staff costs	268.0	61.2	138.7	191.9	88.2	748.0
Share of support costs (see note 9)	79.2	0.0	118.9	39.6	39.6	277.3
Share of governance costs (see note 9)	13.4	0.0	13.4	13.4	6.7	46.9
	<b>415.4</b>	<b>80.3</b>	<b>299.5</b>	<b>244.9</b>	<b>141.8</b>	<b>1,181.9</b>
<i>Analysis by fund</i>						
Restricted funds	33.4	5.8	0.0	0.0	10.4	49.6
Unrestricted funds	382.0	74.5	299.5	244.9	131.4	1,132.3
	<b>415.4</b>	<b>80.3</b>	<b>299.5</b>	<b>244.9</b>	<b>141.8</b>	<b>1,181.9</b>
Group	Provision of info & support	Digital innovations	Raising awareness	Community support	Supporting our young people	Total
	2022	2022	2022	2022	2022	2022
	£'000	£'000	£'000	£'000	£'000	£'000
Direct costs	48.6	23.7	58.5	0.0	10.0	140.8
Staff costs	246.7	51.1	293.8	92.5	75.2	759.3
Share of support costs (see note 9)	131.8	0.0	197.8	65.9	65.9	461.4
Share of governance costs (see note 9)	14.5	0.0	14.5	14.4	7.2	50.6
	<b>441.6</b>	<b>74.8</b>	<b>564.6</b>	<b>172.8</b>	<b>158.3</b>	<b>1,412.1</b>
<i>Analysis by fund</i>						
Restricted funds	24.7	74.8	0.0	0.0	9.1	108.6
Unrestricted funds	416.9	0.0	564.6	172.8	149.2	1,303.5
	<b>441.6</b>	<b>74.8</b>	<b>564.6</b>	<b>172.8</b>	<b>158.3</b>	<b>1,412.1</b>

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2023

8 Expenditure on charitable activities

Charity	Provision of info & support	Digital innovations	Raising awareness	Community support	Supporting our young people	Total
	2023	2023	2023	2023	2023	2023
	£'000	£'000	£'000	£'000	£'000	£'000
Direct costs	54.8	19.1	28.5	0.0	7.3	109.7
Staff costs	268.0	61.2	138.7	191.9	88.2	748.0
Share of support costs (see note 9)	79.1	0.0	118.9	39.6	39.6	277.2
Share of governance costs (see note 9)	13.4	0.0	13.4	13.4	6.7	46.9
	<b>415.3</b>	<b>80.3</b>	<b>299.5</b>	<b>244.9</b>	<b>141.8</b>	<b>1,181.8</b>
<b>Analysis by fund</b>						
Restricted funds	33.4	5.8	0.0	0.0	10.4	49.6
Unrestricted funds	381.9	74.5	299.5	244.9	131.4	1,132.2
	<b>415.3</b>	<b>80.3</b>	<b>299.5</b>	<b>244.9</b>	<b>141.8</b>	<b>1,181.8</b>

Charity	Provision of info & support	Digital innovations	Raising awareness	Community support	Supporting our young people	Total
	2022	2022	2022	2022	2022	2022
	£'000	£'000	£'000	£'000	£'000	£'000
Direct costs	48.6	23.7	58.5	0.0	10.0	140.8
Staff costs	246.7	51.1	293.8	92.5	75.2	759.3
Share of support costs (see note 9)	131.8	0.0	197.8	65.9	65.9	461.4
Share of governance costs (see note 9)	11.9	0.0	14.5	14.4	7.2	48.0
	<b>439.0</b>	<b>74.8</b>	<b>564.6</b>	<b>172.8</b>	<b>158.3</b>	<b>1,409.5</b>
<b>Analysis by fund</b>						
Restricted funds	24.7	74.8	0.0	0.0	9.1	108.6
Unrestricted funds	414.3	0.0	564.6	172.8	149.2	1,300.9
	<b>439.0</b>	<b>74.8</b>	<b>564.6</b>	<b>172.8</b>	<b>158.3</b>	<b>1,409.5</b>

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2023

9 Support costs

Group	Support costs	Governance costs	Total	Support costs	Governance costs	Total
	2023	2023	2023	2022	2022	2022
	£'000	£'000	£'000	£'000	£'000	£'000
Staff costs		36.5	36.5		34.0	34.0
IT	88.2		88.2	97.6		97.6
Office	86.8		86.8	145.5		145.5
Professional and consultancy fees	22.1	2.2	24.3	104.6	9.6	114.2
Irrecoverable VAT	26.3		26.3	56.5		56.5
Other overheads	41.8		41.8	73.1		73.1
Depreciation & dilapidations	51.7		51.7	50.0		50.0
Insurance		4.6	4.6		5.7	5.7
Auditors' remuneration:						
- Audit fees		17.0	17.0		15.8	15.8
- Other services		0.0	0.0		0.0	0.0
	<b>316.9</b>	<b>60.3</b>	<b>377.2</b>	<b>527.3</b>	<b>65.1</b>	<b>592.4</b>
Analysed between						
Fundraising (note 7)	39.6	13.4	53.0	65.9	14.5	80.4
Charitable activities (note 8)	277.3	46.9	324.2	461.4	50.6	512.0
	<b>316.9</b>	<b>60.3</b>	<b>377.2</b>	<b>527.3</b>	<b>65.1</b>	<b>592.4</b>

The above costs were allocated on a headcount basis.

Charity	Support costs	Governance costs	Total	Support costs	Governance costs	Total
	2023	2023	2023	2022	2022	2022
	£'000	£'000	£'000	£'000	£'000	£'000
Staff costs		36.5	36.5		34.0	34.0
IT	88.2		88.2	97.6		97.6
Office	86.7		86.7	145.5		145.5
Professional and consultancy fees	22.1	2.2	24.3	104.6	9.6	114.2
Irrecoverable VAT	26.3		26.3	56.5		56.5
Other overheads	41.8		41.8	73.1		73.1
Depreciation & dilapidations	51.7		51.7	50.0		50.0
Insurance		4.6	4.6		5.7	5.7
Auditors' remuneration:						
- Audit fees		17.0	17.0		13.2	13.2
- Other services			0.0			0.0
Trustee expenses			0.0			0.0
	<b>316.8</b>	<b>60.3</b>	<b>377.1</b>	<b>527.3</b>	<b>62.5</b>	<b>589.8</b>
Analysed between						
Fundraising (note 7)	39.6	13.4	53.0	65.9	14.5	80.4
Charitable activities (note 8)	277.2	46.9	324.1	461.4	48.0	509.4
	<b>316.8</b>	<b>60.3</b>	<b>377.1</b>	<b>527.3</b>	<b>62.5</b>	<b>589.8</b>

The above costs were allocated on a headcount basis.

10 Trustees

None of the Trustees (nor any persons connected with them) received any remuneration during the year, and 1 trustee was reimbursed a total of £12 travelling expenses (2022: £nil).

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY**  
**NOTES TO THE ACCOUNTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2023**

**11 Employees**

**Number of employees**

	<b>2023</b>	<b>2022</b>
	<b>Number</b>	<b>Number</b>
The average monthly number of employees during the year was:		
All employees - Group and Charity	30	31
The average monthly number of full-time equivalent employees during the year was:		
All employees - Group and Charity	26	27

**Employment costs**

	<b>Group</b>		<b>Charity</b>	
	<b>2023</b>	<b>2022</b>	<b>2023</b>	<b>2022</b>
	<b>£'000</b>	<b>£'000</b>	<b>£'000</b>	<b>£'000</b>
Wages and salaries	910.6	905.6	910.6	905.6
Social security	46.8	83.4	46.8	83.4
Pension costs	78.1	31.8	78.1	31.8
	<u>1,035.5</u>	<u>1,020.8</u>	<u>1,035.5</u>	<u>1,020.8</u>

The total amount of redundancy payments made by the Company in the year was £5,100 (2022: £5,499).

The number of employees who received total employee benefits (excluding employer pension costs) of more than £60,000 is as follows:

	<b>2023</b>	<b>2022</b>
	<b>Number</b>	<b>Number</b>
£60,001 - £70,000	0	1
£70,001 - £80,000	1	0

**Remuneration of key management personnel**

The remuneration of key management personnel is as follows:

	<b>2023</b>	<b>2022</b>
	<b>£'000</b>	<b>£'000</b>
Aggregate Compensation	184.9	171.4

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2023

12 Net gains/(losses) on investments

	2023	2022
	£'000	£'000
Revaluation of investments	65.8	(141.6)

13 Tangible and intangible fixed assets - Group and Charity

	Intangible assets	Tangible assets		
	Website development	Improvements to property	Fixtures, fittings & equipment	Total tangible assets
	£'000	£'000	£'000	£'000
<b>Cost</b>				
At 31 December 2022	134.8	25.8	54.7	80.5
Additions	0.0	0.0	4.0	4.0
Disposals	0.0	0.0	0.0	0.0
<b>At 31 December 2023</b>	<b>134.8</b>	<b>25.8</b>	<b>58.7</b>	<b>84.5</b>
<b>Depreciation</b>				
At 31 December 2022	75.2	1.3	28.2	29.5
Charge for the year	33.6	5.1	13.0	18.1
Disposals	0.0	0.0	0.0	0.0
<b>At 31 December 2023</b>	<b>108.8</b>	<b>6.4</b>	<b>41.2</b>	<b>47.6</b>
<b>Carrying amount</b>				
<b>At 31 December 2023</b>	<b>26.0</b>	<b>19.4</b>	<b>17.5</b>	<b>36.9</b>
<b>At 31 December 2022</b>	<b>59.6</b>	<b>24.5</b>	<b>26.5</b>	<b>51.0</b>

14 Fixed asset investments - Group and Charity

	2023	2022
	£'000	£'000
<b>Listed investments</b>		
Market value at 1 January	912.5	1,025.6
Additions (including interest reinvested)	30.2	28.5
Revaluation	65.8	(141.6)
<b>Market value at 31 December</b>	<b>1,008.5</b>	<b>912.5</b>

15 Financial instruments

	2023	2022
	£'000	£'000
<b>Carrying amount of financial assets</b>		
Instruments measured at amortised cost	355.2	362.3
Instruments measured at fair value through profit or loss	1,008.5	912.5
<b>Carrying amount of financial liabilities</b>		
Measured at amortised cost	97.5	102.0

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2023

16 Debtors

	Group		Charity	
	2023 £'000	2022 £'000	2023 £'000	2022 £'000
<b>Amounts falling due within one year:</b>				
Trade debtors	17.7	44.9	17.7	44.9
Amounts owed by group undertakings	0.0	0.0	5.2	5.2
Other debtors	337.5	317.4	337.5	317.4
Prepayments and accrued income	48.6	35.4	48.6	35.4
	<u>403.8</u>	<u>397.7</u>	<u>409.0</u>	<u>402.9</u>

Other debtors include £25.3k relating to long term debtors receivable in greater than one year's time

17 Creditors: amounts falling due within one year

	Group		Charity	
	2023 £'000	2022 £'000	2023 £'000	2022 £'000
Trade creditors	15.7	17.2	15.7	17.2
Other taxes and social security costs	27.7	14.2	27.7	14.2
Other creditors	55.7	53.3	55.7	51.3
Accruals and deferred income	26.1	31.5	25.6	31.5
	<u>125.2</u>	<u>116.2</u>	<u>124.7</u>	<u>114.2</u>

	2023 £'000	2022 £'000
Deferred income included in the financial statements as follows:		
At 1 January	0.0	0.0
Movement during the year	<u>13.8</u>	<u>0.0</u>
At 31 December	<u>13.8</u>	<u>0.0</u>

18 Retirement benefit schemes

Defined contribution schemes

The Charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the Charity in an independently administered fund.

The charge to profit or loss in respect of defined contribution schemes was £46.8k (2022: £31.8k).

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2023

19 Fund reconciliation

The income funds of the Charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

Unrestricted Funds

	Movement in funds				Balance at 31 December 2023
	Balance at 1 January 2023	Incoming resources 2023	Resources expended 2023	Transfer of funds 2023	
	£'000	£'000	£'000	£'000	
Unrestricted	1,369.1	1,809.3	(1,362.2)	(418.8)	1,397.4
Designated - Juvenile Idiopathic Arthritis activities	0.0	10.0	(52.3)	42.3	0.0
Designated - to cover predicted operating losses in next year	125.0			375.0	500.0
Designated - to cover potential investment losses	100.0			0.0	100.0
	<b>1,594.1</b>	<b>1,819.3</b>	<b>(1,414.5)</b>	<b>(1.5)</b>	<b>1,997.4</b>

	Movement in funds				Balance at 31 December 2022
	Balance at 1 January 2022	Incoming resources 2022	Resources expended 2022	Transfer of funds 2022	
	£'000	£'000	£'000	£'000	
Unrestricted	1,871.2	1,553.4	(1,784.2)	(271.3)	1,369.1
Designated - Juvenile Idiopathic Arthritis activities	0.0	38.2	(42.9)	4.7	0.0
Designated - to cover predicted operating losses in next year	0.0	0.0		125.0	125.0
Designated - to cover potential investment losses	0.0	0.0		100.0	100.0
	<b>1,871.2</b>	<b>1,591.6</b>	<b>(1,827.1)</b>	<b>(41.6)</b>	<b>1,594.1</b>

Restricted Funds

	Movement in funds				Balance at 31 December 2023
	Balance at 1 January 2023	Incoming resources 2023	Resources expended 2023	Transfer of funds 2023	
	£'000	£'000	£'000	£'000	
Information video in Hindi	1.1				1.1
Enhanced Right Start	7.8		(8.5)	0.7	0.0
Stress management project	10.5	11.3	(22.6)	0.8	0.0
Blood Monitoring publication	0.0	2.3	(2.3)		0.0
JIA Right Start	0.0	11.5	(10.4)		1.1
Mission RA project	0.0	3.6	(0.8)		2.8
Q Lab project	0.0	20.0	(5.0)		15.0
	<b>19.4</b>	<b>48.7</b>	<b>(49.6)</b>	<b>1.5</b>	<b>20.0</b>

	Movement in funds				Balance at 31 December 2022
	Balance at 1 January 2022	Incoming resources 2022	Resources expended 2022	Transfer of funds 2022	
	£'000	£'000	£'000	£'000	
Development of elearning suite	0.0	15.0	(49.0)	34.0	0.0
Development of online self-management course in Scotland	0.1	0.0	(0.1)	0.0	(0.0)
Information video in Hindi	1.5	0.0	(0.4)	0.0	1.1
Blood Monitoring publication	5.2	0.0	(9.0)	3.8	0.0
Development of exercise support app	0.0	3.1	(6.0)	2.9	0.0
Enhanced Right Start	14.1	10.0	(16.3)	0.0	7.8
JIA Imagined Futures project	10.0	0.0	(10.2)	0.2	0.0
Reprint of Medicines booklet	0.0	2.3	(3.0)	0.7	0.0
JIA video	0.0	2.5	(2.5)	0.0	0.0
Stress management project	0.0	22.6	(12.1)	0.0	10.5
	<b>30.9</b>	<b>55.5</b>	<b>(108.6)</b>	<b>41.6</b>	<b>19.4</b>

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2023

**20 Analysis of net assets between funds - Group**

	Restricted £'000	Unrestricted £'000	Total £'000
<b>Fund balances at 31 December 2023 are represented by:</b>			
Tangible fixed assets	0.0	36.9	36.9
Investments	0.0	1,008.5	1,008.5
Current assets/(liabilities)	20.0	952.0	972.0
	<b>20.0</b>	<b>1,997.4</b>	<b>2,017.4</b>

**Fund balances at 31 December 2022 are represented by:**

	Restricted £'000	Unrestricted £'000	Total £'000
Tangible fixed assets	0.0	51.0	51.0
Investments	0.0	912.5	912.5
Current assets/(liabilities)	19.4	630.6	650.0
	<b>19.4</b>	<b>1,594.1</b>	<b>1,613.5</b>

**Analysis of net assets between funds - Charity**

	Restricted £'000	Unrestricted £'000	Total £'000
<b>Fund balances at 31 December 2023 are represented by:</b>			
Tangible fixed assets	0.0	36.9	36.9
Investments	0.0	1,008.5	1,008.5
Current assets/(liabilities)	20.0	954.7	974.7
	<b>20.0</b>	<b>2,000.1</b>	<b>2,020.1</b>

**Fund balances at 31 December 2022 are represented by:**

	Restricted £'000	Unrestricted £'000	Total £'000
Tangible fixed assets	0.0	51.0	51.0
Investments	0.0	912.5	912.5
Current assets/(liabilities)	19.4	633.2	652.6
	<b>19.4</b>	<b>1,596.7</b>	<b>1,616.1</b>

**21 Commitments under operating leases**

At the reporting end date the group and charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	2023 £'000	2022 £'000
Within one year	47.6	31.6
Between two and five years	77.1	112.5
Over five years	<b>124.7</b>	<b>144.1</b>

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**22 Subsidiary company**

The charity owns the whole of the issued ordinary share capital of NRAS Community Services Ltd (company number: 8953247), a company registered in England. The subsidiary is used for non-primary purpose trading activities. All activities have been consolidated on a line by line basis in the Statement of financial activities. The total net profit is gifted to the charity.

A summary of the results of the subsidiary is shown below:

	<b>2023</b>	<b>2022</b>
	<b>£'000</b>	<b>£'000</b>
Turnover	0.0	0.0
Cost of sales	<u>0.0</u>	<u>0.0</u>
Gross profit	0.0	0.0
Administrative expenses	<u>(0.1)</u>	<u>(2.6)</u>
Net profit	<b>(0.1)</b>	<b>(2.6)</b>
Retained earnings brought forward in subsidiary	(2.6)	4.8
Gift aid to National Rheumatoid Arthritis Society	<u>0.0</u>	<u>(4.8)</u>
Retained earnings carried forward in subsidiary	<b><u>(2.7)</u></b>	<b><u>(2.6)</u></b>
The assets and liabilities were:		
The aggregate of the assets, liabilities and funds was:		
Assets	3.0	4.6
Liabilities	<u>(5.7)</u>	<u>(7.2)</u>
Total net assets	<b><u>(2.7)</u></b>	<b><u>(2.6)</u></b>
Called up share capital	0.0	0.0
Profit and loss reserve	<u>(2.7)</u>	<u>(2.6)</u>
	<b><u>(2.7)</u></b>	<b><u>(2.6)</u></b>

**23 Related party transactions**

There were no related party transactions in the year (2022: nil) requiring disclosure.

**24 Capital Commitments**

As at 31 December 2023 the Charity had capital commitments of £nil (2022: £nil).

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

25 Cash generated from/ (used in) operations	Group		Charity	
	2023 £'000	2022 £'000	2023 £'000	2022 £'000
Surplus/ (loss) for the year	403.9	(288.6)	404.0	(281.2)
Adjustments for:				
Investment income recognised in profit or loss	(34.7)	(28.6)	(34.7)	(28.6)
Fair value gains and losses on investments	(65.8)	141.6	(65.8)	141.6
Gift aid donation from subsidiary				(4.8)
Depreciation and impairment of intangible fixed asset:	33.6	33.7	33.6	33.7
Depreciation and impairment of tangible fixed assets	18.1	15.3	18.1	15.3
Movements in working capital:				
(Increase)/ decrease in debtors	(6.1)	46.3	(6.1)	47.3
Increase/ (decrease) in creditors	9.0	1.8	10.5	2.8
<b>Cash generated from/(used in) operations</b>	<b>358.0</b>	<b>(78.5)</b>	<b>359.6</b>	<b>(73.9)</b>

**26 Analysis of changes in net funds**

	At start of year £'000	Cash flows £'000	At end of year £'000
Cash and cash equivalents	308.9	358.5	667.4
<b>Total</b>	<b>308.9</b>	<b>358.5</b>	<b>667.4</b>

**THE NATIONAL RHEUMATOID ARTHRITIS SOCIETY**

England & Wales - Charity number 1134859

---

# Accounts

---

Charity Registration No. 1134859/SC039721

Company Registration No. 07127101 (England and Wales)

**REPORT OF THE TRUSTEES AND  
AUDITED CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2022  
FOR  
NATIONAL RHEUMATOID ARTHRITIS SOCIETY**

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
LEGAL AND ADMINISTRATIVE INFORMATION**

**Trustees**

Mr R A Boucher  
Mr S Collins  
Mr R Flowerdew  
Mr J Jordan  
Miss E Potter  
Professor P Taylor  
Miss S Webb  
Mrs A Woolf

**CEO**

Mrs C Jacklin

**Charity number**

1134859/ SC039721

**Company number**

07127101

**Registered office**

Suite 3, Beechwood  
Grove Business Park  
White Waltham  
Maidenhead  
Berks  
SL6 3LW

**Auditors**

Moore Kingston Smith LLP  
The Shipping Building  
The Old Vinyl Factory  
Blyth Road  
Hayes  
UB3 1HA

**Bankers**

HSBC  
35 High Street  
Maidenhead  
SL6 1JQ

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
CONTENTS**

	<b>Page</b>
Trustees' report	1-13
Statement of Trustees' responsibilities	12
Statement as to disclosure to our auditors	13
Independent auditors' report	14-17
Consolidated Statement of financial activities	18
Company Statement of financial activities	19
Consolidated and Company Balance Sheets	20
Consolidated Statement of Cash Flows	21
Notes to the accounts	22-36

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2022**

The Trustees present their report and audited consolidated accounts for the year ended 31 December 2022. The Trustees have adopted the provisions of the Statement of Recommended Practice (SORP) "Accounting and Reporting by Charities" (FRS 102) in preparing the annual report and financial statements of the Charity.

The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the Charity's governing document, the Charities Act 2011, the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015)."

### **Chair's Report**

2022 has been a year of positive change for the National Rheumatoid Arthritis Society (NRAS). Firstly, we emerged from two years of Covid related pressures and restrictions which both increased the demand for our services, particularly our helpline and advisory activities, and reduced our ability to raise funds through volunteer fundraising and other events.

Secondly, we have now settled into our new offices near Maidenhead in Berkshire after a huge amount of planning and work by the team. The move, whilst of course disruptive in the short term, will generate significant long-term cost savings for the charity. The new office, though smaller than our previous base, is a pleasant working environment and well-suited to the needs of our flexible team.


Financially, we had budgeted to make a loss in the year, planning to use our strong reserves position to enable us to continue activities at the same level despite anticipated funding reductions. In practice, I am pleased to report that the loss in the year was much less than forecast, due to higher than expected income and slightly reduced costs, despite the one-off costs of office re-location. Fundraising across all areas remains challenging however with the exception of legacies which continues to grow; in 2022 we recorded our highest ever income from legacies. Whilst we are always enormously grateful to all those who leave bequests to NRAS, broadening and diversifying our income streams continues to be one of our most important objectives, both to grow funding in absolute terms and to increase its stability and predictability.

The year was also marked by our very successful Gala Dinner held in Windsor. Whilst the event was a huge amount of work and a major organisational challenge, it achieved its objectives: raising funds and saying a big thank you to our award winners. It was greatly enjoyed by all who attended.

In terms of outputs, NRAS has continued to develop new ways to reach and help those who need its services, in particular those who are newly diagnosed, when the support, information and advice we provide can make such a difference. During the year we have added to the range of our well researched advisory publications which provide a wealth of useful information made available free to all. Recognising the growing importance of the digital sphere, we have continued to develop our engaging SMILE RA e-learning programme, adding new modules on Meet The Team, Managing Pain and Flares and finally Medicines. Our Right Start initiative also continues to go from strength to strength, reaching out to those who have been newly diagnosed and connecting them to support, information and practical advice.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2022**

None of this would be possible without the tremendous and ongoing efforts of our staff and volunteers, together with the generosity of our funders. We are fortunate indeed to be able to rely on the efforts and skills of our committed team and I would like to take this opportunity to thank you all on behalf of the Board.

A rectangular box containing a handwritten signature in black ink. The signature appears to read "S. Collins".

Simon Collins  
Chair of Trustees

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2022**

**Our purpose and activities**

Guidance from the Charity Commission has been used to review and develop NRAS's aims and objectives so that activities are clearly focused to derive good public benefit.

**Objectives and activities**

The objects of the Charity (the "Objects") are for the public benefit to promote the relief of people living with RA and JIA by:

- Raising awareness and understanding of Rheumatoid Arthritis (RA) and Juvenile Idiopathic Arthritis (JIA), including awareness of the severity of the diseases and their social and economic costs;
- Providing information on RA and JIA, including information on their treatments and drugs available;
- Advancing all aspects of the care and treatment of RA and JIA and the management of these diseases in their totality;
- Providing education on the diseases generally and to individuals and their families and carers in all aspects of RA and JIA, including their treatment and management, and providing information about available support;
- Supporting individuals in relation to RA and JIA and their families and carers, including putting people in touch with each other to encourage self-help and support where appropriate;  
Working alongside NHS rheumatology health professionals to provide the best care for patients as well as support the clinical staff in their roles.

**Our vision and mission**

Our vision is life without limits for all those with RA and JIA.

Our mission is to enable the RA and JIA community to thrive by providing access to support, expert knowledge, engagement, campaigning, and research, all of which is informed by those living with these complex, and currently incurable, auto-immune diseases.

Underpinning all of these mission goals is our commitment to:

- Improving the equality and equity of access to the best care across the UK;
- Providing and promoting the best supported self-management resources for those living with RA and JIA;
- Harnessing digital solutions to meet the changing requirements of the individual and the NHS;
- Analysing the impact of our services to better inform our future plans;
- Ensuring the sustainability of the charity and its services by investigating opportunities for longer term engagement with funders and paid-for NRAS services;
- Investing in the continuous development of NRAS colleagues, Volunteers, Ambassadors and Trustees ensuring we maintain the highest level of expertise and knowledge to support our beneficiaries and govern the organisation.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2022**

**Our principal activities**

We are committed to providing support, evidenced-based information, services, education, campaigning and patient advocacy of the highest quality to, and on behalf of all, those affected by RA and JIA as well as their families. We also support health professionals in the field of rheumatology and primary care through provision of free health professional membership of NRAS and free patient referral programme and information so that we can help them to help their patients.

Our front-line services include:

- A Helpline which operates 30 hours per week and is managed by a team of four colleagues;
- An online peer support community;
- Local and virtual groups;
- A peer-to-peer telephone support programme;
- A supported self-management modular e-learning programme;
- Information booklets;
- Websites packed with information and downloadable resources;
- Patient events (both in person and virtually)
- A membership scheme

Living with RA and JIA is not just about having physical and medical needs. These incurable diseases have a huge impact on emotional wellbeing and quality of life on both the individual and their family. We will continue to strive to help people by supporting *all* their needs in a holistic way whether physical, medical, emotional, mental, social, economic and/or employment related needs as well as those relating to access to benefits.

We are at the table at a national level whenever standards and guidelines, RA/JIA pathways and access to treatment are being discussed. We conduct our own social research and publish key reports on a topic of importance to people with RA/JIA periodically.

Translational scientific and medical research has revolutionised the field of auto-immune conditions such as RA and JIA in the few decades and whilst we do not fund medical research ourselves, we do support a growing number of academic and clinical research studies throughout the UK on an ongoing basis. We also support recruitment to clinical studies and provide expert volunteers to advise on issues of Patient and Public Involvement. We do conduct our own funded major social research studies often in partnership with an academic institute. In 2022, we continued to play a pivotal role in COVID-19 research by supporting UK, European and Global data gathering.


In 2022, we continued the development of our suite of e-learning self-management programmes, devised and produced by our founder and now National Patient Champion, Ailsa Bosworth MBE. Further modules are due for release in 2023. We hope that these engaging and interactive online e-learning modules will eventually be prescribed by health professionals for the benefit of their patients.

Also in 2022 we launched a new service to support families with a child diagnosed with juvenile idiopathic arthritis (JIA). This new service is modelled on our similar service for rheumatoid arthritis (New2RA Right Start) and is called New2JIA Right Start.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2022**

**Achievements, performance and financial review**

**Net income increased from £1.497m to £1.647m**



Against a background of a war in Europe, inflation and a cost-of-living crisis, our performance in 2022 was commendable with overall income up 10% on 2021. The biggest contributor to this growth was income from legacy gifts which was up 47%, or £247.5k, on 2021. Gifts from legacies continue to be an important source of income for the Charity and we are immensely grateful to our very generous benefactors whose gifts in recent years have enabled us to secure the viability of the Charity and to continue to provide our services to those in need.

During 2022 we generated £561.4k of income through donations, pledges and gifts in kind, which represented a drop of 5% on 2021 and reflected the tough economic conditions we all face. These figures also include donations received from pharmaceutical companies who manufacture and market medicines for RA and/or JIA. This income amounted to £166.3k in 2022 (2021: £198.3k). As well as helping to fund the core services that we deliver to our beneficiaries, these relationships provide NRAS with access to important information about clinical trial data and help to inform and educate our team members on RA and JIA. NRAS is now perceived by most pharmaceutical companies working in the area of immunology and rheumatology as a key expert partner in contributing to advisory boards and employee training, as well as providing support in the development of their own patient-facing support resources.


Support for NRAS was also received through grants from trusts and foundations and in 2022 this amounted to £137.0k. We would like to express particular thanks to the following organisations who all donated over £2,000 each: Garfield Weston Foundation, James Tudor Foundation, PF Charitable Trust, Vandervell Foundation, Pilkington Charities Fund, The Lady Hind Trust, The Eveson Trust, Edith

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2022**

Florence Spencer Memorial Trust, The William and Mabel Morris Charitable Trust, The Hobson Charity Limited and D'Oyly Carte Charitable Trust.

All income received through fundraising in 2022 contributed to enabling the Charity to provide a full programme of resources, activities and support, which benefits those living with RA and JIA in the UK, their families, schools and the healthcare professionals who care for them. NRAS would like to acknowledge and thank all the individuals, companies, trusts and foundations that have supported our work this year.

**Total expenditure increased from £1.380m to £1.794m**



Overall expenditure increased by 30% compared with the prior year largely driven by increasing staff costs, investment in our CRM systems and costs associated with the office relocation. Throughout the year we continued to focus on maintaining the suite of core services that we provide to our communities and to extending the range, and reach, of those services where costs allowed.

In line with market trends, the Charity reported a loss on its investment portfolio of over 13%, equivalent to £141.6k.

The Charity reported a consolidated net loss of £288.6k in 2022, compared with a net gain of £244.9k in 2021.

The Charity's wholly owned trading subsidiary, NRAS Community Services Limited, was largely dormant in 2022. The company delivered a small loss of £2.6k on its activities.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2022**

***Balance sheet shows net assets of £1.6m***

Net assets in the year reduced by £288.6k reflecting:


- Losses on revaluation of investments of £141.6k
- A reduction of £120.6k on cash at bank
- A small decrease of £26.4k on fixed assets and other current assets.

**Reserves policy**

***Unrestricted reserves totalled £1594.1k at the end of the year.***

During the year the Charity reviewed its reserves policy to ensure it remains consistent with its aims to ensure long-term financial sustainability. The Charity has set aside £225k of designated reserves to support the continued delivery of its core services throughout 2023 and also to cover potential investments revaluations. The Charity will also continue to hold a minimum of six months' operating costs in cash and investments. Investments and cash balances as at 31 December 2022 were valued in aggregate at £1,221.4k and six months' operating costs amount to £896k, meaning that this target was comfortably met in 2022.

Free reserves as at 31 December 2022 were £473.4k. Free reserves are defined as unrestricted funds which have not been earmarked and may be used generally to further the charity's objectives.



We will work hard to ensure that our funds are used judiciously so that we return the biggest benefit to our beneficiaries for each pound invested. We will continue the expansion of our supported self-management suite of modules and broaden our digital offerings as well invest in campaigns to raise awareness of RA and JIA.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2022**

**Going concern**

*The charity continues to prepare financial statements on the basis that it is a going concern.*

Our healthy cash balance and investment portfolio means that we have sufficient liquidity to ensure that we can meet our future obligations as they become due for the foreseeable future.

**Fundraising practices**

The charity complies with the regulatory standards for fundraising. We are registered with the Fundraising Regulator and are committed to the Fundraising Promise and adherence to the Code of Fundraising Practice. This report covers the requirements charities must follow as set out in the Charities Act 2011 and the Charities Social and Protection Act 2016.

Our fundraising effort involves encouraging donations through a variety of events, applying for funds from grant-making bodies and operating a weekly lottery. Our fundraising team comprises paid employees only and we do not use the services of any professional fundraisers. All direct marketing is undertaken by the fundraising department to ensure that it is not unreasonably intrusive nor persistent. All marketing material contains clear instructions on how a person can be removed from mailing lists.

We operate our lottery compliantly under licence from our local authority and all administration is handled by a certified External Lottery Manager with the Gambling Commission.

Our website outlines our complaints policy for the public and clearly explains how an individual can complain. We received no complaints this year in relation to fundraising activities. We have published our vulnerable persons policy on our website. In addition to our policy we have an agreed operating procedure to protect vulnerable people. Our fundraisers, who are all paid employees, are familiarised with the code of conduct to ensure that it is applied properly.

**Investment Policy and Objectives**

Longer-term assets are invested with the aim of at least maintaining the real value of capital (i.e. against inflation) within an appropriate risk profile. The Charity's investment objectives are to invest for the long-term (five years plus) in a diversified portfolio ensuring that there is sufficient liquidity available to fund any shortfalls or unfunded commitments.

Investments are managed by external professional fund managers as permitted by the relevant acts and the charity commission guidelines. The Charity aims to be a responsible investor and its professional fund managers are expected to take account of Environmental, Social and Governance (ESG) issues in their investment analysis and decision-making process and to engage with trustees when appropriate, including the provision of periodic reports covering ESG issues.

Investment performance reports are received quarterly from the fund managers and the Trustees review performance annually with the fund managers.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2022**

**Future plans**

The Trustees approve and adopt strategic plans for the Charity every three years and detailed budgets are prepared annually to support these initiatives and demonstrate how the objectives will be delivered within the constraints of predicted funding available. The budget is reviewed on a quarterly basis and appropriate management decisions are taken in light of any material forecast variances.

The Charity's strategic plan for 2022-2025 was finalised in 2021 and set out that the Charity will continue to support and stand shoulder-to-shoulder with the entire rheumatology community working towards our vision of life without limits for all living with RA and JIA.

We will work collaboratively to remove barriers to being able to access the right treatment, at the right time in the right place, provided by the right professional. We will work to reduce discrimination within the workplace and the wider society towards people with inflammatory arthritis. We will also champion the best evidence-based healthcare provision no matter where in the UK someone lives and we will support all those who work within the health service to provide the best holistic care without being hampered by a system which prevents them from achieving this.

**Structure, governance and management**

**Governing document**

The Charity is controlled by its governing documents, the memorandum and articles, and constitutes a limited by guarantee company as defined by the Companies Act 2006.

The Charity is a company limited by guarantee and does not have any share capital.

None of the Trustees has any beneficial interest in the company. All of the Trustees are members of the company and guarantee to contribute £1 each in the event of a winding up.

**Trustees**

The Trustees, who are also the directors for the purpose of company law, and who served during the year were:

Mr RA Boucher  
Mr S Collins (Chair)  
Ms L Cook (resigning 13 June 2023)  
Mr R Flowerdew  
Mr J D Jordan (Treasurer)  
Ms E Potter  
Dr G Taylor (resigned 7 June 2022)  
Professor P Taylor (appointed 7 June 2022)  
Ms S Webb  
Mrs A Woolf (appointed 7 June 2022)

As set out in the articles (as amended in June 2019), Trustees are required to retire after three years in office. A retiring trustee shall be eligible for re-election. Mr R Flowerdew, Miss E Potter and Miss S Webb will therefore retire from office at the AGM on 13<sup>th</sup> June 2023 and will seek re-election.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2022**

**Trustee induction and training**

New Trustees are briefed on their legal obligations under Charity law, the content of the constitution and decision-making process, the business plan and recent financial performance of the Charity. As part of the process they meet key employees and other Trustees and may attend additional, relevant external training as required.

**Organisation**

The body of Trustees consists of not fewer than four and no more than twenty trustees and administers the Charity through the Senior Executives.

**Related parties and co-operation with other organisations**

None of our trustees receives remuneration or other benefit from their work with the charity. Any connection between a trustee or senior manager of the charity with a supplier or other party with which the Charity transacts must be disclosed to the full board of trustees. In the current year no such related party transactions were reported.

**Pay policy for senior staff**

Remuneration for key management personnel is benchmarked against the voluntary sector and is set by the Trustees. The pay of senior staff is reviewed annually and normally increased in accordance with average earnings.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2022**

**Risk management**

*The trustees have a risk management strategy including a formal risk evaluation which is carried out each year.*

<b>Risk Category</b>	<b>Mitigation and Actions</b>
<p><b>Financial performance and resilience</b> Significant reduction in income streams and cashflow due to economic climate could affect the future viability of the Charity</p>	<ul style="list-style-type: none"> <li>• Fundraising strategy focusing on provision of regular, predictable, unrestricted income streams</li> <li>• Annual budget setting process and quarterly reviews with focus on cash flows and financing of operational plans</li> <li>• Monthly management accounts detailing key performance indicators and reserves coverage</li> </ul>
<p><b>Protecting the Charity's assets</b> Market fluctuations caused by economic instability could negatively impact our investment portfolio and reduce the financial assets available to the Charity.</p>	<ul style="list-style-type: none"> <li>• Investment policy is set so as to maintain an appropriate and prudent risk strategy</li> <li>• Investments are managed by qualified external advisers</li> </ul>
<p><b>Maintaining a stable team</b> Competitive recruitment markets resulting in high levels of vacancies could impact our ability to deliver our full range of core services and lead to over-reliance on key members of the team</p>	<ul style="list-style-type: none"> <li>• Regular benchmarking of remuneration packages to ensure competitive within the charity sector</li> <li>• Continue to prioritise staff wellbeing to maximise retention</li> <li>• Work underway on succession planning</li> </ul>
<p><b>IT Security</b> Failure to ensure integrity and security of data could lead to data loss or theft, potentially resulting in fines, reputational damage and impact delivery of our core services</p>	<ul style="list-style-type: none"> <li>• Engagement of third party IT consultants to manage our IT systems and controls</li> </ul>
<p><b>Data integrity and governance including GDPR</b> Failure to meet our regulatory obligations could lead to fines, reputational damage and impact delivery of our core services</p>	<ul style="list-style-type: none"> <li>• Appointment of third party data protection specialists to identify and monitor risks and ensure compliance with regulations</li> </ul>
<p><b>Attracting and retaining Trustees</b> Failure to attract trustees with a range of skills could affect the future viability of the Charity</p>	<ul style="list-style-type: none"> <li>• Continue to work with our network of partners and colleagues to identify suitable candidates</li> </ul>

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2022**

**Auditors**

In accordance with the company's articles, a resolution proposing that Moore Kingston Smith LLP be re-appointed as auditor of the company will be put at a General Meeting.

**Trustees' responsibilities in relation to the financial statements**

The Trustees, who are also the directors of National Rheumatoid Arthritis Society for the purpose of company law, are responsible for preparing the Trustees' Report and the accounts in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare accounts for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure of the charitable company for that year.

In preparing these accounts the Trustees are required to:

- Select suitable accounting policies and then apply them consistently;
- Observe the methods and principles in the Charities SORP (FRS 102);
- Make judgments and estimates that are reasonable and prudent;
- State whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- Prepare the accounts on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the accounts comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2022**



**Statement as to disclosure to our auditors**

In so far as the trustees are aware at the time of approving our Trustees' annual report:  
There is no relevant information, being information needed by the auditor in connection with preparing their report, of which the group's auditor is unaware, and  
The trustees, having made enquiries of fellow trustees and the group's auditor that they ought to have individually taken, have each taken all steps that he/ she is obliged to take as a trustee, in order to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

S Collins  
Chair of Trustees

J Jordan  
Treasurer/ Trustee

A rectangular box containing a handwritten signature in cursive script that reads "S. Collins".A handwritten signature in cursive script that reads "Jordan".

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2022**

**Opinion**

We have audited the financial statements of National Rheumatoid Arthritis Society (the 'parent charitable company') and its subsidiary (the 'group') for the year ended 31 December 2022 which comprise the Consolidated Statement of Financial Activities, (including the Consolidated Summary Income and Expenditure Account), the Group and Parent Charitable Company Balance Sheets, the Consolidated Statement of Cash Flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the group's and the parent charitable company's affairs as at 31 December 2021 and of the group's incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 (as amended), regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011.

**Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

**Other information**

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained in the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2022**

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

**Opinions on other matters prescribed by the Companies Act 2006**

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' annual report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the trustees' annual report has been prepared in accordance with applicable legal requirements.

**Matters on which we are required to report by exception**

In the light of the knowledge and understanding of the group and parent charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the trustees' annual report.

We have nothing to report in respect of the following matters where the Companies Act 2006, the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011 require us to report to you if, in our opinion:

- the parent charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent charitable company's financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies exemption in preparing the trustees' annual report and from preparing a strategic report.

**Responsibilities of trustees**

As explained more fully in the trustees' responsibilities statement set out on page 12, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the group and parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or parent charitable company or to cease operations, or have no realistic alternative but to do so.

**Auditor's Responsibilities for the audit of the financial statements**

We have been appointed as auditor under Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, the Companies Act 2006 and Section 151 of the Charities Act 2011 and report to you in accordance with regulations made under those Acts.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2022**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the group and parent charitable company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.
- Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the group and parent charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the group or parent charitable company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit report.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

**Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud**

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

The objectives of our audit in respect of fraud, are; to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2022**

regarding the assessed risks of material misstatement due to fraud, through designing and implementing appropriate responses to those assessed risks; and to respond appropriately to instances of fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the charitable company.

Our approach was as follows:

- We obtained an understanding of the legal and regulatory requirements applicable to the charitable company and considered that the most significant are the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 (as amended), regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended), the Charities Act 2011, the Charity SORP, and UK financial reporting standards as issued by the Financial Reporting Council.
- We obtained an understanding of how the charitable company complies with these requirements by discussions with management and those charged with governance.
- We assessed the risk of material misstatement of the financial statements, including the risk of material misstatement due to fraud and how it might occur, by holding discussions with management and those charged with governance.
- We inquired of management and those charged with governance as to any known instances of non-compliance or suspected non-compliance with laws and regulations.
- Based on this understanding, we designed specific appropriate audit procedures to identify instances of non-compliance with laws and regulations. This included making enquiries of management and those charged with governance and obtaining additional corroborative evidence as required.

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

**Use of our report**

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006; and to the charity's trustees, as a body, in accordance with Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, and in respect of the consolidated financial statements, in accordance with Chapter 3 of Part 8 of the Charities Act 2011. Our audit work has been undertaken so that we might state to the charitable company's members and trustees those matters which we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to any party other than the charitable company, the charitable company's members, as a body, and the charity's trustees, as a body for our audit work, for this report, or for the opinion we have formed.

Luke Holt (Senior Statutory Auditor) *Moore Kingston Smith LLP* Date: 16 June 2023

for and on behalf of Moore Kingston Smith LLP, Statutory Auditor

The Shipping Building  
The Old Vinyl Factory  
Blyth Road  
Hayes, London  
UB3 1HA

Moore Kingston Smith LLP is eligible to act as auditor in terms of Section 1212 of the Companies Act 2006.

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES (Including Income and Expenditure Account)  
FOR THE YEAR ENDED 31 DECEMBER 2022

		Unrestricted	Restricted	Total	Unrestricted	Restricted	Total
		funds	funds	funds	funds	funds	funds
		2022	2022	2022	2021	2021	2021
	Notes	£'000	£'000	£'000	£'000	£'000	£'000
<b>Income from:</b>							
Donations and legacies	3	1,334.4	0.0	1,334.4	1,117.1	0.0	1,117.1
Charitable activities	4	202.9	55.5	258.4	249.2	63.1	312.3
Other trading activities	5	25.7	0.0	25.7	42.1	0.0	42.1
Investment income	6	28.6	0.0	28.6	25.5	0.0	25.5
<b>Total income</b>		<b>1,591.6</b>	<b>55.5</b>	<b>1,647.1</b>	<b>1,433.9</b>	<b>63.1</b>	<b>1,497.0</b>
<b>Expenditure on:</b>							
Raising funds	7	382.0	0.0	382.0	320.5	0.0	320.5
Charitable activities	8	1,303.5	108.6	1,412.1	936.2	123.2	1,059.4
<b>Total resources expended</b>		<b>1,685.5</b>	<b>108.6</b>	<b>1,794.1</b>	<b>1,256.7</b>	<b>123.2</b>	<b>1,379.9</b>
Net income/(expenditure) before investments		(93.9)	(53.1)	(147.0)	177.2	(60.1)	117.1
Net gains/(losses) on investments	12	(141.6)	0.0	(141.6)	127.8	0.0	127.8
Gross transfers between funds		0.0	0.0	0.0	0.0	0.0	0.0
<b>Net movement in funds</b>		<b>(235.5)</b>	<b>(53.1)</b>	<b>(288.6)</b>	<b>305.0</b>	<b>(60.1)</b>	<b>244.9</b>
Fund balances at 1 January 2022		1,871.2	30.9	1,902.1	1,600.4	56.8	1,657.2
Transfer between funds		(41.6)	41.6	0.0	(34.2)	34.2	0.0
<b>Fund balances at 31 December 2022</b>		<b>1,594.1</b>	<b>19.4</b>	<b>1,613.5</b>	<b>1,871.2</b>	<b>30.9</b>	<b>1,902.1</b>

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

The notes at pages 22 to 36 form part of these accounts.

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
COMPANY STATEMENT OF FINANCIAL ACTIVITIES (Including Income and Expenditure Account)  
FOR THE YEAR ENDED 31 DECEMBER 2022

		Unrestricted funds 2022	Restricted funds 2022	Total funds 2022	Unrestricted funds 2021	Restricted funds 2021	Total funds 2021
	Notes	£'000	£'000	£'000	£'000	£'000	£'000
<b>Income from:</b>							
Donations and legacies	3	1,339.2	0.0	1,339.2	1,118.6	0.0	1,118.6
Charitable activities	4	202.9	55.5	258.4	249.2	63.1	312.3
Other trading activities	5	25.7	0.0	25.7	34.5	0.0	34.5
Investment income	6	28.6	0.0	28.6	25.5	0.0	25.5
<b>Total income</b>		<b>1,596.4</b>	<b>55.5</b>	<b>1,651.9</b>	<b>1,427.8</b>	<b>63.1</b>	<b>1,490.9</b>
<b>Expenditure on:</b>							
Raising funds	7	382.0	0.0	382.0	320.5	0.0	320.5
Charitable activities	8	1,300.9	108.6	1,409.5	933.3	123.2	1,056.5
<b>Total resources expended</b>		<b>1,682.9</b>	<b>108.6</b>	<b>1,791.5</b>	<b>1,253.8</b>	<b>123.2</b>	<b>1,377.0</b>
Net income/(expenditure) before investments		(86.5)	(53.1)	(139.6)	174.0	(60.1)	113.9
Net gains/(losses) on investments	12	(141.6)	0.0	(141.6)	127.8	0.0	127.8
Gross transfers between funds		0.0	0.0	0.0	0.0	0.0	0.0
<b>Net movement in funds</b>		<b>(228.1)</b>	<b>(53.1)</b>	<b>(281.2)</b>	<b>301.8</b>	<b>(60.1)</b>	<b>241.7</b>
Fund balances at 1 January		1,866.4	30.9	1,897.3	1,598.8	56.8	1,655.6
Transfer between funds		(41.6)	41.6	0.0	(34.2)	34.2	0.0
<b>Fund balances at 31 December</b>		<b>1,596.7</b>	<b>19.4</b>	<b>1,616.1</b>	<b>1,866.4</b>	<b>30.9</b>	<b>1,897.3</b>

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

The notes at pages 22 to 36 form part of these accounts.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
CONSOLIDATED AND CHARITY BALANCE SHEETS  
FOR THE YEAR ENDED 31 DECEMBER 2022**

	Notes	Group		Charity	
		2022 £'000	2021 £'000	2022 £'000	2021 £'000
<b>Fixed assets</b>					
Intangible assets	13	59.6	93.3	59.6	93.3
Tangible assets	13	51.0	24.1	51.0	24.1
Investments	14	912.5	1,025.6	912.5	1,025.6
		<b>1,023.1</b>	<b>1,143.0</b>	<b>1,023.1</b>	<b>1,143.0</b>
<b>Current assets</b>					
Debtors	16	397.7	444.0	402.9	450.2
Cash at bank and in hand		308.9	429.5	304.3	415.5
		<b>706.6</b>	<b>873.5</b>	<b>707.2</b>	<b>865.7</b>
<b>Liabilities:</b>					
Creditors: amounts falling due within one year	17	(116.2)	(114.4)	(114.2)	(111.4)
<b>Net current assets</b>		<b>590.4</b>	<b>759.1</b>	<b>593.0</b>	<b>754.3</b>
<b>Total assets less current liabilities</b>		<b>1,613.5</b>	<b>1,902.1</b>	<b>1,616.1</b>	<b>1,897.3</b>
<b>Income funds</b>					
Unrestricted funds	19	1,594.1	1,871.2	1,596.7	1,866.4
Restricted funds	19	19.4	30.9	19.4	30.9
		<b>1,613.5</b>	<b>1,902.1</b>	<b>1,616.1</b>	<b>1,897.3</b>

The Trustees have prepared group accounts in accordance with section 398 of the Companies Act 2006 and section 138 of the Charities Act 2011 and constitute the annual accounts required by the Companies Act 2006 and are for circulation to trustees of the company.

These accounts are prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 and are for circulation to the members of the company.

The parent charity income was £1,647.1k in 2022 (2021: £1,489.4k) and its loss for the year was £286.0k (2021: surplus of £240.2k).

The notes at pages 22 to 36 form part of these accounts.

The accounts were approved by the Board of Trustees on 13th June 2023



J Jordan  
Treasurer/Trustee

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
CONSOLIDATED STATEMENT OF CASH FLOWS  
FOR THE YEAR ENDED 31 DECEMBER 2022**

	Notes	Group		Charity	
		2022 £'000	2021 £'000	2022 £'000	2021 £'000
<b>Cash flows from operating activities</b>					
Cash used in operations	25	(78.5)	(282.9)	(73.9)	(282.8)
<b>Investing activities</b>					
Purchase of intangible fixed assets		0.0	(24.7)	0.0	(24.7)
Purchase of tangible fixed assets		(42.2)	(10.8)	(42.2)	(10.8)
Purchase of investments		(28.5)	(25.9)	(28.5)	(25.9)
Interest received		28.6	25.5	28.6	25.5
Gift aid donation from subsidiary		0.0	0.0	4.8	1.5
<b>Net cash used in investing activities</b>		<u>(42.1)</u>	<u>(35.9)</u>	<u>(37.3)</u>	<u>(34.4)</u>
<b>Net decrease in cash and cash equivalents</b>		<u>(120.6)</u>	<u>(318.8)</u>	<u>(111.2)</u>	<u>(317.2)</u>
Cash and cash equivalents at beginning of year		429.5	748.3	415.5	732.7
<b>Cash and cash equivalents at end of year</b>		<u>308.9</u>	<u>429.5</u>	<u>304.3</u>	<u>415.5</u>

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2022**

**1 Accounting policies**

**Charity information**

National Rheumatoid Arthritis Society is a private company limited by guarantee incorporated in England and Wales and Scotland. The registered office is Suite 3, Beechwood, Grove Business Park, White Waltham, Berkshire, SL6 3LW

**1.1 Accounting convention**

These accounts have been prepared in accordance with the charity's governing document, the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102.

The accounts are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £'000.

The accounts have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include listed investments and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

**Preparation of consolidated financial statements**

These consolidated financial statements incorporate the financial statements of the Charity and its subsidiary undertaking, NRAS Community Services Limited, made up to 31 December 2022. Intercompany transactions, balances and unrealised gains on transactions between the Charity and its subsidiary are eliminated. Accounting policies of subsidiary undertakings have been changed where necessary to ensure consistency with the policies adopted by the Group. The income of the trading subsidiary is included in the Consolidated Statement of Financial Activities within other trading activities. Expenditure is included in wages and support costs.

**1.2 Going concern**

At the time of approving the accounts, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. This expectation is based on the strong investments and cash position, reflecting a significant amount of unrestricted funds and the financial performance of the Charity. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the accounts.

**1.3 Charitable funds**

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The cost of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

**1.4 Incoming resources**

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2022**

**1 Accounting policies**

**(Continued)**

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is probable. If the amount is not known, the legacy is treated as a contingent asset.

The charity receives grants in respect of charitable activities run by the charity. Income from grants are recognised at fair value when the charity has entitlement after any performance conditions have been met, it is probable that the income will be received and the amount can be measured reliably.

Income from trading activities includes income earned from fundraising events and trading activities to raise funds for the charity. Income is received in exchange for supplying goods and services in order to raise funds and is recognised when entitlement has occurred.

Subscription income is recognised on a rolling basis from the date of membership.

Income is measured at the fair value of the consideration received or receivable and represents amounts receivable for services provided in the normal course of business, net of discounts, VAT and other sales related taxes.

**1.5 Resources expended**

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Expenditure is recognised where there is a legal or constructive obligation to make payments to third parties, it is probable that the settlement will be required and the amount of the obligation can be measured reliably. It is categorised under the following headings:

Costs of raising funds includes costs related to fundraising events, merchandising and advertising;

Expenditure on charitable activities includes staff costs and support costs relating to different projects conducted during the year (see note 8).

Irrecoverable VAT is charged as an expense against the activity for which expenditure arose.

**Support costs allocation**

Support costs include both direct expenditure incurred on charitable activities and those costs which assist the work of the charity including office and administrative costs. They are all incurred directly in the furthering of the charity's aims and purposes. Distinction has been made for those costs relating to the raising of funds and to governance, these costs have been analysed separately.

Fundraising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities.

The bases on which support costs have been allocated are set out in Note 9.

Fundraising costs are specified in Note 7.

Governance costs are specified in Note 9.

Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to that category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

**1 Accounting policies**

(Continued)

**1.6 Intangible and tangible fixed assets and depreciation**

Intangible and tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Improvements to property	20% straight line or lease period if shorter
Website development	25% straight line
Fixtures, fittings & equipment	25% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in net income/(expenditure) for the year.

**1.7 Impairment of fixed assets**

At each reporting end date, the charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

**1.8 Cash and cash equivalents**

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

**1.9 Financial instruments**

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

**Basic financial assets**

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

**1 Accounting policies**

(Continued)

***Basic financial liabilities***

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

***Derecognition of financial liabilities***

Financial liabilities are derecognised when the Charity's contractual obligations expire or are discharged or cancelled.

**1.10 Fixed asset investments**

Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

**1.11 Employee benefits**

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employments of an employee or to provide termination benefits.

**1.12 Leases**

Rentals payable under operating leases, including any lease incentives received, are charged to income on a straight line basis over the term of the relevant lease.

**2 Critical accounting estimates and judgements**

In the application of the charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2022

**3 Donations and legacies**

	Group		Charity	
	2022	2021	2022	2021
	£'000	£'000	£'000	£'000
Donations and gifts	561.4	591.6	566.2	593.1
Legacies receivable	773.0	525.5	773.0	525.5
	<u>1,334.4</u>	<u>1,117.1</u>	<u>1,339.2</u>	<u>1,118.6</u>
<i>Analysis by fund</i>				
Restricted funds	0.0	0.0	0.0	0.0
Unrestricted funds	<u>1,334.4</u>	<u>1,117.1</u>	<u>1,339.2</u>	<u>1,118.6</u>
	<u>1,334.4</u>	<u>1,117.1</u>	<u>1,339.2</u>	<u>1,118.6</u>

**4 Income from charitable activities**

	Group		Charity	
	2022	2021	2022	2021
	£'000	£'000	£'000	£'000
Subscriptions	83.1	81.7	83.1	81.7
Lottery income	30.0	22.2	30.0	22.2
Research studies	8.3	0.0	8.3	0.0
Grants	137.0	208.4	137.0	208.4
	<u>258.4</u>	<u>312.3</u>	<u>258.4</u>	<u>312.3</u>
<i>Analysis by fund</i>				
Restricted funds	55.5	63.1	55.5	63.1
Unrestricted funds	<u>202.9</u>	<u>249.2</u>	<u>202.9</u>	<u>249.2</u>
	<u>258.4</u>	<u>312.3</u>	<u>258.4</u>	<u>312.3</u>

**5 Other trading activities**

	Group		Charity	
	2022	2021	2022	2021
	£'000	£'000	£'000	£'000
Merchandising and other trading income	25.7	34.5	25.7	34.5
Trading subsidiary income	<u>0.0</u>	<u>7.6</u>	<u>0.0</u>	<u>0.0</u>
	<u>25.7</u>	<u>42.1</u>	<u>25.7</u>	<u>34.5</u>

**6 Investments**

	Group		Charity	
	2022	2021	2022	2021
	£'000	£'000	£'000	£'000
Income from listed investments	<u>28.6</u>	<u>25.5</u>	<u>28.6</u>	<u>25.5</u>
	<u>28.6</u>	<u>25.5</u>	<u>28.6</u>	<u>25.5</u>

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2022

7 Expenditure on raising funds

	Group and Charity	
	2022 £'000	2021 £'000
Staging fundraising events	74.0	43.7
Staff costs	227.6	201.9
Support costs	65.9	64.1
Governance costs	14.5	10.8
Expenditure on raising funds	<b>382.0</b>	<b>320.5</b>
<i>Analysis by fund</i>		
Restricted funds	0.0	0.0
Unrestricted funds	<b>382.0</b>	<b>320.5</b>
	<b>382.0</b>	<b>320.5</b>

8 Expenditure on charitable activities

Group	Provision of info & support	Digital innovations	Raising awareness	Community support	Supporting our young people	Total
	2022	2022	2022	2022	2022	2022
	£'000	£'000	£'000	£'000	£'000	£'000
Direct costs	48.6	23.7	58.5	0.0	10.0	140.8
Staff costs	246.7	51.1	293.8	92.5	75.2	759.3
Share of support costs (see note 9)	131.8	0.0	197.8	65.9	65.9	461.4
Share of governance costs (see note 9)	14.5	0.0	14.5	14.4	7.2	50.6
	<b>441.6</b>	<b>74.8</b>	<b>564.6</b>	<b>172.8</b>	<b>158.3</b>	<b>1,412.1</b>
<i>Analysis by fund</i>						
Restricted funds	24.7	74.8	0.0	0.0	9.1	108.6
Unrestricted funds	416.9	0.0	564.6	172.8	149.2	1,303.5
	<b>441.6</b>	<b>74.8</b>	<b>564.6</b>	<b>172.8</b>	<b>158.3</b>	<b>1,412.1</b>

Group	Provision of info & support	Digital innovations	Raising awareness	Community support	Supporting our young people	Total
	2021	2021	2021	2021	2021	2021
	£'000	£'000	£'000	£'000	£'000	£'000
Direct costs	31.8	38.3	21.2	0.0	17.0	108.3
Staff costs	233.5	42.5	219.6	143.6	50.1	689.3
Share of support costs (see note 9)	64.1	0.0	64.1	64.0	32.0	224.2
Share of governance costs (see note 9)	10.8	0.0	10.7	10.7	5.4	37.6
	<b>340.2</b>	<b>80.8</b>	<b>315.6</b>	<b>218.3</b>	<b>104.5</b>	<b>1,059.4</b>
<i>Analysis by fund</i>						
Restricted funds	21.3	80.8	8.9	0.0	12.2	123.2
Unrestricted funds	318.9	0.0	306.7	218.3	92.3	936.2
	<b>340.2</b>	<b>80.8</b>	<b>315.6</b>	<b>218.3</b>	<b>104.5</b>	<b>1,059.4</b>

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2022

8 Expenditure on charitable activities

Charity	Provision of info & support	Digital innovations	Raising awareness	Community support	Supporting our young people	Total
	2022	2022	2022	2022	2022	2022
	£'000	£'000	£'000	£'000	£'000	£'000
Direct costs	48.6	23.7	58.5	0.0	10.0	140.8
Staff costs	246.7	51.1	293.8	92.5	75.2	759.3
Share of support costs (see note 9)	131.8	0.0	197.8	65.9	65.9	461.4
Share of governance costs (see note 9)	11.9	0.0	14.5	14.4	7.2	48.0
	<b>439.0</b>	<b>74.8</b>	<b>564.6</b>	<b>172.8</b>	<b>158.3</b>	<b>1,409.5</b>
<b>Analysis by fund</b>						
Restricted funds	24.7	74.8	0.0	0.0	9.1	108.6
Unrestricted funds	414.3	0.0	564.6	172.8	149.2	1,300.9
	<b>439.0</b>	<b>74.8</b>	<b>564.6</b>	<b>172.8</b>	<b>158.3</b>	<b>1,409.5</b>

Charity	Provision of info & support	Digital innovations	Raising awareness	Community support	Supporting our young people	Total
	2021	2021	2021	2021	2021	2021
	£'000	£'000	£'000	£'000	£'000	£'000
Direct costs	31.8	38.3	21.2	0.0	17.0	108.3
Staff costs	233.5	42.5	219.6	143.6	50.1	689.3
Share of support costs (see note 9)	64.7	0.0	64.1	64.0	32.0	224.8
Share of governance costs (see note 9)	7.3	0.0	10.7	10.7	5.4	34.1
	<b>337.3</b>	<b>80.8</b>	<b>315.6</b>	<b>218.3</b>	<b>104.5</b>	<b>1,056.5</b>
<b>Analysis by fund</b>						
Restricted funds	21.3	80.8	8.9	0.0	12.2	123.2
Unrestricted funds	316.0	0.0	306.7	218.3	92.3	933.3
	<b>337.3</b>	<b>80.8</b>	<b>315.6</b>	<b>218.3</b>	<b>104.5</b>	<b>1,056.5</b>

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2022

9 Support costs

Group	Support costs	Governance costs	Total	Support costs	Governance costs	Total
	2022	2022	2022	2021	2021	2021
	£'000	£'000	£'000	£'000	£'000	£'000
Staff costs		34.0	34.0		23.5	23.5
IT	97.6		97.6	79.5		79.5
Office	145.5		145.5	116.6		116.6
Professional and consultancy fees	104.6	9.6	114.2	16.5	0.0	16.5
Irrecoverable VAT	56.5		56.5	(1.7)		(1.7)
Other overheads	73.1		73.1	38.6		38.6
Depreciation & dilapidations	50.0		50.0	38.8		38.8
Insurance		5.7	5.7		5.4	5.4
Auditors' remuneration:						
- Audit fees		15.8	15.8		12.0	12.0
- Other services		0.0	0.0		7.5	7.5
	<b>527.3</b>	<b>65.1</b>	<b>592.4</b>	<b>288.3</b>	<b>48.4</b>	<b>336.7</b>
Analysed between						
Fundraising (note 7)	65.9	14.5	80.4	64.1	10.8	74.9
Charitable activities (note 8)	461.4	50.6	512.0	224.2	37.6	261.8
	<b>527.3</b>	<b>65.1</b>	<b>592.4</b>	<b>288.3</b>	<b>48.4</b>	<b>336.7</b>

The above costs were allocated on a headcount basis.

Charity	Support costs	Governance costs	Total	Support costs	Governance costs	Total
	2022	2022	2022	2021	2021	2021
	£'000	£'000	£'000	£'000	£'000	£'000
Staff costs		34.0	34.0		23.5	23.5
IT	97.6		97.6	79.5		79.5
Office	145.5		145.5	116.6		116.6
Professional and consultancy fees	104.6	9.6	114.2	16.5	0.0	16.5
Irrecoverable VAT	56.5		56.5	(1.7)		(1.7)
Other overheads	73.1		73.1	39.2		39.2
Depreciation & dilapidations	50.0		50.0	38.8		38.8
Insurance		5.7	5.7		5.4	5.4
Auditors' remuneration:						
- Audit fees		13.2	13.2		8.5	8.5
- Other services			0.0		7.5	7.5
Trustee expenses			0.0			0.0
	<b>527.3</b>	<b>62.5</b>	<b>589.8</b>	<b>288.9</b>	<b>44.9</b>	<b>333.8</b>
Analysed between						
Fundraising (note 7)	65.9	14.5	80.4	64.1	10.8	74.9
Charitable activities (note 8)	461.4	48.0	509.4	224.8	34.1	258.9
	<b>527.3</b>	<b>62.5</b>	<b>589.8</b>	<b>288.9</b>	<b>44.9</b>	<b>333.8</b>

The above costs were allocated on a headcount basis.

10 Trustees

None of the Trustees (nor any persons connected with them) received any remuneration during the year, and they were reimbursed a total of £nil travelling expenses (2021: £nil).

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2022**

**11 Employees**

**Number of employees**

	<b>2022 Number</b>	<b>2021 Number</b>
The average monthly number of employees during the year was:		
All employees - Group and Charity	31	32
The average monthly number of full-time equivalent employees during the year was:		
All employees - Group and Charity	27	24

**Employment costs**

	<b>Group</b>		<b>Charity</b>	
	<b>2022 £'000</b>	<b>2021 £'000</b>	<b>2022 £'000</b>	<b>2021 £'000</b>
Wages and salaries	905.6	829.3	905.6	829.3
Social security	83.4	69.1	83.4	69.1
Pension costs	31.8	16.3	31.8	16.3
	<u>1,020.8</u>	<u>914.7</u>	<u>1,020.8</u>	<u>914.7</u>

The total amount of redundancy payments made by the Company in the year was £5,499 (2021: £10,000).

The number of employees who received total employee benefits (excluding employer pension costs) of more than £60,000 is as follows:

	<b>2022 Number</b>	<b>2021 Number</b>
£60,001 - £70,000	1	1

**Remuneration of key management personnel**

The remuneration of key management personnel is as follows:

	<b>2022 £'000</b>	<b>2021 £'000</b>
Aggregate Compensation	171.4	223.8

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2022

12 Net gains/(losses) on investments

	2022	2021
	£'000	£'000
Revaluation of investments	(141.6)	127.8

13 Tangible and intangible fixed assets - Group and Charity

	Intangible assets	Tangible assets		
	Website development	Improvements to property	Fixtures, fittings & equipment	Total tangible assets
	£'000	£'000	£'000	£'000
<b>Cost</b>				
At 31 December 2021	298.9	61.7	140.9	202.6
Additions	0.0	25.8	16.4	42.2
Disposals	(164.1)	(61.7)	(102.6)	(164.3)
<b>At 31 December 2022</b>	<b>134.8</b>	<b>25.8</b>	<b>54.7</b>	<b>80.5</b>
<b>Depreciation</b>				
At 31 December 2021	205.6	59.7	118.8	178.5
Charge for the year	33.7	3.3	12.0	15.3
Disposals	(164.1)	(61.7)	(102.6)	(164.3)
<b>At 31 December 2022</b>	<b>75.2</b>	<b>1.3</b>	<b>28.2</b>	<b>29.5</b>
<b>Carrying amount</b>				
<b>At 31 December 2022</b>	<b>59.6</b>	<b>24.5</b>	<b>26.5</b>	<b>51.0</b>
<b>At 31 December 2021</b>	<b>93.3</b>	<b>2.0</b>	<b>22.1</b>	<b>24.1</b>

14 Fixed asset investments - Group and Charity

	2022	2021
	£'000	£'000
<b>Listed investments</b>		
Market value at 1 January	1,025.6	871.9
Additions (including interest reinvested)	28.5	25.9
Revaluation	(141.6)	127.8
<b>Market value at 31 December</b>	<b>912.5</b>	<b>1,025.6</b>

15 Financial instruments

	2022	2021
	£'000	£'000
<b>Carrying amount of financial assets</b>		
Instruments measured at amortised cost	362.3	398.6
Instruments measured at fair value through profit or loss	912.5	1,025.6
<b>Carrying amount of financial liabilities</b>		
Measured at amortised cost	102.0	95.9

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2022**

**16 Debtors**

	Group		Charity	
	2022 £'000	2021 £'000	2022 £'000	2021 £'000
<b>Amounts falling due within one year:</b>				
Trade debtors	44.9	85.6	44.9	85.6
Amounts owed by group undertakings	0.0	0.0	5.2	6.2
Other debtors	317.4	313.0	317.4	313.0
Prepayments and accrued income	35.4	45.4	35.4	45.4
	<u>397.7</u>	<u>444.0</u>	<u>402.9</u>	<u>450.2</u>

Other debtors include £25.3k relating to long term debtors receivable in greater than one year's time

**17 Creditors: amounts falling due within one year**

	Group		Charity	
	2022 £'000	2021 £'000	2022 £'000	2021 £'000
Trade creditors	17.2	9.2	17.2	9.2
Other taxes and social security costs	14.2	18.5	14.2	18.5
Other creditors	53.3	17.7	51.3	14.7
Accruals and deferred income	31.5	69.0	31.5	69.0
	<u>116.2</u>	<u>114.4</u>	<u>114.2</u>	<u>111.4</u>

	2022 £'000	2021 £'000
Deferred income included in the financial statements as follows:		
At 1 January	0.0	41.1
Movement during the year	0.0	(41.1)
At 31 December	<u>0.0</u>	<u>0.0</u>

Income was deferred in 2020 in relation to grants received which related to services that were delivered in 2021.

**18 Retirement benefit schemes**

**Defined contribution schemes**

The Charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the Charity in an independently administered fund.

The charge to profit or loss in respect of defined contribution schemes was £31.8k (2021: £16.3k).

## 19 Fund reconciliation

The income funds of the Charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

### Unrestricted Funds

	Movement in funds				Balance at 31 December 2022
	Balance at 1 January 2022	Incoming resources 2022	Resources expended 2022	Transfer of funds 2022	
	£'000	£'000	£'000	£'000	£'000
Unrestricted	1,871.2	1,553.4	(1,784.2)	(271.3)	1,369.1
Designated - Juvenile Idiopathic Arthritis activities	0.0	38.2	(42.9)	4.7	0.0
Designated - to cover predicted operating losses in next year	0.0	0.0		125.0	125.0
Designated - to cover potential investment losses	0.0	0.0		100.0	100.0
	<b>1,871.2</b>	<b>1,591.6</b>	<b>(1,827.1)</b>	<b>(41.6)</b>	<b>1,594.1</b>

	Movement in funds				Balance at 31 December 2021
	Balance at 1 January 2021	Incoming resources 2021	Resources expended 2021	Transfer of funds 2021	
	£'000	£'000	£'000	£'000	£'000
Unrestricted	1,600.4	1,386.4	(1,036.6)	(79.0)	1,871.2
Designated - Juvenile Idiopathic Arthritis activities	0.0	47.5	(92.3)	44.8	0.0
	<b>1,600.4</b>	<b>1,433.9</b>	<b>(1,128.9)</b>	<b>(34.2)</b>	<b>1,871.2</b>

### Restricted Funds

	Movement in funds				Balance at 31 December 2022
	Balance at 1 January 2022	Incoming resources 2022	Resources expended 2022	Transfer of funds 2022	
	£'000	£'000	£'000	£'000	£'000
Development of elearning suite	0.0	15.0	(49.0)	34.0	0.0
Development of online self-management course in Scotland	0.1	0.0	(0.1)	0.0	(0.0)
Information video in Hindi	1.5	0.0	(0.4)	0.0	1.1
Blood Monitoring publication	5.2	0.0	(9.0)	3.8	0.0
Development of exercise support app	0.0	3.1	(6.0)	2.9	0.0
Enhanced Right Start	14.1	10.0	(16.3)	0.0	7.8
JIA Imagine Futures project	10.0	0.0	(10.2)	0.2	0.0
Reprint of Medicines booklet	0.0	2.3	(3.0)	0.7	0.0
JIA video	0.0	2.5	(2.5)	0.0	0.0
Stress management project	0.0	22.6	(12.1)	0.0	10.5
	<b>30.9</b>	<b>55.5</b>	<b>(108.6)</b>	<b>41.6</b>	<b>19.4</b>

	Movement in funds				Balance at 31 December 2021
	Balance at 1 January 2021	Incoming resources 2021	Resources expended 2021	Transfer of funds 2021	
	£'000	£'000	£'000	£'000	£'000
Development of elearning suite	0.0	15.0	(44.9)	29.9	0.0
Development of online self-management course in Scotland	12.2	0.0	(13.9)	1.8	0.1
Re-development of DAS app	11.3	0.0	(11.6)	0.3	0.0
JIA publications	10.5	0.0	(12.2)	1.7	0.0
Information video in Hindi	5.0	0.0	(3.5)	0.0	1.5
Blood Monitoring publication	8.9	0.0	(3.7)	0.0	5.2
Community pharmacy engagement	8.9	0.0	(8.9)	0.0	0.0
Development of exercise support app	0.0	6.3	(6.8)	0.5	0.0
Right Start evaluation project	0.0	31.8	(17.7)	0.0	14.1
JIA Imagined Futures project	0.0	10.0	0.0	0.0	10.0
	<b>56.8</b>	<b>63.1</b>	<b>(123.2)</b>	<b>34.2</b>	<b>30.9</b>

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2022**

**20 Analysis of net assets between funds - Group**

	Restricted £'000	Unrestricted £'000	Total £'000
<b>Fund balances at 31 December 2022 are represented by:</b>			
Tangible fixed assets	0.0	51.0	51.0
Investments	0.0	912.5	912.5
Current assets/(liabilities)	19.4	630.6	650.0
	<u>19.4</u>	<u>1,594.1</u>	<u>1,613.5</u>

**Fund balances at 31 December 2021 are represented by:**

	Restricted £'000	Unrestricted £'000	Total £'000
Tangible fixed assets	0.0	24.1	24.1
Investments	0.0	1,025.6	1,025.6
Current assets/(liabilities)	30.9	821.5	852.4
	<u>30.9</u>	<u>1,871.2</u>	<u>1,902.1</u>

**Analysis of net assets between funds - Charity**

	Restricted £'000	Unrestricted £'000	Total £'000
<b>Fund balances at 31 December 2022 are represented by:</b>			
Tangible fixed assets	0.0	51.0	51.0
Investments	0.0	912.5	912.5
Current assets/(liabilities)	19.4	633.2	652.6
	<u>19.4</u>	<u>1,596.7</u>	<u>1,616.1</u>

**Fund balances at 31 December 2021 are represented by:**

	Restricted £'000	Unrestricted £'000	Total £'000
Tangible fixed assets	0.0	24.1	24.1
Investments	0.0	1,025.6	1,025.6
Current assets/(liabilities)	30.9	816.7	847.6
	<u>30.9</u>	<u>1,866.4</u>	<u>1,897.3</u>

**21 Commitments under operating leases**

At the reporting end date the group and charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	2022 £'000	2021 £'000
Within one year	31.6	81.2
Between two and five years	112.5	16.9
Over five years	0.0	0.0
	<u>144.1</u>	<u>98.1</u>

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY**  
**NOTES TO THE ACCOUNTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2022**

**22 Subsidiary company**

The charity owns the whole of the issued ordinary share capital of NRAS Community Services Ltd (company number: 8953247), a company registered in England. The subsidiary is used for non-primary purpose trading activities. All activities have been consolidated on a line by line basis in the Statement of financial activities.

The total net profit is gifted to the charity.

A summary of the results of the subsidiary is shown below:

	<b>2022</b>	<b>2021</b>
	<b>£'000</b>	<b>£'000</b>
Turnover	0.0	7.6
Cost of sales	<u>0.0</u>	<u>0.0</u>
Gross profit	0.0	7.6
Administrative expenses	<u>(2.6)</u>	<u>(2.8)</u>
Net profit	<b>(2.6)</b>	<b>4.8</b>
Retained earnings brought forward in subsidiary	4.8	1.5
Gift aid to National Rheumatoid Arthritis Society	<u>(4.8)</u>	<u>(1.5)</u>
Retained earnings carried forward in subsidiary	<b>(2.6)</b>	<b>4.8</b>
The assets and liabilities were:		
The aggregate of the assets, liabilities and funds was:		
Assets	4.6	14.0
Liabilities	<u>(7.2)</u>	<u>(9.2)</u>
Total net assets	<b>(2.6)</b>	<b>4.8</b>
Called up share capital	0.0	0.0
Profit and loss reserve	<u>(2.6)</u>	<u>4.8</u>
	<b>(2.6)</b>	<b>4.8</b>

**23 Related party transactions**

There were no related party transactions in the year (2021: nil) requiring disclosure.

**24 Capital Commitments**

As at 31 December 2022 the Charity had capital commitments of £nil (2021: £nil).

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY**  
**NOTES TO THE ACCOUNTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2022**

25 Cash (used in)/ generated from operations	Group		Charity	
	2022 £'000	2021 £'000	2022 £'000	2021 £'000
(Loss)/ Surplus for the year	(288.6)	244.9	(281.2)	241.7
Adjustments for:				
Investment income recognised in profit or loss	(28.6)	(25.5)	(28.6)	(25.5)
Fair value gains and losses on investments	141.6	(127.8)	141.6	(127.8)
Gift aid donation from subsidiary			(4.8)	(1.5)
Depreciation and impairment of intangible fixed asset	33.7	29.4	33.7	29.4
Depreciation and impairment of tangible fixed assets	15.3	9.4	15.3	9.4
Movements in working capital:				
(Increase)/ decrease in debtors	46.3	(329.3)	47.3	(329.3)
Increase/ (decrease) in creditors	1.8	(84.0)	2.8	(79.2)
<b>Cash (used in)/ generated from operations</b>	<b>(78.5)</b>	<b>(282.9)</b>	<b>(73.9)</b>	<b>(282.8)</b>

**26 Analysis of changes in net funds**

	At start of year £'000	Cash flows £'000	At end of year £'000
Cash	429.5	(120.6)	308.9
<b>Total</b>	<b>429.5</b>	<b>(120.6)</b>	<b>308.9</b>

**THE NATIONAL RHEUMATOID ARTHRITIS SOCIETY**

England & Wales - Charity number 1134859

---

# Accounts

---

Charity Registration No. 1134859/SC039721

Company Registration No. 07127101 (England and Wales)

**REPORT OF THE TRUSTEES AND  
AUDITED CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2021  
FOR  
NATIONAL RHEUMATOID ARTHRITIS SOCIETY**

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
LEGAL AND ADMINISTRATIVE INFORMATION**

**Trustees**

Mr R A Boucher  
Mr S Collins  
Miss L Cook  
Mr R Flowerdew  
Mr J Jordan  
Miss E Potter  
Dr G Taylor  
Miss S Webb

**CEO**

Mrs C Jacklin

**Charity number**

1134859/ SC039721

**Company number**

07127101

**Registered office**

Ground Floor  
4 The Switchback  
Gardner Road  
Maidenhead  
Berks  
SL6 7RJ

**Auditors**

Moore Kingston Smith LLP  
The Shipping Building  
The Old Vinyl Factory  
Blyth Road  
Hayes  
UB3 1HA

**Bankers**

HSBC  
35 High Street  
Maidenhead  
SL6 1JQ

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
CONTENTS**

	<b>Page</b>
Trustees' report	1-8
Statement of Trustees' responsibilities	8
Statement as to disclosure to our auditors	9
Independent auditors' report	10-13
Consolidated Statement of financial activities	14
Company Statement of financial activities	15
Consolidated and Company Balance Sheets	16
Consolidated Statement of Cash Flows	17
Notes to the accounts	18-32

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2021**

The Trustees present their report and audited consolidated accounts for the year ended 31 December 2021. The Trustees have adopted the provisions of the Statement of Recommended Practice (SORP) "Accounting and Reporting by Charities" (FRS 102) in preparing the annual report and financial statements of the Charity.

The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the Charity's governing document, the Charities Act 2011, the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015)."

### **Chair's Report**

After the challenges presented in 2020 at the onset of the COVID-19 pandemic, we all thought that 2021 would be a year for getting back to normal. That did not prove to be the case as the pandemic kept its grip on the world and presented us all with yet more challenges in our daily lives: ongoing threats to health, both physical and mental, lockdowns, uncertainty, and no prospect of an end in sight. If anything, the challenges of 2021 surpassed those of 2020 as everyone wearied of the constant battle day in, day out. Our beneficiaries needed more help and support than ever before. Our staff and volunteers worked harder, and our fundraisers, without whom we would not exist, continued to give their precious energy, creativity and resources to help us to help others.

With the prospect of yet more cancellations and deferrals of events which traditionally form the basis of our core fundraising activity, we had to respond by devising even more novel and creative alternatives to help fund the support we provide to those living with Rheumatoid Arthritis (RA) and Juvenile Idiopathic Arthritis (JIA). We hosted online fundraising events, held an online Christmas show for the second year running, and held a very successful virtual Wear Purple campaign for young people with JIA. In September we launched our virtual challenge #DoThe20Challenge to coincide with our 20<sup>th</sup> anniversary which caught the imagination of our fundraisers and resulted in many inventive challenges being successfully completed and shared with our wider community via our social media platforms.

We have been very fortunate over recent years to benefit from generous gifts in wills which have provided us with certainty over our ability to continue to fund our core services for the foreseeable future and 2021 was no exception. Such gifts are crucial to the sustainability of the charity and we extend our heartfelt thanks to the generosity of the people whose legacy will live on through the work that we do.

The success of our fundraising, coupled with the generous legacy bequests, has allowed us to continue providing our full range of services to our beneficiaries and also to invest in new services relevant for the digital world in which we now live. In 2021 we extended engagement across all service areas. NRAS's New2RA Right Start and Living With referral programmes both saw double-digit growth in the year and calls into our Helpline team grew by 4% year-on-year. We launched our suite of e-learning self-management programme, SMILE-RA, (Self Management Individualised Learning Environment) with the first four modules now live via our website. Registrations so far have surpassed all expectations and we look forward to the launch of further modules in 2022. Demand for our publications also grew during 2021, with over 15,000 booklets either downloaded from our website, despatched to individuals, or sent in bulk to hospitals. NRAS's RA Awareness Week in September was a resounding success with record-breaking registrations for our wellbeing events across the week.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2021**


We celebrated a major campaign success in 2021 when NICE (National Institute for Health & Care Excellence) announced a reduction in the threshold criteria for access to some of the advanced therapies available on the NHS for those living with 'moderate active' RA. This followed a four-year campaign led by NRAS in collaboration with the British Society for Rheumatology and marks an incredible achievement which will have the potential to improve the lives of thousands of people in England & Wales. The change has brought England and Wales more in line with the rest of Western Europe and the Scottish SMC (Scottish Medicines Consortium) has also adopted NICE's recommendation. This change in access is the first major step in our work to ensure that people across the UK are not unfairly restricted in their options of medicines just because of where they live. We will continue to campaign for further revisions of NICE guidelines and improved translation of such guidelines into clinical practice across the UK.

We responded to our beneficiaries' requests for more mental health and wellbeing support by expanding our virtual Wellbeing programme. During 2021 we ran 13 courses offering support to 270 people and the success of the programme means it will become a permanent feature of our suite of offerings. In December, we were delighted to launch our new membership programmes aimed at providing people living with RA a choice of level of membership package tailored to their individual needs and circumstances.

2021 was an important year for NRAS as it celebrated its 20<sup>th</sup> birthday. Our original plans to celebrate this milestone were derailed by the pandemic and the ongoing social restrictions but we marked the event with a twentieth anniversary edition of our Members' magazine and an online 20<sup>th</sup> Anniversary Celebration with special guest appearances from Theresa May MP and Ailsa Bosworth MBE, amongst others. We plan to hold a Gala Dinner on 9<sup>th</sup> September 2022 to celebrate all that we have achieved over the last 21 years, to thank our fundraisers, Volunteers, supporters and medical advisers and to recognise all those who have helped us to help others.

I am pleased to report that through judicious planning and sheer hard work, the Charity has finished 2021 stronger and more resilient than ever before. We delivered income of £1.497m, up 20% on 2020, and reported a net gain of £245,000. Our balance sheet is healthy with £430,000 cash in bank at the end of the year and over £1m in liquid investments. This strong financial position enables us to look to 2022 and beyond with confidence that we will continue to support the RA and JIA communities, reaching more people through the expansion and development of our services. We will focus on the development of our digital strategy, identifying how to broaden our offerings across multiple platforms and work to get our self-management programmes embedded within patient pathways. Work will continue on extending our reach with a particular focus on connecting more with ethnic minorities and socially deprived communities. These are exciting times ahead!

Of course, none of this would be possible without the commitment of all colleagues here at NRAS, as well as to our Members and Volunteers, and of course our very generous donors so on behalf of the Board of Trustees, I would like to extend my sincere thanks to all those who have worked so hard to deliver vital services to all those people who need them.



Simon Collins  
Chair of Trustees

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2021**

**Our purpose and activities**

Guidance from the Charity Commission has been used to review and develop NRAS's aims and objectives so that activities are clearly focused to derive good public benefit.

***Objectives and activities***

The objects of the Charity (the "Objects") are for the public benefit to promote the relief of people living with RA and JIA by:

- Raising awareness and understanding of Rheumatoid Arthritis (RA) and Juvenile Idiopathic Arthritis (JIA), including awareness of the severity of the diseases and their social and economic costs;
  - Providing information on RA and JIA, including information on their treatments and drugs available;
  - Advancing all aspects of the care and treatment of RA and JIA and the management of these diseases in their totality;
  - Providing education on the diseases generally and to individuals and their families and carers in all aspects of RA and JIA, including their treatment and management, and providing information about available support;
  - Supporting individuals in relation to RA and JIA and their families and carers, including putting people in touch with each other to encourage self-help and support where appropriate;
- Working alongside NHS rheumatology health professionals to provide the best care for patients as well as support the clinical staff in their roles.

***Our vision and mission***

Our vision is life without limits for all those with RA and JIA.

Our mission is to enable the RA and JIA community to thrive by providing access to support, expert knowledge, engagement, campaigning, and research, all of which is informed by those living with these complex, and currently incurable, auto-immune diseases.

Underpinning all of these mission goals is our commitment to:

- Improving the equality and equity of access to the best care across the UK;
- Providing and promoting the best supported self-management resources for those living with RA and JIA;
- Harnessing digital solutions to meet the changing requirements of the individual and the NHS;
- Analysing the impact of our services to better inform our future plans;
- Ensuring the sustainability of the charity and its services by investigating opportunities for longer term engagement with funders and paid-for NRAS services;
- Investing in the continuous development of NRAS colleagues, Volunteers, Ambassadors and Trustees ensuring we maintain the highest level of expertise and knowledge to support our beneficiaries and govern the organisation.

***Our principal activities***

We are committed to providing support, evidenced-based information, services, education, campaigning and patient advocacy of the highest quality to, and on behalf of all, those affected by RA and JIA as well as their families.

Our front-line services, including the Helpline, online peer support community, local and virtual groups, peer-to-peer telephone support programme, wellbeing courses, supported self-management modules, information booklets, websites and patient events (both in person and virtually) to continue to offer high quality, accessible and relevant support as a priority. The ability to work is an important health outcome and we have specific resources relating to the workplace for employees and employers as

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2021**

well as up to date information on benefits including Personal Independence Payments. Both of these important subjects are frequently raised by people calling our Helpline.

We are a membership organisation and provide a magazine twice a year to our Members, as well as other benefits. We also support health professionals in the field of rheumatology and primary care through provision of free health professional membership of NRAS and free patient referral programme and information so that we can 'help them to help their patients'.

Living with RA and JIA is not just about having physical and medical needs. These incurable diseases have a huge impact on emotional well-being and quality of life both of the individual and their family. The recent physical isolation of many living with inflammatory arthritis endured as a result of the COVID-19 pandemic has exacerbated mental health issues even further. NRAS has responded to this by offering online wellbeing sessions and other support tools such a referral to a counselling assessment as part of our Wellbeing Membership packages. We will continue to strive to help people by supporting **all** their needs in a holistic way whether physical, medical, emotional, mental, social, economic and/or employment related needs as well as those relating to access to benefits.

We are at the table at a national level whenever standards and guidelines, RA/JIA pathways and access to treatment are being discussed. We conduct our own social research and publish key reports on a topic of importance to people with RA/JIA periodically.

Translational scientific and medical research has revolutionised the field of auto-immune conditions such as RA and JIA in the past 20 years and whilst we do not conduct or fund medical research ourselves, we do support a growing number of academic and clinical research studies throughout the UK on an ongoing basis. We also support recruitment to clinical studies and provide expert volunteers to advise on issues of Patient and Public Involvement. We do conduct our own funded major social research studies often in partnership with an academic partnering institute. In 2021, we continued to play a pivotal role in COVID-19 research by supporting UK, European and Global data gathering.

We launched the first four modules in a new suite of e-learning self-management programmes, devised and produced by our founder and now National Patient Champion, Ailsa Bosworth MBE. Further modules are due for release in 2022. We hope that these engaging and interactive online e-learning modules will eventually be prescribed by health professionals for the benefit of their patients.

### **Achievements and performance**

During 2021 we generated £591.6k of income through donations, pledges and gifts in kind, compared to £698.7k in 2020. This was an incredible achievement given that the traditional fundraising landscape continued to be affected throughout the year by the pandemic with many events either cancelled or curtailed. These figures also include donations received from pharmaceutical companies who manufacture and market medicines for RA and/or JIA. This income amounted to £198.3k in 2021 (2020: £239.8k). As well as helping to fund the core services that we deliver to our beneficiaries, these relationships provide NRAS with access to important information about clinical trial data and help to inform and educate our team members on RA and JIA. NRAS is now perceived by most pharmaceutical companies working in the area of immunology and rheumatology as a key expert partner in contributing to advisory boards and employee training, as well as providing support in the development of their own patient-facing support resources. We have teamed up with some pharmaceutical companies in 2021 to deliver exciting projects into communities to help raise awareness of RA. In one such project, we partnered with AbbVie to begin a pilot on an enhanced version of our Right Start programme to demonstrate the impact and outcomes of the Right Start intervention not only on individual patients but the working practices of rheumatology health professionals.

Gifts from legacies are an important source of income for the Charity and we are immensely grateful to our very generous benefactors whose gifts in recent years have enabled us to secure the viability of the Charity and to continue to provide our services to those in need. We were very fortunate in 2021

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2021**

to benefit from a number of very generous bequests as a result of which our income in 2021 from such gifts raised £525.5k, accounting for 35% of our total income, up from £139.6k in 2020.

Support for NRAS was also received through grants from trusts and foundations and in 2021 this amounted to £208.4k, including £19.8k of furlough grants received from HMRC. We would like to express particular thanks to the following organisations who all donated over £2,000 each: Garfield Weston Foundation, The Rank Foundation, The National Lottery Community Lottery Fund, Children in Need, The February Foundation, Vandervell Foundation, The CM Lowe Charitable Foundation, C Brewer and Sons, The Willie and Mabel Morris Charitable Trust, The Lady Hind Trust, Joseph Strong Frazer Trust, Hospital Saturday Fund, Eveson Charitable Trust and HC Beer.

All income received through fundraising in 2021 contributed to enabling the Charity to provide a full programme of resources, activities and support, which benefits those living with RA and JIA in the UK, their families, schools and the healthcare professionals who care for them. NRAS would like to acknowledge and thank all the individuals, companies, trusts and foundations that have supported our work this year.

### **Financial Review**

The principal funding sources of income for the Charity were donations and legacies of £1,117.1k, grants of £208.4k and membership income of £81.7k. Overall, consolidated income in 2021 was £1,497.0k compared to £1,242.4k in 2020, representing an increase of 20%. This represents a commendable performance in a year overshadowed by the COVID-19 pandemic with all the associated curtailment of fundraising events and other restrictions on daily life.

Overall expenditure increased by 7% compared with the prior year largely driven by increasing staff costs and ever-increasingly complex IT and infrastructure requirements.

The Charity reported a consolidated net gain of £244.9k in 2021, compared with a net deficit of £46.0k in 2020.

The Charity's wholly owned trading subsidiary, NRAS Community Services Limited, provided some research support to a number of companies in 2021. The company delivered a profit of £4.8k on its activities.

### ***Reserves policy and going concern***

Our balance sheet remains strong with unrestricted reserves of £1,871.2k at the end of the year.

The Charity has established a reserves policy as part of its plans to ensure its long-term financial sustainability and its policy is to hold a minimum of six months' operating costs in cash and investments. Investments and cash balances as at 31 December 2021 were valued in aggregate at £1,455.1k and six months' operating costs amount to £679k, meaning that this target was comfortably met in 2021 and the charity had surplus 'free funds' of £776.1k.

The Charity will retain its policy of a conservative approach to its reserves which has served it well during these challenging times and we will ensure that we continue to retain at least six months' operating costs in cash and investments. We will work hard to ensure that our funds are used judiciously so that we return the biggest benefit to our beneficiaries for each pound invested. We will continue the expansion of our supported self-management suite of modules and broaden our digital offerings as well invest in campaigns to raise awareness of RA and JIA. It is likely that the Charity will need to use some of these surplus 'free funds' to enable it to continue to deliver its core services in 2022.

Our healthy cash balance and investment portfolio means that we have sufficient liquidity to ensure that we can meet our future obligations as they become due for the foreseeable future.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2021**

***Fundraising practices***

The charity complies with the regulatory standards for fundraising. We are registered with the Fundraising Regulator and are committed to the Fundraising Promise and adherence to the Code of Fundraising Practice. This report covers the requirements charities must follow as set out in the Charities Act 2016.

Our fundraising effort involves encouraging donations through a variety of events, applying for funds from grant-making bodies and operating a weekly lottery. Our fundraising team comprises paid employees only and we do not use the services of any professional fundraisers. All direct marketing is undertaken by the fundraising department to ensure that it is not unreasonably intrusive nor persistent. All marketing material contains clear instructions on how a person can be removed from mailing lists.

We operate our lottery compliantly under licence from our local authority and all administration is handled by a certified External Lottery Manager with the Gambling Commission.

Our website outlines our complaints policy for the public and clearly explains how an individual can complain. We received no complaints this year in relation to fundraising activities. We have published our vulnerable persons policy on our website. In addition to our policy we have an agreed operating procedure to protect vulnerable people. Our fundraisers, who are all paid employees, are familiarised with the code of conduct to ensure that it is applied properly.

***Investment Policy and Objectives***

Longer-term assets are invested with the aim of at least maintaining the real value of capital (i.e. against inflation) within an appropriate risk profile. The Charity's investment objectives are to invest for the long-term (five years plus) in a diversified portfolio ensuring that there is sufficient liquidity available to fund any shortfalls or unfunded commitments.

Investments are managed by external professional fund managers as permitted by the relevant acts and the charity commission guidelines. The Charity aims to be a responsible investor and its professional fund managers are expected to take account of Environmental, Social and Governance (ESG) issues in their investment analysis and decision-making process and to engage with trustees when appropriate, including the provision of periodic reports covering ESG issues.

Investment performance reports are received quarterly from the fund managers and the Trustees review performance annually with the fund managers.

***Future plans***

The Trustees approve and adopt strategic plans for the Charity every three years and detailed budgets are prepared annually to support these initiatives and demonstrate how the objectives will be delivered within the constraints of predicted funding available. The budget is reviewed on a quarterly basis and appropriate management decisions are taken in light of any material forecast variances.

The Charity's strategic plan for 2022-2025 was finalised in 2021 and set out that the Charity will continue to support and stand shoulder-to-shoulder with the entire rheumatology community working towards our vision of life without limits for all living with RA and JIA.

We will work collaboratively to remove barriers to being able to access the right treatment, at the right time in the right place, provided by the right professional. We will work to reduce discrimination within the workplace and the wider society towards people with inflammatory arthritis. We will also champion the best evidence-based healthcare provision no matter where in the UK someone lives and we will support all those who work within the health service to provide the best holistic care without being hampered by a system which prevents them from achieving this.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2021**

**Structure, governance and management**

***Governing document***

The Charity is controlled by its governing documents, the memorandum and articles, and constitutes a limited by guarantee company as defined by the Companies Act 2006.

The Charity is a company limited by guarantee and does not have any share capital. None of the Trustees has any beneficial interest in the company. All of the Trustees are members of the company and guarantee to contribute £1 each in the event of a winding up.

***Trustees***

The Trustees, who are also the directors for the purpose of company law, and who served during the year were:

Mr RA Boucher  
Mr S Collins (Chair)  
Mr S J Crowther (resigned 22 June 2021)  
Ms L Cook  
Mr R Flowerdew  
Mrs K Fox (resigned 15 September 2021)  
Mrs Z Ide (resigned 22 June 2021)  
Mr J D Jordan (Treasurer) (appointed 22 June 2021)  
Ms E Potter  
Dr G Taylor (resigning 7 June 2022)  
Ms S Webb

As set out in the articles (as amended in June 2019), Trustees are required to retire after three years in office. A retiring trustee shall be eligible for re-election. Mr S Collins and Mr R Boucher will therefore retire from office at the AGM on 7<sup>th</sup> June 2022 and will seek re-election.

***Trustee induction and training***

New Trustees undergo an orientation day to brief them on their legal obligations under Charity law, the content of the constitution and decision-making process, the business plan and recent financial performance of the Charity. As part of the process they meet key employees and other Trustees and may attend additional, relevant external training as required.

***Organisation***

The body of Trustees consists of not fewer than four and no more than twenty trustees and administers the Charity through the Senior Executives.

***Related parties and co-operation with other organisations***

None of our trustees receives remuneration or other benefit from their work with the charity. Any connection between a trustee or senior manager of the charity with a supplier or other party with which the Charity transacts must be disclosed to the full board of trustees. In the current year no such related party transactions were reported.

***Pay policy for senior staff***

Remuneration for key management personnel is benchmarked against the voluntary sector and is set by the Trustees. The pay of senior staff is reviewed annually and normally increased in accordance with average earnings.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2021**

***Risk management***

The trustees have a risk management strategy including a formal risk evaluation which is carried out each year.

The key risks are identified below:

- Adequacy of cash to run the Charity. Costs are monitored closely throughout the year. The Charity constantly monitors the cash position and future cash requirements. Fundraising strategy is developed with an emphasis on the provision of regular and predictable income streams. A minimum of 6 months of operating costs is targeted to be held in reserves as cash and realisable investments.
- Investment of surplus cash. Investments are managed by qualified external advisers with a view to maintaining an appropriate and prudent risk strategy for the Charity whilst retaining the real value of the capital.
- Reliance on key individuals. This is recognised and the senior management team work with staff to ensure teams are diverse as possible to reduce over reliance on any one individual. Key personnel have a three-month notice period. Succession planning is in place and is revised periodically to account for any senior staff movement.
- IT security. A support contract is in place with 3rd party IT experts covering all aspects of IT performance and security. Internal security is in place and monitored and updated where appropriate.
- Data protection. The charity carries out regular reviews to ensure that its policies and procedures are in line with regulations and best practice.
- Attracting and retaining Trustees. The Charity periodically reviews the number of Trustees to ensure that there is a minimum number of Trustees on the board with the right spread of skills and experience to meet the current and future needs of the Charity.

**Auditors**

In accordance with the company's articles, a resolution proposing that Moore Kingston Smith LLP be re-appointed as auditor of the company will be put at a General Meeting.

**Trustees' responsibilities in relation to the financial statements**

The Trustees, who are also the directors of National Rheumatoid Arthritis Society for the purpose of company law, are responsible for preparing the Trustees' Report and the accounts in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare accounts for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure of the charitable company for that year.

In preparing these accounts the Trustees are required to:

- Select suitable accounting policies and then apply them consistently;
- Observe the methods and principles in the Charities SORP (FRS 102);
- Make judgments and estimates that are reasonable and prudent;
- State whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- Prepare the accounts on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT)  
FOR THE YEAR ENDED 31 DECEMBER 2021**

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the accounts comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.


**Statement as to disclosure to our auditors**

In so far as the trustees are aware at the time of approving our Trustees' annual report:  
There is no relevant information, being information needed by the auditor in connection with preparing their report, of which the group's auditor is unaware, and  
The trustees, having made enquiries of fellow trustees and the group's auditor that they ought to have individually taken, have each taken all steps that he/ she is obliged to take as a trustee, in order to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions

S Collins  
Chair of Trustees

J Jordan  
Treasurer/ Trustee

A rectangular box containing a handwritten signature in black ink that reads "S. Collins".A handwritten signature in black ink that reads "Jordan".

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
INDEPENDENT AUDITOR'S REPORT  
TO THE MEMBERS AND TRUSTEES OF NATIONAL RHEUMATOID ARTHRITIS SOCIETY**

**Opinion**

We have audited the financial statements of National Rheumatoid Arthritis Society (the 'parent charitable company') and its subsidiary (the 'group') for the year ended 31 December 2021 which comprise the Consolidated Statement of Financial Activities, (including the Consolidated Summary Income and Expenditure Account), the Group and Parent Charitable Company Balance Sheets, the Consolidated Statement of Cash Flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the group's and the parent charitable company's affairs as at 31 December 2021 and of the group's incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 (as amended), regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011.

**Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

**Other information**

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained in the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
INDEPENDENT AUDITOR'S REPORT  
TO THE MEMBERS AND TRUSTEES OF NATIONAL RHEUMATOID ARTHRITIS SOCIETY**

inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

**Opinions on other matters prescribed by the Companies Act 2006**

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' annual report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the trustees' annual report has been prepared in accordance with applicable legal requirements.

**Matters on which we are required to report by exception**

In the light of the knowledge and understanding of the group and parent charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the trustees' annual report.

We have nothing to report in respect of the following matters where the Companies Act 2006, the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011 require us to report to you if, in our opinion:

- the parent charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent charitable company's financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made, or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies exemption in preparing the trustees' annual report and from preparing a strategic report.

**Responsibilities of trustees**

As explained more fully in the trustees' responsibilities statement set out on page 8, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the group and parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or parent charitable company or to cease operations, or have no realistic alternative but to do so.

**Auditor's Responsibilities for the audit of the financial statements**

We have been appointed as auditor under Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, the Companies Act 2006 and Section 151 of the Charities Act 2011 and report to you in accordance with regulations made under those Acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
INDEPENDENT AUDITOR'S REPORT  
TO THE MEMBERS AND TRUSTEES OF NATIONAL RHEUMATOID ARTHRITIS SOCIETY**

includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the group and parent charitable company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.
- Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the group and parent charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the group or parent charitable company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit report.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

**Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud**

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

The objectives of our audit in respect of fraud, are; to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud, through designing and implementing appropriate responses to those assessed risks; and to respond appropriately to instances

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
INDEPENDENT AUDITOR'S REPORT  
TO THE MEMBERS AND TRUSTEES OF NATIONAL RHEUMATOID ARTHRITIS SOCIETY**

of fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the charitable company.

Our approach was as follows:

- We obtained an understanding of the legal and regulatory requirements applicable to the charitable company and considered that the most significant are the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 (as amended), regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended), the Charities Act 2011, the Charity SORP, and UK financial reporting standards as issued by the Financial Reporting Council.
- We obtained an understanding of how the charitable company complies with these requirements by discussions with management and those charged with governance.
- We assessed the risk of material misstatement of the financial statements, including the risk of material misstatement due to fraud and how it might occur, by holding discussions with management and those charged with governance.
- We inquired of management and those charged with governance as to any known instances of non-compliance or suspected non-compliance with laws and regulations.
- Based on this understanding, we designed specific appropriate audit procedures to identify instances of non-compliance with laws and regulations. This included making enquiries of management and those charged with governance and obtaining additional corroborative evidence as required.

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

**Use of our report**

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006; and to the charity's trustees, as a body, in accordance with Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, and in respect of the consolidated financial statements, in accordance with Chapter 3 of Part 8 of the Charities Act 2011. Our audit work has been undertaken so that we might state to the charitable company's members and trustees those matters which we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to any party other than the charitable company, the charitable company's members, as a body, and the charity's trustees, as a body for our audit work, for this report, or for the opinion we have formed.

Luke Holt (Senior Statutory Auditor) *Moore Kingston Smith LLP* Date: 13 June 2022

for and on behalf of Moore Kingston Smith LLP, Statutory Auditor

The Shipping Building  
The Old Vinyl Factory  
Blyth Road  
Hayes, London  
UB3 1HA

Moore Kingston Smith LLP is eligible to act as auditor in terms of Section 1212 of the Companies Act 2006.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY**  
**CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES (Including Income and Expenditure Account)**  
**FOR THE YEAR ENDED 31 DECEMBER 2021**

		Unrestricted funds 2021	Restricted funds 2021	Total funds 2021	Unrestricted funds 2020	Restricted funds 2020	Total funds 2020
	Notes	£'000	£'000	£'000	£'000	£'000	£'000
<b>Income from:</b>							
Donations and legacies	3	1,117.1	0.0	1,117.1	791.3	47.0	838.3
Charitable activities	4	249.2	63.1	312.3	299.9	43.9	343.8
Other trading activities	5	42.1	0.0	42.1	37.1	0.0	37.1
Investment income	6	25.5	0.0	25.5	23.2	0.0	23.2
<b>Total income</b>		<b>1,433.9</b>	<b>63.1</b>	<b>1,497.0</b>	<b>1,151.5</b>	<b>90.9</b>	<b>1,242.4</b>
<b>Expenditure on:</b>							
Raising funds	7	320.5	0.0	320.5	246.6	0.0	246.6
Charitable activities	8	936.2	123.2	1,059.4	895.3	146.4	1,041.7
<b>Total resources expended</b>		<b>1,256.7</b>	<b>123.2</b>	<b>1,379.9</b>	<b>1,141.9</b>	<b>146.4</b>	<b>1,288.3</b>
Net income/(expenditure) before investments		177.2	(60.1)	117.1	9.6	(55.5)	(45.9)
Net gains/(losses) on investments	12	127.8	0.0	127.8	(0.1)	0.0	(0.1)
Gross transfers between funds		0.0	0.0	0.0	0.0	0.0	0.0
<b>Net movement in funds</b>		<b>305.0</b>	<b>(60.1)</b>	<b>244.9</b>	<b>9.5</b>	<b>(55.5)</b>	<b>(46.0)</b>
Fund balances at 1 January 2021		1,600.4	56.8	1,657.2	1,670.4	32.8	1,703.2
Transfer between funds		(34.2)	34.2	0.0	(79.5)	79.5	0.0
<b>Fund balances at 31 December 2021</b>		<b>1,871.2</b>	<b>30.9</b>	<b>1,902.1</b>	<b>1,600.4</b>	<b>56.8</b>	<b>1,657.2</b>

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

The notes at pages 18 to 32 form part of these accounts.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY**  
**COMPANY STATEMENT OF FINANCIAL ACTIVITIES (Including Income and Expenditure Account)**  
**FOR THE YEAR ENDED 31 DECEMBER 2021**

		Unrestricted	Restricted	Total	Unrestricted	Restricted	Total
		funds	funds	funds	funds	funds	funds
		2021	2021	2021	2020	2020	2020
	Notes	£'000	£'000	£'000	£'000	£'000	£'000
<b>Income from:</b>							
Donations and legacies	3	1,118.6	0.0	1,118.6	797.6	47.0	844.6
Charitable activities	4	249.2	63.1	312.3	299.9	43.9	343.8
Other trading activities	5	34.5	0.0	34.5	30.9	0.0	30.9
Investment income	6	25.5	0.0	25.5	23.2	0.0	23.2
<b>Total income</b>		<b>1,427.8</b>	<b>63.1</b>	<b>1,490.9</b>	<b>1,151.6</b>	<b>90.9</b>	<b>1,242.5</b>
<b>Expenditure on:</b>							
Raising funds	7	320.5	0.0	320.5	246.6	0.0	246.6
Charitable activities	8	933.3	123.2	1,056.5	890.7	146.4	1,037.1
<b>Total resources expended</b>		<b>1,253.8</b>	<b>123.2</b>	<b>1,377.0</b>	<b>1,137.3</b>	<b>146.4</b>	<b>1,283.7</b>
Net income/(expenditure) before investments		174.0	(60.1)	113.9	14.3	(55.5)	(41.2)
Net gains/(losses) on investments	12	127.8	0.0	127.8	(0.1)	0.0	(0.1)
Gross transfers between funds		0.0	0.0	0.0	0.0	0.0	0.0
<b>Net movement in funds</b>		<b>301.8</b>	<b>(60.1)</b>	<b>241.7</b>	<b>14.2</b>	<b>(55.5)</b>	<b>(41.3)</b>
Fund balances at 1 January		1,598.8	56.8	1,655.6	1,664.1	32.8	1,696.9
Transfer between funds		(34.2)	34.2	0.0	(79.5)	79.5	0.0
<b>Fund balances at 31 December</b>		<b>1,866.4</b>	<b>30.9</b>	<b>1,897.3</b>	<b>1,598.8</b>	<b>56.8</b>	<b>1,655.6</b>

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

The notes at pages 18 to 32 form part of these accounts.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
CONSOLIDATED AND CHARITY BALANCE SHEETS  
FOR THE YEAR ENDED 31 DECEMBER 2021**

	Notes	Group		Charity	
		2021	2020	2021	2020
		£'000	£'000	£'000	£'000
		As restated		As restated	
<b>Fixed assets</b>					
Intangible assets	13	93.3	98.0	93.3	98.0
Tangible assets	13	24.1	22.7	24.1	22.7
Investments	14	1,025.6	871.9	1,025.6	871.9
		<b>1,143.0</b>	<b>992.6</b>	<b>1,143.0</b>	<b>992.6</b>
<b>Current assets</b>					
Debtors	16	444.0	114.7	450.2	120.9
Cash at bank and in hand		429.5	748.3	415.5	732.7
		<b>873.5</b>	<b>863.0</b>	<b>865.7</b>	<b>853.6</b>
<b>Liabilities:</b>					
Creditors: amounts falling due within one year	17	(114.4)	(198.4)	(111.4)	(190.6)
		<b>759.1</b>	<b>664.6</b>	<b>754.3</b>	<b>663.0</b>
<b>Net current assets</b>					
		<b>1,902.1</b>	<b>1,657.2</b>	<b>1,897.3</b>	<b>1,655.6</b>
<b>Total assets less current liabilities</b>					
<b>Income funds</b>					
Unrestricted funds	19	1,871.2	1,600.4	1,866.4	1,598.8
Restricted funds	19	30.9	56.8	30.9	56.8
		<b>1,902.1</b>	<b>1,657.2</b>	<b>1,897.3</b>	<b>1,655.6</b>

The Trustees have prepared group accounts in accordance with section 398 of the Companies Act 2006 and section 138 of the Charities Act 2011 and constitute the annual accounts required by the Companies Act 2006 and are for circulation to trustees of the company.

These accounts are prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 and are for circulation to the members of the company.

The parent charity Income was £1,489.4k in 2021 (2020: £1,236.3k) and its surplus for the year was £240.2k (2020: deficit of £47.5k).

The notes at pages 18 to 32 form part of these accounts.

The accounts were approved by the Board of Trustees on 7th June 2022



J Jordan  
Treasurer/Trustee

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
CONSOLIDATED STATEMENT OF CASH FLOWS  
FOR THE YEAR ENDED 31 DECEMBER 2021**

	Notes	Group		Charity	
		2021 £'000	2020 £'000	2021 £'000	2020 £'000
<b>Cash flows from operating activities</b>					
Cash (used in)/ generated from operations	25	(282.9)	474.4	(282.8)	493.1
<b>Investing activities</b>					
Purchase of intangible fixed assets		(24.7)	(66.5)	(24.7)	(66.5)
Purchase of tangible fixed assets		(10.8)	(6.1)	(10.8)	(6.1)
Purchase of investments		(25.9)	(73.2)	(25.9)	(73.2)
Interest received		25.5	23.2	25.5	23.2
Gift aid donation from subsidiary		0.0	0.0	1.5	6.2
<b>Net cash used in investing activities</b>		<u>(35.9)</u>	<u>(122.6)</u>	<u>(34.4)</u>	<u>(116.4)</u>
<b>Net increase/(decrease) in cash and cash equivalents</b>		<u>(318.8)</u>	<u>351.8</u>	<u>(317.2)</u>	<u>376.7</u>
Cash and cash equivalents at beginning of year		748.3	396.5	732.7	356.0
<b>Cash and cash equivalents at end of year</b>		<u><b>429.5</b></u>	<u><b>748.3</b></u>	<u><b>415.5</b></u>	<u><b>732.7</b></u>

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2021**

**1 Accounting policies**

**Charity information**

National Rheumatoid Arthritis Society is a private company limited by guarantee incorporated in England and Wales and Scotland. The registered office is Ground Floor, 4 Switchback, Gardner Road, Maidenhead, Berks, SL6 7RJ.

**1.1 Accounting convention**

These accounts have been prepared in accordance with the charity's governing document, the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102.

The accounts are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £,000.

The accounts have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include listed investments and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

**Preparation of consolidated financial statements**

These consolidated financial statements incorporate the financial statements of the Charity and its subsidiary undertaking, NRAS Community Services Limited, made up to 31 December 2021. Intercompany transactions, balances and unrealised gains on transactions between the Charity and its subsidiary are eliminated. Accounting policies of subsidiary undertakings have been changed where necessary to ensure consistency with the policies adopted by the Group. The income of the trading subsidiary is included in the Consolidated Statement of Financial Activities within other trading activities. Expenditure is included in wages and support costs.

**1.2 Going concern**

At the time of approving the accounts, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. This expectation is based on the strong investments and cash position, reflecting a significant amount of unrestricted funds and the financial performance of the Charity. Thus the Trustees' continue to adopt the going concern basis of accounting in preparing the accounts.

**1.3 Charitable funds**

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The cost of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

**1.4 Incoming resources**

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

**1 Accounting policies**

**(Continued)**

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is probable. If the amount is not known, the legacy is treated as a contingent asset.

The charity receives grants in respect of charitable activities run by the charity. Income from grants are recognised at fair value when the charity has entitlement after any performance conditions have been met, it is probable that the income will be received and the amount can be measured reliably.

Income from trading activities includes income earned from fundraising events and trading activities to raise funds for the charity. Income is received in exchange for supplying goods and services in order to raise funds and is recognised when entitlement has occurred.

Subscription income is recognised on a rolling basis from the date of membership.

Income is measured at the fair value of the consideration received or receivable and represents amounts receivable for services provided in the normal course of business, net of discounts, VAT and other sales related taxes.

**1.5 Resources expended**

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Expenditure is recognised where there is a legal or constructive obligation to make payments to third parties, it is probable that the settlement will be required and the amount of the obligation can be measured reliably. It is categorised under the following headings:

Costs of raising funds includes costs related to fundraising events, merchandising and advertising;

Expenditure on charitable activities includes staff costs and support costs relating to different projects conducted during the year (see note 8).

Irrecoverable VAT is charged as an expense against the activity for which expenditure arose.

**Support costs allocation**

Support costs include both direct expenditure incurred on charitable activities and those costs which assist the work of the charity including office and administrative costs. They are all incurred directly in the furthering of the charity's aims and purposes. Distinction has been made for those costs relating to the raising of funds and to governance, these costs have been analysed separately.

Fundraising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities.

The bases on which support costs have been allocated are set out in Note 9.

Fundraising costs are specified in Note 7.

Governance costs are specified in Note 9.

Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to that category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

**1 Accounting policies**

(Continued)

**1.6 Intangible and tangible fixed assets and depreciation**

Intangible and tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Improvements to property	20% straight line or lease period if shorter
Website development	25% straight line
Fixtures, fittings & equipment	25% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in net income/(expenditure) for the year.

**1.7 Impairment of fixed assets**

At each reporting end date, the charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

**1.8 Cash and cash equivalents**

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

**1.9 Financial instruments**

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

**Basic financial assets**

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

**1 Accounting policies**

(Continued)

***Basic financial liabilities***

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future receipts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

***Derecognition of financial liabilities***

Financial liabilities are derecognised when the Charity's contractual obligations expire or are discharged or cancelled.

**1.10 Fixed asset investments**

Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year. Transaction costs are expensed as incurred.

**1.11 Employee benefits**

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employments of an employee or to provide termination benefits.

**1.12 Leases**

Rentals payable under operating leases, including any lease incentives received, are charged to income on a straight line basis over the term of the relevant lease.

**2 Critical accounting estimates and judgements**

In the application of the charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2021

**3 Donations and legacies**

	Group		Charity	
	2021	2020	2021	2020
	£'000	£'000	£'000	£'000
Donations and gifts	591.6	698.7	593.1	705.0
Legacies receivable	525.5	139.6	525.5	139.6
	<u>1,117.1</u>	<u>838.3</u>	<u>1,118.6</u>	<u>844.6</u>
<i>Analysis by fund</i>				
Restricted funds	0.0	47.0	0.0	47.0
Unrestricted funds	1,117.1	791.3	1,118.6	797.6
	<u>1,117.1</u>	<u>838.3</u>	<u>1,118.6</u>	<u>844.6</u>

**4 Income from charitable activities**

	Group		Charity	
	2021	2020	2021	2020
	£'000	£'000	£'000	£'000
Subscriptions	81.7	86.1	81.7	86.1
Lottery income	22.2	17.2	22.2	17.2
Grants	208.4	240.5	208.4	240.5
	<u>312.3</u>	<u>343.8</u>	<u>312.3</u>	<u>343.8</u>
<i>Analysis by fund</i>				
Restricted funds	63.1	43.9	63.1	43.9
Unrestricted funds	249.2	299.9	249.2	299.9
	<u>312.3</u>	<u>343.8</u>	<u>312.3</u>	<u>343.8</u>

**5 Other trading activities**

	Group		Charity	
	2021	2020	2021	2020
	£'000	£'000	£'000	£'000
Merchandising and other trading income	34.5	30.9	34.5	30.9
Trading subsidiary income	7.6	6.2	0.0	0.0
	<u>42.1</u>	<u>37.1</u>	<u>34.5</u>	<u>30.9</u>

**6 Investments**

	Group		Charity	
	2021	2020	2021	2020
	£'000	£'000	£'000	£'000
Income from listed investments	25.5	23.1	25.5	23.1
Interest receivable	0.0	0.1	0.0	0.1
	<u>25.5</u>	<u>23.2</u>	<u>25.5</u>	<u>23.2</u>

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY**  
**NOTES TO THE ACCOUNTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2021**

**7 Expenditure on raising funds**

	Group and Charity	
	2021	2020
	£'000	£'000
Staging fundraising events	43.7	20.1
Staff costs	201.9	168.8
Support costs	64.1	48.5
Governance costs	10.8	9.2
Expenditure on raising funds	<b>320.5</b>	<b>246.6</b>
<i>Analysis by fund</i>		
Restricted funds	<b>0.0</b>	<b>0.0</b>
Unrestricted funds	<b>320.5</b>	<b>246.6</b>
	<b>320.5</b>	<b>246.6</b>

**8 Expenditure on charitable activities**

Group	Provision of info & support	Digital innovations	Raising awareness	Community support	Supporting our young people	Total
	2021	2021	2021	2021	2021	2021
	£'000	£'000	£'000	£'000	£'000	£'000
Direct costs	31.8	38.3	21.2	0.0	17.0	108.3
Staff costs	233.5	42.5	219.6	143.6	50.1	689.3
Share of support costs (see note 9)	64.1	0.0	64.1	64.0	32.0	224.2
Share of governance costs (see note 9)	10.8	0.0	10.7	10.7	5.4	37.6
	<b>340.2</b>	<b>80.8</b>	<b>315.6</b>	<b>218.3</b>	<b>104.5</b>	<b>1,059.4</b>
<i>Analysis by fund</i>						
Restricted funds	21.3	80.8	8.9	0.0	12.2	123.2
Unrestricted funds	318.9	0.0	306.7	218.3	92.3	936.2
	<b>340.2</b>	<b>80.8</b>	<b>315.6</b>	<b>218.3</b>	<b>104.5</b>	<b>1,059.4</b>

Group	Provision of info & support	Digital innovations	Raising awareness	Community support	Supporting our young people	Total
	2020	2020	2020	2020	2020	2020
	£'000	£'000	£'000	£'000	£'000	£'000
Direct costs	34.6	73.4	35.4	0.3	7.4	151.1
Staff costs	222.8	38.7	228.2	78.2	83.6	651.5
Share of support costs (see note 9)	75.3	8.5	65.4	25.6	26.3	201.1
Share of governance costs (see note 9)	14.2	1.6	12.4	4.8	5.0	38.0
	<b>346.9</b>	<b>122.2</b>	<b>341.4</b>	<b>108.9</b>	<b>122.3</b>	<b>1,041.7</b>
<i>Analysis by fund</i>						
Restricted funds	1.1	122.2	23.1	0.0	0.0	146.4
Unrestricted funds	345.8	0.0	318.3	108.9	122.3	895.3
	<b>346.9</b>	<b>122.2</b>	<b>341.4</b>	<b>108.9</b>	<b>122.3</b>	<b>1,041.7</b>

## 8 Expenditure on charitable activities

Charity	Provision of info & support	Digital innovations	Raising awareness	Community support	Supporting our young people	Total
	2021	2021	2021	2021	2021	2021
	£'000	£'000	£'000	£'000	£'000	£'000
Direct costs	31.8	38.3	21.2	0.0	17.0	108.3
Staff costs	233.5	42.5	219.6	143.6	50.1	689.3
Share of support costs (see note 9)	64.7	0.0	64.1	64.0	32.0	224.8
Share of governance costs (see note 9)	7.3	0.0	10.7	10.7	5.4	34.1
	<b>337.3</b>	<b>80.8</b>	<b>315.6</b>	<b>218.3</b>	<b>104.5</b>	<b>1,056.5</b>
<b>Analysis by fund</b>						
Restricted funds	21.3	80.8	8.9	0.0	12.2	123.2
Unrestricted funds	316.0	0.0	306.7	218.3	92.3	933.3
	<b>337.3</b>	<b>80.8</b>	<b>315.6</b>	<b>218.3</b>	<b>104.5</b>	<b>1,056.5</b>

Charity	Provision of info & support	Digital innovations	Raising awareness	Community support	Supporting our young people	Total
	2020	2020	2020	2020	2020	2020
	£'000	£'000	£'000	£'000	£'000	£'000
Direct costs	34.6	73.4	35.4	0.3	7.4	151.1
Staff costs	222.8	38.7	228.2	78.2	83.6	651.5
Share of support costs (see note 9)	75.3	8.5	65.4	25.6	26.3	201.1
Share of governance costs (see note 9)	9.6	1.6	12.4	4.8	5.0	33.4
	<b>342.3</b>	<b>122.2</b>	<b>341.4</b>	<b>108.9</b>	<b>122.3</b>	<b>1,037.1</b>
<b>Analysis by fund</b>						
Restricted funds	1.1	122.2	23.1	0.0	0.0	146.4
Unrestricted funds	341.2	0.0	318.3	108.9	122.3	890.7
	<b>342.3</b>	<b>122.2</b>	<b>341.4</b>	<b>108.9</b>	<b>122.3</b>	<b>1,037.1</b>

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY**  
**NOTES TO THE ACCOUNTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2021**

**9 Support costs**

Group	Support costs	Governance costs	Total	Support costs	Governance costs	Total
	2021	2021	2021	2020	2020	2020
	£'000	£'000	£'000	£'000	£'000	£'000
Staff costs		23.5	23.5		23.6	23.6
IT	79.5		79.5	59.1		59.1
Office	116.6		116.6	121.8		121.8
Other overheads	53.4		53.4	49.8		49.8
Depreciation & dilapidations	38.8		38.8	18.9		18.9
Insurance		5.4	5.4		5.8	5.8
Professional fees			0.0		0.0	0.0
Auditors' remuneration:			0.0			0.0
Audit fees		12.0	12.0		13.0	13.0
Other services		7.5	7.5		4.8	4.8
Trustee expenses			0.0			0.0
	<b>288.3</b>	<b>48.4</b>	<b>336.7</b>	<b>249.6</b>	<b>47.2</b>	<b>296.8</b>
Analysed between						
Fundraising (note 7)	64.1	10.8	74.9	48.5	9.2	57.7
Charitable activities (note 8)	224.2	37.6	261.8	201.1	38.0	239.1
	<b>288.3</b>	<b>48.4</b>	<b>336.7</b>	<b>249.6</b>	<b>47.2</b>	<b>296.8</b>

The above costs were allocated on a headcount basis.

Charity	Support costs	Governance costs	Total	Support costs	Governance costs	Total
	2021	2021	2021	2020	2020	2020
	£'000	£'000	£'000	£'000	£'000	£'000
Staff costs		23.5	23.5		23.6	23.6
IT	79.5		79.5	59.1		59.1
Office	116.6		116.6	121.8		121.8
Other overheads	54.1		54.1	49.8		49.8
Depreciation & dilapidations	38.8		38.8	18.9		18.9
Insurance		5.4	5.4		5.8	5.8
Professional fees			0.0			0.0
Auditors' remuneration:			0.0			0.0
Audit fees		8.5	8.5		8.4	8.4
Other services		4.8	4.8		4.8	4.8
Trustee expenses			0.0			0.0
	<b>289.0</b>	<b>42.2</b>	<b>331.2</b>	<b>249.6</b>	<b>42.6</b>	<b>292.2</b>
Analysed between						
Fundraising (note 7)	64.1	10.8	74.9	48.5	9.2	57.7
Charitable activities (note 8)	224.8	34.1	258.9	201.1	33.4	234.5
	<b>288.9</b>	<b>44.9</b>	<b>333.8</b>	<b>249.6</b>	<b>42.6</b>	<b>292.2</b>

The above costs were allocated on a headcount basis.

**10 Trustees**

None of the Trustees (nor any persons connected with them) received any remuneration during the year, and they were reimbursed a total of £nil travelling expenses (2020: £nil).

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY**  
**NOTES TO THE ACCOUNTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2021**

**11 Employees**

**Number of employees**

	<b>2021</b>	<b>2020</b>
	<b>Number</b>	<b>Number</b>
The average monthly number of employees during the year was:		
All employees - Group and Charity	32	28
The average monthly number of full-time equivalent employees during the year was:		
All employees - Group and Charity	24	23

**Employment costs**

	<b>Group</b>		<b>Charity</b>	
	<b>2021</b>	<b>2020</b>	<b>2021</b>	<b>2020</b>
	<b>£'000</b>	<b>£'000</b>	<b>£'000</b>	<b>£'000</b>
Wages and salaries	829.3	761.5	829.3	761.5
Social security	69.1	66.9	69.1	66.9
Pension costs	16.3	15.5	16.3	15.5
	<u>914.7</u>	<u>843.9</u>	<u>914.7</u>	<u>843.9</u>

The total amount of redundancy payments made by the Company in the year was £10,000 (2020: £nil).

The number of employees who received total employee benefits (excluding employer pension costs) of more than £60,000 is as follows:

	<b>2021</b>	<b>2020</b>
	<b>Number</b>	<b>Number</b>
£60,001 - £70,000	1	1

**Remuneration of key management personnel**

The remuneration of key management personnel is as follows:

	<b>2021</b>	<b>2020</b>
	<b>£'000</b>	<b>£'000</b>
Aggregate Compensation	223.8	214.5

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2021

12 Net gains/(losses) on investments

	2021	2020
	£'000	£'000
Revaluation of investments	127.8	(0.1)

13 Tangible and intangible fixed assets - Group and Charity

	Intangible assets	Tangible assets		Total tangible assets £'000
	Website development £'000	Improvements to property £'000	Fixtures, fittings & equipment £'000	
<b>Cost</b>				
At 31 December 2020	274.2	61.7	130.1	191.8
Additions	24.7	0.0	10.8	10.8
<b>At 31 December 2021</b>	<b>298.9</b>	<b>61.7</b>	<b>140.9</b>	<b>202.6</b>
<b>Depreciation</b>				
At 31 December 2020	176.2	59.0	110.1	169.1
Charge for the year	29.4	0.7	8.7	9.4
<b>At 31 December 2021</b>	<b>205.6</b>	<b>59.7</b>	<b>118.8</b>	<b>178.5</b>
<b>Carrying amount</b>				
At 31 Decemeber 2021	93.3	2.0	22.1	24.1
At 31 December 2020	98.0	2.7	20.0	22.7

The comparatives for 2020 have been restated to reflect the website development costs as intangible assets.

14 Fixed asset investments - Group and Charity

	2021	2020
	£'000	£'000
Listed investments		
Market value at 1 January	871.9	798.8
Additions (including interest reinvested)	25.9	73.2
Revaluation	127.8	(0.1)
<b>Market value at 31 December</b>	<b>1,025.6</b>	<b>871.9</b>

15 Financial instruments

	2021	2020
	£'000	£'000
<b>Carrying amount of financial assets</b>		
Instruments measured at amortised cost	398.6	70.6
Instruments measured at fair value through profit or loss	1,025.6	871.9
<b>Carrying amount of financial liabilities</b>		
Measured at amortised cost	95.9	179.3

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY**  
**NOTES TO THE ACCOUNTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2021**

**16 Debtors**

	Group		Charity	
	2021 £'000	2020 £'000	2021 £'000	2020 £'000
<b>Amounts falling due within one year:</b>				
Trade debtors	85.6	14.3	85.6	14.3
Amounts owed by group undertakings	0.0	0.0	6.2	6.2
Other debtors	313.0	56.3	313.0	56.3
Prepayments and accrued income	45.4	44.1	45.4	44.1
	<b>444.0</b>	<b>114.7</b>	<b>450.2</b>	<b>120.9</b>

**17 Creditors: amounts falling due within one year**

	Group		Charity	
	2021 £'000	2020 £'000	2021 £'000	2020 £'000
Trade creditors	9.2	51.9	9.2	51.9
Other taxes and social security costs	18.5	19.1	18.5	19.1
Other creditors	17.7	22.6	14.7	17.8
Accruals and deferred income	69.0	104.8	69.0	101.8
	<b>114.4</b>	<b>198.4</b>	<b>111.4</b>	<b>190.6</b>

	2021 £'000	2020 £'000
Deferred income included in the financial statements as follows:		
At 1 January	41.1	0.0
Movement during the year	(41.1)	41.1
At 31 December	<b>0.0</b>	<b>41.1</b>

Income was deferred in 2020 in relation to grants received which related to services that were delivered in 2021.

**18 Retirement benefit schemes**

**Defined contribution schemes**

The Charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the Charity in an independently administered fund.

The charge to profit or loss in respect of defined contribution schemes was £16.3k (2020: £15.5k).

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2021

19 Fund reconciliation

The income funds of the Charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

Unrestricted Funds

	Movement in funds				Balance at 31 December 2021 £'000
	Balance at 1 January 2021	Incoming resources 2021	Resources expended 2021	Transfer of funds 2021	
	£'000	£'000	£'000	£'000	
Unrestricted	1,600.4	1,386.4	(1,036.6)	(79.0)	1,871.2
Designated - Juvenile Idiopathic Arthritis activities	0.0	47.5	(92.3)	44.8	0.0
	<b>1,600.4</b>	<b>1,433.9</b>	<b>(1,128.9)</b>	<b>(34.2)</b>	<b>1,871.2</b>

	Movement in funds				Balance at 31 December 2020 £'000
	Balance at 1 January 2020	Incoming resources 2020	Resources expended 2020	Transfer of funds 2020	
	£'000	£'000	£'000	£'000	
Unrestricted	1,670.4	1,095.5	(1,019.7)	(145.8)	1,600.4
Designated - Juvenile Idiopathic Arthritis activities	0.0	56.0	(122.3)	66.3	0.0
	<b>1,670.4</b>	<b>1,151.5</b>	<b>(1,142.0)</b>	<b>(79.5)</b>	<b>1,600.4</b>

Restricted Funds

	Movement in funds				Balance at 31 December 2021 £'000
	Balance at 1 January 2021	Incoming resources 2021	Resources expended 2021	Transfer of funds 2021	
	£'000	£'000	£'000	£'000	
Development of elearning suite	0.0	15.0	(44.9)	29.9	0.0
Development of online self-management course in Scotland	12.2	0.0	(13.9)	1.8	0.1
Re-development of DAS app	11.3	0.0	(11.6)	0.3	(0.0)
JIA publications	10.5	0.0	(12.2)	1.7	0.0
Information video in Hindi	5.0	0.0	(3.5)		1.5
Blood Monitoring publication	8.9	0.0	(3.7)		5.2
Community pharmacy engagement	8.9	0.0	(8.9)		0.0
Development of exercise support app	0.0	6.3	(6.8)	0.5	0.0
Enhanced Right Start	0.0	31.8	(17.7)		14.1
JIA Imagine Futures project	0.0	10.0	0.0	0.0	10.0
	<b>56.8</b>	<b>63.1</b>	<b>(123.2)</b>	<b>34.2</b>	<b>30.9</b>

	Movement in funds				Balance at 31 December 2020 £'000
	Balance at 1 January 2020	Incoming resources 2020	Resources expended 2020	Transfer of funds 2020	
	£'000	£'000	£'000	£'000	
Development of elearning suite	2.8	15.0	(97.3)	79.5	0.0
Development of online self-management course in Scotland	9.7	19.4	(16.9)	0.0	12.2
Re-development of DAS app	19.3	0.0	(8.0)	0.0	11.3
JIA publications	0.0	9.5	0.0	0.0	9.5
JIA family support day	1.0	0.0	0.0	0.0	1.0
Information video in Hindi	0.0	5.0	0.0	0.0	5.0
Blood Monitoring publication	0.0	10.0	(1.1)	0.0	8.9
Community pharmacy engagement	0.0	32.0	(23.1)	0.0	8.9
	<b>32.8</b>	<b>90.9</b>	<b>(146.4)</b>	<b>79.5</b>	<b>56.8</b>

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY**  
**NOTES TO THE ACCOUNTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2021**

**20 Analysis of net assets between funds - Group**

	Restricted £'000	Unrestricted £'000	Total £'000
<b>Fund balances at 31 December 2021 are represented by:</b>			
Tangible fixed assets	0.0	24.1	24.1
Investments	0.0	1,025.6	1,025.6
Current assets/(liabilities)	30.9	821.5	852.4
	<b>30.9</b>	<b>1,871.2</b>	<b>1,902.1</b>

**Fund balances at 31 December 2020 are represented by:**

	Restricted £'000	Unrestricted £'000	Total £'000
Tangible fixed assets	0.0	120.7	120.7
Investments	0.0	871.9	871.9
Current assets/(liabilities)	56.8	607.8	664.6
	<b>56.8</b>	<b>1,600.4</b>	<b>1,657.2</b>

**Analysis of net assets between funds - Charity**

	Restricted £'000	Unrestricted £'000	Total £'000
<b>Fund balances at 31 December 2021 are represented by:</b>			
Tangible fixed assets	0.0	24.1	24.1
Investments	0.0	1,025.6	1,025.6
Current assets/(liabilities)	30.9	816.7	847.6
	<b>30.9</b>	<b>1,866.4</b>	<b>1,897.3</b>

**Fund balances at 31 December 2020 are represented by:**

	Restricted £'000	Unrestricted £'000	Total £'000
Tangible fixed assets	0.0	120.7	120.7
Investments	0.0	871.9	871.9
Current assets/(liabilities)	56.8	606.2	663.0
	<b>56.8</b>	<b>1,598.8</b>	<b>1,655.6</b>

**21 Commitments under operating leases**

At the reporting end date the group and charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	2021 £'000	2020 £'000
Within one year	81.2	101.7
Between two and five years	16.9	116.2
Over five years	0.0	2.9
	<b>98.1</b>	<b>220.8</b>

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY**  
**NOTES TO THE ACCOUNTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2021**

**22 Subsidiary company**

The charity owns the whole of the issued ordinary share capital of NRAS Community Services Ltd (company number: 8953247), a company registered in England. The subsidiary is used for non-primary purpose trading activities. All activities have been consolidated on a line by line basis in the Statement of financial activities.

The total net profit is gifted to the charity.

A summary of the results of the subsidiary is shown below:

	<b>2021</b>	<b>2020</b>
	<b>£'000</b>	<b>£'000</b>
Turnover	7.6	6.1
Cost of sales	0.0	0.0
Gross profit	<u>7.6</u>	<u>6.1</u>
Administrative expenses	(2.8)	(4.6)
Net profit	<u><b>4.8</b></u>	<u><b>1.5</b></u>
Retained earnings brought forward in subsidiary	1.5	6.2
Gift aid to National Rheumatoid Arthritis Society	(1.5)	(6.2)
Retained earnings carried forward in subsidiary	<u><b>4.8</b></u>	<u><b>1.5</b></u>
The assets and liabilities were:		
The aggregate of the assets, liabilities and funds was:		
Assets	14.0	15.6
Liabilities	<u>(9.2)</u>	<u>(14.1)</u>
Total net assets	<u><b>4.8</b></u>	<u><b>1.5</b></u>
Called up share capital	0.0	0.0
Profit and loss reserve	<u>4.8</u>	<u>1.5</u>
	<u><b>4.8</b></u>	<u><b>1.5</b></u>

**23 Related party transactions**

There were no related party transactions in the year (2020: nil) requiring disclosure.

**24 Capital Commitments**

As at 31 December 2021 the Charity had capital commitments of £nil (2020: £nil).

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY**  
**NOTES TO THE ACCOUNTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2021**

25 Cash (used in)/ generated from operations	Group		Charity	
	2021 £'000	2020 £'000	2021 £'000	2020 £'000
(Loss)/ Surplus for the year	244.9	(46.0)	241.7	(41.3)
Adjustments for:				
Investment income recognised in profit or loss	(25.5)	(23.2)	(25.5)	(23.2)
Fair value gains and losses on investments	(127.8)	0.1	(127.8)	0.1
Gift aid donation from subsidiary			(1.5)	(6.2)
Depreciation and impairment of intangible fixed asset	29.4	12.0	29.4	12.0
Depreciation and impairment of tangible fixed assets	9.4	6.9	9.4	6.9
Movements in working capital:				
(Increase)/ decrease in debtors	(329.3)	504.6	(329.3)	529.5
Increase/ (decrease) in creditors	(84.0)	20.0	(79.2)	15.3
<b>Cash (used in)/ generated from operations</b>	<b>(282.9)</b>	<b>474.4</b>	<b>(282.8)</b>	<b>493.1</b>

**26 Analysis of changes in net funds**

	At start of year £'000	Cash flows £'000	At end of year £'000
Cash	748.3	(318.8)	429.5
<b>Total</b>	<b>748.3</b>	<b>(318.8)</b>	<b>429.5</b>

**THE NATIONAL RHEUMATOID ARTHRITIS SOCIETY**

England & Wales - Charity number 1134859

---

# Accounts

---

Charity Registration No. 1134859/SC039721

Company Registration No. 07127101 (England and Wales)

**REPORT OF THE TRUSTEES AND  
AUDITED CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2020  
FOR  
NATIONAL RHEUMATOID ARTHRITIS SOCIETY**



**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
LEGAL AND ADMINISTRATIVE INFORMATION**

**Trustees**

Mr S J Crowther  
Ms K J Fox  
Dr G Taylor  
Ms Z C Ide  
Mr R A Boucher  
Mr S Collins  
Mr R Flowerdew  
Miss S Webb  
Miss E Potter  
Miss L Cook

**CEO**

Mrs C Jacklin

**Charity number**

1134859/ SC039721

**Company number**

07127101

**Registered office**

Ground Floor  
4 The Switchback  
Gardner Road  
Maidenhead  
Berks  
SL6 7RJ

**Auditors**

Moore Kingston Smith LLP  
The Shipping Building  
The Old Vinyl Factory  
Blyth Road  
Hayes  
UB3 1HA

**Bankers**

HSBC  
35 High Street  
Maidenhead  
SL6 1JQ



**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
CONTENTS**

	<b>Page</b>
Trustees' report	1-10
Statement of Trustees' responsibilities	10
Statement as to disclosure to our auditors	11
Independent auditors' report	12 - 16
Consolidated Statement of financial activities	17
Company Statement of financial activities	18
Consolidated and Company Balance Sheets	19
Consolidated Statement of Cash Flows	20
Notes to the accounts	21-35



# **NATIONAL RHEUMATOID ARTHRITIS SOCIETY TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) FOR THE YEAR ENDED 31 DECEMBER 2020**

The Trustees present their report and audited consolidated accounts for the year ended 31 December 2020. The Trustees have adopted the provisions of the Statement of Recommended Practice (SORP) "Accounting and Reporting by Charities" (FRS 102) in preparing the annual report and financial statements of the Charity.

The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the Charity's governing document, the Charities Act 2011, the Companies Act 2006 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015)."

## **Chair's Report**

When my predecessor presented his valedictory Chair's Report on 2019's performance back in June 2020, the world was already in the grip of the COVID-19 pandemic and we were all too aware of the catastrophic impact it was wreaking across our communities, our livelihoods, our businesses and our charities. Here at NRAS we had already budgeted for income levels in 2020 to return to more normalised levels of around £1.2m after the record-breaking levels reported in 2019. Like many charities though, we then found ourselves facing huge uncertainty in the Spring of 2020 as the reality of the COVID-19 pandemic began to take effect; the country was effectively shut down and our lives changed beyond all recognition. For the Charity the impact was twofold: vital income sources were cut off when fundraising events across the country were cancelled whilst meanwhile demand for our services was increasing exponentially.

The Charity was fortunate that it was in a stronger position than many others having built up unrestricted reserves held in cash and investments which were equivalent to almost a year's worth of operating costs by December 2019. This gave both us, and more importantly our funders, the assurance that we were financially resilient and with some careful planning would be able to continue delivering our much-needed services to our beneficiaries. Indeed, as the pandemic took hold, we found the demand for our services reached levels never experienced before. At the peak of the pandemic, calls to our Helpline increased 600% and engagement with our Facebook Live events and the NRAS RA Awareness Week (RAAW) broke many records. Applications to join our Membership scheme went up by over 40% and traffic to our newly-launched websites has already increased significantly, despite the NRAS site only launching in December 2020.


Our entire NRAS team worked hard throughout the year developing new and innovative ways of raising funds to enable us to continue to deliver these essential services. They also demonstrated great flexibility by adapting quickly to working from home. For the first time in our history, we ran a cash appeal which donors reacted very generously to. We held online fundraising events and our

wonderful supporters found many new ways of raising funds within the constraints of the COVID era. We developed relationships with new funders, and were successful in a number of grant applications, including the National Lottery Communities Fund. As well as all of this, we continued to work with our pharmaceutical partners who likewise responded generously to our call for core funding as well as helping us to deliver new services into the community.

As a result of this fantastic team effort by the whole NRAS community, the Charity generated income of £1.242m in 2020 which was just above our original target for the year - a result that seemed almost unimaginable back in March 2020. At the same time, through judicious management of our finances and strict control of costs, the Charity restricted its deficit in the year to £46,000 thus ensuring that our unrestricted reserves remain healthy and giving us comfort that we will be able to continue delivering our much-needed services into 2021 and beyond.

As we look to the future, we aim to continue working closely with all our partners, as well as developing relationships with new funders, to enable us to serve the whole RA and JIA communities, including reaching ethnic minorities and socially deprived communities that desperately need our help. With the future still uncertain, in terms of how quickly and how long it will be before we may return to old ways of living and engaging with people, we will continue to focus on developing and utilising digital mechanisms to deliver services to our communities.

On behalf of the Board of Trustees, I would like to extend my sincere thanks to all colleagues here at NRAS, as well as to our Members and Volunteers, and of course our very generous donors, who have all worked so hard to deliver vital services to all those people who need them.

A rectangular box containing a handwritten signature in black ink. The signature appears to be 'S. Collins' written in a cursive style.

Simon Collins  
Chair of Trustees

22 June 2021

## **Our purpose and activities**

Guidance from the Charity Commission has been used to review and develop NRAS's aims and objectives so that activities are clearly focused to derive good public benefit.

### ***Objectives and activities***

The objects of the Charity (the "Objects") are for the public benefit to promote the relief of people living with RA and JIA by:

- Raising awareness and understanding of Rheumatoid Arthritis (RA) and Juvenile Idiopathic Arthritis (JIA), including awareness of the severity of the diseases and their social and economic costs;
  - Providing information on RA and JIA, including information on their treatments and drugs available;
  - Advancing all aspects of the care and treatment of RA and JIA and the management of these diseases in their totality;
  - Providing education on the diseases generally and to individuals and their families and carers in all aspects of RA and JIA, including their treatment and management, and providing information about available support;
  - Supporting individuals in relation to RA and JIA and their families and carers, including putting people in touch with each other to encourage self-help and support where appropriate;
- Working alongside NHS rheumatology health professionals to provide the best care for patients as well as support the clinical staff in their roles.

### ***Our vision***

Our vision is a world not burdened by RA and JIA.

Our mission is to enable the RA and JIA community to thrive by providing support, expert knowledge, engagement, campaigning, and research, all of which is informed by those living with these complex, and currently incurable, auto-immune diseases.

### ***Our principal activities***

We are committed to providing support, information, services, education, campaigning and patient advocacy of the highest quality to, and on behalf of all, those affected by RA and JIA as well as their families.

Our front-line services, including the Helpline, online peer support community, local and now virtual groups, peer-to-peer telephone support programme, information booklets, websites and patient events (both in person and virtually) to continue to offer high quality, accessible and relevant support as a priority. Work is an important health outcome and we have specific resources relating to the workplace for employees and employers as well as up to date information on benefits

including Personal Independence Payments. Both of these important subjects are frequently raised by people calling our Helpline.

We are a membership organisation and provide a magazine three times per year to our Members, among other benefits. We also support health professionals in the field of rheumatology and primary care through training programmes and provision of free health professional membership of NRAS and free patient information so that we can 'help them to help their patients'.

Living with RA and JIA is not just about having physical and medical needs. These incurable diseases have a huge impact on emotional well-being and quality of life both of the individual and their family and our 2018 Report on Emotional Health And Wellbeing Matters addressed these issues in detail. The recent physical isolation of many living with inflammatory arthritis endured as a result of the COVID-19 pandemic has exacerbated mental health issues even further. NRAS has responded to this by offering online wellbeing sessions and other support tools. We will continue to strive to help people by supporting *all* their needs in a holistic way whether physical, medical, emotional, mental, social, economic and/or employment related needs as well as those relating to access to benefits and the built environment, housing and transport.

We are at the table at a national level whenever standards and guidelines, RA/JIA pathways and access to treatment are being discussed. We conduct our own social research and publish key reports on a topic of importance to people with RA/JIA periodically.

Translational scientific and medical research has revolutionised the field of auto-immune conditions such as RA and JIA in the past 20 years and whilst we do not conduct or fund medical research ourselves, we do support a growing number of academic and clinical research studies throughout the UK on an ongoing basis. We also support recruitment to clinical studies and provide expert volunteers to advise on issues of Patient and Public Involvement. We do conduct our own funded major social research studies often in partnership with an academic partnering institute. In 2020, we have played a pivotal role in COVID-19 research by supporting UK, European and Global data gathering.

We are providers of supported self-management group training programmes, but have experienced difficulty getting such courses commissioned by Clinical Commissioning Groups or Health Boards, principally due to the financial constraints in the NHS. We have now started development of these programmes into engaging and interactive online e-learning modules which ultimately health professionals will be able to 'prescribe' for the benefit of their patients.

## **Achievements and performance**

It turned out to be incredibly fortuitous that in Autumn 2019 the Charity invested in new technology and new working practices to enable our colleagues to benefit from more flexible working, both in terms of time and location. This investment enabled us to move very swiftly to an operational model of full remote working at the start of the first lockdown in March 2020 without compromising the majority of the services we deliver.

We were able to continue work on developing our two new websites and these were both launched successfully in 2020 with the JIA website launched first in July, followed by the main NRAS website in December. We also continued the development of a suite of e-learning modules, pioneered by our National Patient Champion, Ailsa Bosworth, MBE. The launch of the first modules was unfortunately delayed by the COVID-19 pandemic and our first four modules are now expected to be launched in

mid-2021. The launch is much-anticipated by Health Care professionals as it will provide an important tool in improving patient outcomes, especially as we expect access to NHS services will continue to be affected for some time to come.

As a direct response to the impact that the pandemic was having on our beneficiaries, we accelerated work to introduce a number of new services. Here4U was launched in late spring 2020 which put patients in touch with peers who were able to provide support, information and reassurance at a time when access to hospital rheumatology services was heavily impacted by COVID-19. We also launched our Chatbot which provides a wealth of information on our website via an interactive tool which directs people to appropriate resource(s) by responding to key words in questions posed.

Our annual campaign to raise awareness of RA, usually held in June, was moved to September and focussed on mental health and wellbeing. The format was different to previous years due to COVID-19 restrictions and was held entirely online. It was hugely successful, tapping into a key concern amongst the RA community that we serve. We also moved our annual Wear Purple for JIA appeal from June to November. This event, held to raise funds for young people diagnosed with Juvenile Idiopathic Arthritis, has traditionally consisted of fundraising events held in schools or individuals' homes and thus presented our fundraisers with a unique challenge given that we were heading into our second lockdown at the same time. Not to be put off by such obstacles, they all did a fantastic job and we look forward to holding the event back at its usual time of June and in its usual format this year.

During 2020 we generated £698.7k of income through donations, pledges and gifts in kind, compared to £649.1k in 2019. This was an incredible achievement given that all our traditional fundraising events were cancelled in 2020. These figures also include donations received from pharmaceutical companies who manufacture and market medicines for RA and/or JIA. This income amounted to £239.8k in 2020 (2019: £172.3k). As well as helping to fund the core services that we deliver to our beneficiaries, these relationships provide NRAS with access to important information about clinical trial data and help to inform and educate our team members on RA and JIA. NRAS is now perceived by most pharmaceutical companies working in the area of immunology and rheumatology as a key expert partner in contributing to advisory boards and employee training, as well as providing support in the development of their own patient-facing support resources. We have teamed up with some pharmaceutical companies in 2020 to deliver exciting projects into communities to help raise awareness of RA. In one such project, we partnered with Fresenius Kabi to deliver training and information materials to 20 pharmacies as part of a trial to identify and signpost individuals suspected of or having RA to NRAS and hence onwards to appropriate health services. We hope to roll this service out more widely in 2021 if the feasibility study has proven the concept to be of benefit. We RA Priority was another highly successful public-facing awareness campaign which we partnered with Gilead Pharmaceuticals on, reaching many thousands of people via social media and mainstream media during RA Awareness Week.

Gifts from legacies are an important source of income for the Charity and we are immensely grateful to our very generous benefactors whose gifts in recent years have enabled us to secure the viability of the Charity and to continue to provide our services to those in need. Our income in 2020 from such gifts raised £139.6k, accounting for 11.2% of our total income.

Support for NRAS was also received through grants from trusts, foundations and livery companies and in 2020 this amounted to £240.5k, including £40.6k of furlough grants received from HMRC. We would like to express particular thanks to the following organisations who all donated over £2,000 each: The Schroder Foundation, Health and Social Care Alliance Scotland, The National Lottery

Community Lottery Fund, James Tudor Foundation, Berkshire Community Foundation, The Leathersellers' Company Charitable Fund, The David Brownlow Charitable Foundation, Children's Arthritis Trust, PF Charitable Trust, The Willie and Mabel Morris Charitable Trust, Hospital Saturday Fund, Peter Harrison Foundation, Pilkington Charities' Fund, The John Coates Charitable Trust, Buckinghamshire Community Foundation, The Roger and Jean Jefcoate Trust, Edith Florence Spencer Memorial trust, The D'Oyly Carte Charitable Trust, The CM Lowe Charitable Foundation, The Lady Hind Trust, Joseph Strong Frazer Trust, St John's Beaumont School, Healthcare at Home, Royal Institute of Chartered Surveyors, PhonicsPlay and The 29<sup>th</sup> May 1961 Charitable Trust.

All income received through fundraising in 2020 contributed to enabling the Charity to provide a full programme of resources, activities and support, which benefits those living with RA and JIA in the UK, their families, schools and the healthcare professionals who support them. NRAS would like to acknowledge and thank all the individuals, companies, livery companies, trusts and foundations that have supported our work this year.

## **Financial Review**

The principal funding sources of income for the Charity were donations and legacies of £838.3k, grants of £240.5k and membership income of £86.1k. Overall, consolidated income in 2020 was £1,242.4k compared to £1,841.5k in 2019. Whilst this is a decrease of 33% on prior year, 2019 figures did include a very generous legacy bequest and after adjusting for this amount, the like-for-like comparison reflects a decrease in income of 11%. This represents a commendable performance in a year overshadowed by the COVID-19 pandemic with all the associated curtailment of fundraising events and other restrictions on daily life.

Overall expenditure remained at similar levels in 2020 compared with the prior year reflecting the efforts made to constrain expenditure as far as possible without adversely impacting services.

The Charity reported a consolidated net deficit of £46.0k in 2020, compared with a net gain of £616.2k in 2019. Our balance sheet remains strong with unrestricted reserves of £1,600.4k and a healthy cash balance of £748.3k at the end of the year.

The Charity will retain its policy of a conservative approach to its reserves which has served it well during these challenging times. We will ensure that we retain at least six months' operating costs in cash and investments and we will work hard to ensure that our funds are used judiciously so that we return the biggest benefit to our beneficiaries for each pound invested. We will continue to enhance our websites and broaden our digital offerings as well invest in campaigns to raise awareness of RA and JIA. It is likely that the Charity will need to use some of its unrestricted reserves to enable it to continue to deliver its core services in 2021 whilst restrictions on daily life continue.

The Charity's wholly owned trading subsidiary, NRAS Community Services Limited, provided some research support to a number of companies in 2020. The company delivered a profit of £1.5k on its activities.

### ***Investment Policy and Objectives***

Investments are managed by professional fund managers as permitted by the relevant acts and the charity commission guidelines. The overall objective of the fund managers is to maintain an appropriate level of risk whilst retaining the real value of capital through long term investments. Reports are received quarterly from the fund managers and the Trustees review performance annually with the fund managers.

### ***Reserves policy and going concern***

The Charity's policy is to hold a minimum of six months' operating costs in cash and investments in order to ensure the sustainability of the Charity which was comfortably met in 2020, despite the pressures brought to bear from the COVID-19 pandemic. This policy is based on trustees' judgement given their knowledge of the organisation and its income streams and it is reviewed each year.

Whilst the pandemic will continue to have an impact on our income generated in 2021, our healthy cash balance has meant that we have sufficient liquidity to ensure that we can meet our future obligations as they become due for the foreseeable future.

### **Future plans**

The Trustees approve and adopt strategic plans for the Charity every three years and detailed budgets are prepared annually to support these initiatives and demonstrate how the objectives will be delivered within the constraints of predicted funding available. The budget is reviewed on a quarterly basis and appropriate management decisions are taken in light of any material forecast variances.

The Charity's strategic plan for 2019 – 2021 was finalised in 2018 and set out that the Charity will continue to focus on providing the best support for people with RA and JIA, their families and the health professionals who care for them. It also set out an exciting future programme working with strategic partners to deliver transformational change to some of the key information resources that we provide by developing a suite of e-learning modules which will be available on a new digital platform.

Work is already underway to develop and refine our strategy for 2022 and beyond and this will revolve around the development of a comprehensive digital strategy and increasing our reach into more diverse communities.

The COVID-19 pandemic reinforced the importance of the work the Charity does in the RA and JIA community and we were pleased to be able to provide support, information and advice to many people in their hour of need. As described elsewhere in this report, the impact of the pandemic on the Charity has been far-reaching, not least in terms of its ability to raise the much-needed funds to enable it to continue to deliver these vital services. As a direct response to the crisis, in March 2020 the Charity reviewed its strategic plans and all its current projects in detail and took the difficult decision to temporarily suspend work on the development of some of its new services that were scheduled for release in early 2020, including its e-learning suite. These projects were all re-started in Summer 2020 and are expected to be launched in mid-2021.

### **Structure, governance and management**

#### ***Governing document***

The Charity is controlled by its governing documents, the memorandum and articles, and constitutes a limited by guarantee company as defined by the Companies Act 2006.

The Charity is a company limited by guarantee and does not have any share capital.

None of the Trustees has any beneficial interest in the company. All of the Trustees are members of the company and guarantee to contribute £1 each in the event of a winding up.

## ***Trustees***

The Trustees, who are also the directors for the purpose of company law, and who served during the year were:

Mr RA Boucher  
Mr S Collins (Chair)  
Ms L Cook  
Mr SJ Crowther (Treasurer resigning 22<sup>nd</sup> June 2021)  
Mr R Flowerdew  
Ms K Fox  
Ms ZC Ide (resigning 22<sup>nd</sup> June 2021)  
Ms E Potter  
Dr G Taylor  
Ms S Webb

As set out in the articles (as amended in June 2019), Trustees are required to retire after three years in office. A retiring trustee shall be eligible for re-election. No trustees are scheduled for retirement in 2021.

Mr SJ Crowther and Ms ZC Ide have both chosen to retire as Trustees at the AGM June 2021 and we thank them for outstanding contributions and wise counsel during the period that they both served.

## ***Trustee induction and training***

New Trustees undergo an orientation day to brief them on their legal obligations under Charity law, the content of the constitution and decision-making process, the business plan and recent financial performance of the Charity. As part of the process they meet key employees and other Trustees and may attend additional, relevant external training as required.

## ***Organisation***

The body of Trustees consists of not fewer than four and no more than twenty trustees and administers the Charity through the Senior Executives.

## ***Related parties and co-operation with other organisations***

None of our trustees receives remuneration or other benefit from their work with the charity. Any connection between a trustee or senior manager of the charity with a supplier or other party with which the Charity transacts must be disclosed to the full board of trustees. In the current year no such related party transactions were reported.

## ***Pay policy for senior staff***

Remuneration for key management personnel is benchmarked against the voluntary sector and is set by the Trustees. The pay of senior staff is reviewed annually and normally increased in accordance with average earnings.

## ***Risk management***

The trustees have a risk management strategy including a formal risk evaluation which is carried out each year.

The key risks are identified below:

- Adequacy of cash to run the Charity. Costs are monitored closely throughout the year. The Charity constantly monitors the cash position and future cash requirements. Fundraising strategy is developed with an emphasis on the provision of regular and predictable income streams. Reserves of a minimum of 6 months operating costs are held as cash and realisable investments.
- Investment of surplus cash. Investments are managed by qualified external advisers with a view to maintaining an appropriate and prudent risk strategy for the Charity whilst retaining the real value of the capital.
- Reliance on key individuals. This is recognised and the senior management team work with staff to ensure teams are diverse as possible to reduce over reliance on any one individual. Key personnel have a three-month notice period. Succession planning is in place and is revised periodically to account for any senior staff movement.
- IT security. A support contract is in place with 3rd party IT experts covering all aspects of IT performance and security. Internal security is in place and monitored and updated where appropriate.
- Data protection. The charity carries out regular reviews to ensure that its policies and procedures are in line with regulations and best practice.
- Attracting and retaining Trustees. The Charity periodically reviews the number of Trustees to ensure that there is a minimum number of Trustees on the board with the right spread of skills and experience to meet the current and future needs of the Charity.

## **Auditors**

In accordance with the company's articles, a resolution proposing that Moore Kingston Smith LLP be re-appointed as auditor of the company will be put at a General Meeting.

## **Trustees' responsibilities in relation to the financial statements**

The Trustees, who are also the directors of National Rheumatoid Arthritis Society for the purpose of company law, are responsible for preparing the Trustees' Report and the accounts in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare accounts for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure of the charitable company for that year.

In preparing these accounts the Trustees are required to:

- Select suitable accounting policies and then apply them, consistently;
- Observe the methods and principles in the Charities SORP (FRS 102);
- Make judgments and estimates that are reasonable and prudent;
- State whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- Prepare the accounts on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the accounts comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.


## Statement as to disclosure to our auditors

In so far as the trustees are aware at the time of approving our Trustees' annual report:  
There is no relevant information, being information needed by the auditor in connection with preparing their report, of which the group's auditor is unaware, and  
The trustees, having made enquiries of fellow trustees and the group's auditor that they ought to have individually taken, have each taken all steps that he/ she is obliged to take as a trustee, in order to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions

S Collins  
Chair of Trustees

SJ Crowther  
Treasurer/ Trustee

A rectangular box containing a handwritten signature in cursive script that reads "S. Collins".A handwritten signature in cursive script, appearing to read "SJ Crowther", with a long horizontal flourish extending to the right.

22 June 2021

## **Independent Auditor's Report to the Members and Trustees of the National Rheumatoid Arthritis Society**

### ***Opinion***

We have audited the financial statements of National Rheumatoid Arthritis Society for the year ended 31 December 2020 which comprise the Consolidated Statement of Financial Activities (including the Consolidated Summary Income and Expenditure Account), the Group and Parent Charitable Company Balance Sheets, the Consolidated Statement of Cash Flows and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102. The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the group's and the parent charitable company's affairs as at 31 December 2020 and of the group's incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 (as amended), regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011.

### ***Basis for opinion***

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs(UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### ***Conclusions relating to going concern***

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

### ***Other information***

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

### ***Opinions on other matters prescribed by the Companies Act 2006***

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' annual report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the trustees' annual report have been prepared in accordance with applicable legal requirements.

### ***Matters on which we are required to report by exception***

In the light of the knowledge and understanding of the group and parent charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the trustees' annual report.

We have nothing to report in respect of the following matters where the Companies Act 2006, the Charities Accounts (Scotland) Regulations 2006 (as amended) and the Charities Act 2011 require us to report to you if, in our opinion:

- the parent charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent charitable company's financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies exemption in preparing the Trustees' Annual Report and from preparing a strategic report.

### ***Responsibilities of trustees***

As explained more fully in the trustees' responsibilities statement set out on page [x], the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the group and parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or parent charitable company or to cease operations, or have no realistic alternative but to do so.

### ***Auditor's responsibilities for the audit of the financial statements***

We have been appointed as auditor under Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, the Companies Act 2006 and Section 151 of the Charities Act 2011 and report to you in accordance with regulations made under those Acts.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

### ***Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud***

The objectives of our audit in respect of fraud, are; to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud, through designing and implementing appropriate responses to those assessed risks; and to respond appropriately to instances of fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the charitable company.

Our approach was as follows:

- We obtained an understanding of the legal and regulatory requirements applicable to the charitable company and considered that the most significant are [the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 (as amended), regulations 6 and 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended), the Charities Act 2011,

the Charity SORP, and UK financial reporting standards as issued by the Financial Reporting Council

- We obtained an understanding of how the charitable company and group complies with these requirements by discussions with management and those charged with governance.
- We assessed the risk of material misstatement of the financial statements, including the risk of material misstatement due to fraud and how it might occur, by holding discussions with management and those charged with governance.
- We inquired of management and those charged with governance as to any known instances of non-compliance or suspected non-compliance with laws and regulations.
- Based on this understanding, we designed specific appropriate audit procedures to identify instances of non-compliance with laws and regulations. This included making enquiries of management and those charged with governance and obtaining additional corroborative evidence as required.

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purposes of expressing an opinion on the effectiveness of the group and parent charitable company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustees.
- Conclude on the appropriateness of the trustees' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the group and parent charitable company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the group or parent charitable company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the group to express an opinion on the consolidated financial

statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit report.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

***Use of our report***

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006; and to the charity's trustees, as a body, in accordance with Section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005, and in respect of the consolidated financial statements, in accordance with Chapter 3 of Part 8 of the Charities Act 2011. Our audit work has been undertaken so that we might state to the charitable company's members and trustees those matters which we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to any party other than the charitable company, the charitable company's members, as a body, and the charity's trustees, as a body for our audit work, for this report, or for the opinion we have formed.

*Moore Kingston Smith LLP*

Date: 22 June 2021

Mahmood Ramji (Senior Statutory Auditor)  
for and on behalf of Moore Kingston Smith LLP, Statutory Auditor

The Shipping Building  
The Old Vinyl Factory  
Blyth Road  
Hayes, London  
UB3 1HA

Moore Kingston Smith LLP is eligible to act as auditor in terms of Section 1212 of the Companies Act 2006.

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES (Including Income and Expenditure Account)  
FOR THE YEAR ENDED 31 DECEMBER 2020

		Unrestricted	Restricted	Total	Unrestricted	Restricted	Total
		funds	funds	funds	funds	funds	funds
		2020	2020	2020	2019	2019	2019
	Notes	£'000	£'000	£'000	As restated £'000	As restated £'000	As restated £'000
<b>Income from:</b>							
Donations and legacies	3	791.3	47.0	838.3	1,350.4	59.1	1,409.5
Charitable activities	4	299.9	43.9	343.8	313.9	40.7	354.6
Other trading activities	5	37.1	0.0	37.1	48.2	0.0	48.2
Investment income	6	23.2	0.0	23.2	29.2	0.0	29.2
<b>Total income</b>		<b>1,151.5</b>	<b>90.9</b>	<b>1,242.4</b>	<b>1,741.7</b>	<b>99.8</b>	<b>1,841.5</b>
<b>Expenditure on:</b>							
Raising funds	7	246.6	0.0	246.6	228.6	0.0	228.6
Charitable activities	8	895.3	146.4	1,041.7	996.2	67.0	1,063.2
<b>Total resources expended</b>		<b>1,141.9</b>	<b>146.4</b>	<b>1,288.3</b>	<b>1,224.8</b>	<b>67.0</b>	<b>1,291.8</b>
Net income/(expenditure)		9.6	(55.5)	(45.9)	516.9	32.8	549.7
Net gains/(losses) on investments	12	(0.1)	0.0	(0.1)	66.5	0.0	66.5
Gross transfers between funds		0.0	0.0	0.0	0.0	0.0	0.0
<b>Net movement in funds</b>		<b>9.5</b>	<b>(55.5)</b>	<b>(46.0)</b>	<b>583.4</b>	<b>32.8</b>	<b>616.2</b>
Fund balances at 1 January 2020		1,670.4	32.8	1,703.2	1,087.0	0.0	1,087.0
Transfer between funds		(79.5)	79.5	0.0	0.0	0.0	0.0
<b>Fund balances at 31 December 2020</b>		<b>1,600.4</b>	<b>56.8</b>	<b>1,657.2</b>	<b>1,670.4</b>	<b>32.8</b>	<b>1,703.2</b>

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

The notes at pages 21 to 35 form part of these accounts.

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
 COMPANY STATEMENT OF FINANCIAL ACTIVITIES (Including Income and Expenditure Account)  
 FOR THE YEAR ENDED 31 DECEMBER 2020

		Unrestricted	Restricted	Total	Unrestricted	Restricted	Total
		funds	funds	funds	funds	funds	funds
		2020	2020	2020	2019	2019	2019
	Notes	£'000	£'000	£'000	As restated £'000	As restated £'000	As restated £'000
<b>Income from:</b>							
Donations and legacies	3	797.6	47.0	844.6	1,366.2	59.1	1,425.3
Charitable activities	4	299.9	43.9	343.8	313.9	40.7	354.6
Other trading activities	5	30.9	0.0	30.9	25.9	0.0	25.9
Investment income	6	23.2	0.0	23.2	29.2	0.0	29.2
<b>Total income</b>		<b>1,151.6</b>	<b>90.9</b>	<b>1,242.5</b>	<b>1,735.2</b>	<b>99.8</b>	<b>1,835.0</b>
<b>Expenditure on:</b>							
Raising funds	7	246.6	0.0	246.6	228.6	0.0	228.6
Charitable activities	8	890.7	146.4	1,037.1	980.1	67.0	1,047.1
<b>Total resources expended</b>		<b>1,137.3</b>	<b>146.4</b>	<b>1,283.7</b>	<b>1,208.7</b>	<b>67.0</b>	<b>1,275.7</b>
Net income/(expenditure)		14.3	(55.5)	(41.2)	526.5	32.8	559.3
Net gains/(losses) on investments	12	(0.1)	0.0	(0.1)	66.5	0.0	66.5
Gross transfers between funds		0.0	0.0	0.0	0.0	0.0	0.0
<b>Net movement in funds</b>		<b>14.2</b>	<b>(55.5)</b>	<b>(41.3)</b>	<b>593.0</b>	<b>32.8</b>	<b>625.8</b>
Fund balances at 1 January		1,664.1	32.8	1,696.9	1,071.1	0.0	1,071.1
Transfer between funds		(79.5)	79.5	0.0	0.0	0.0	0.0
<b>Fund balances at 31 December</b>		<b>1,598.8</b>	<b>56.8</b>	<b>1,655.6</b>	<b>1,664.1</b>	<b>32.8</b>	<b>1,696.9</b>

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

The notes at pages 21 to 35 form part of these accounts.

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
CONSOLIDATED AND CHARITY BALANCE SHEETS  
FOR THE YEAR ENDED 31 DECEMBER 2020**

	Notes	Group		Charity	
		2020 £'000	2019 £'000	2020 £'000	2019 £'000
<b>Fixed assets</b>					
Tangible assets	13	120.7	67.0	120.7	67.0
Investments	14	871.9	798.8	871.9	798.8
		<u>992.6</u>	<u>865.8</u>	<u>992.6</u>	<u>865.8</u>
<b>Current assets</b>					
Debtors	16	114.7	619.3	120.9	650.5
Cash at bank and in hand		748.3	396.5	732.7	356.0
		<u>863.0</u>	<u>1,015.8</u>	<u>853.6</u>	<u>1,006.5</u>
<b>Liabilities:</b>					
Creditors: amounts falling due within one year	17	(198.4)	(178.4)	(190.6)	(175.4)
		<u>664.6</u>	<u>837.4</u>	<u>663.0</u>	<u>831.1</u>
<b>Net current assets</b>		<u>664.6</u>	<u>837.4</u>	<u>663.0</u>	<u>831.1</u>
		<u>1,657.2</u>	<u>1,703.2</u>	<u>1,655.6</u>	<u>1,696.9</u>
<b>Total assets less current liabilities</b>					
		<u>1,657.2</u>	<u>1,703.2</u>	<u>1,655.6</u>	<u>1,696.9</u>
<b>Income funds</b>					
Unrestricted funds	19	1,600.4	1,670.4	1,598.8	1,664.1
Restricted funds	19	56.8	32.8	56.8	32.8
		<u>1,657.2</u>	<u>1,703.2</u>	<u>1,655.6</u>	<u>1,696.9</u>

The charity is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 December 2020, although an audit has been carried out under section 144 of the Charities Act 2011. No trustee of the charity has deposited notice, pursuant to section 476, requiring an audit of these accounts under the requirements of the Companies Act 2006.

The Trustees have prepared group accounts in accordance with section 398 of the Companies Act 2006 and section 138 of the Charities Act 2011 and constitute the annual accounts required by the Companies Act 2006 and are for circulation to trustees of the company.

These accounts are prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 and are for circulation to the members of the company.

The notes at pages 21 to 35 form part of these accounts.

The accounts were approved by the Board of Trustees on 22 June 2021

SJ Crowther  
Treasurer/Trustee

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
CONSOLIDATED STATEMENT OF CASH FLOWS  
FOR THE YEAR ENDED 31 DECEMBER 2020

	Notes	Group		Charity	
		2020 £'000	2019 £'000	2020 £'000	2019 £'000
<b>Cash flows from operating activities</b>					
Cash generated from operations	25	474.4	27.8	493.1	6.9
<b>Investing activities</b>					
Purchase of tangible fixed assets		(72.6)	(68.6)	(72.6)	(68.6)
Purchase of investments		(73.2)	(28.8)	(73.2)	(28.8)
Interest received		23.2	29.2	23.2	29.2
Gift aid donation from subsidiary				6.2	15.8
<b>Net cash used in investing activities</b>		<b>(122.6)</b>	<b>(68.2)</b>	<b>(116.4)</b>	<b>(52.4)</b>
<b>Net cash used in financing activities</b>		<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>
<b>Net increase/(decrease) in cash and cash equivalents</b>		<b>351.8</b>	<b>(40.4)</b>	<b>376.7</b>	<b>(45.5)</b>
Cash and cash equivalents at beginning of year		396.5	436.9	356.0	401.5
<b>Cash and cash equivalents at end of year</b>		<b>748.3</b>	<b>396.5</b>	<b>732.7</b>	<b>356.0</b>

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2020**

**1 Accounting policies**

**Charity information**

National Rheumatoid Arthritis Society is a private company limited by guarantee incorporated in England and Wales and Scotland. The registered office is Ground Floor, 4 Switchback, Gardner Road, Maidenhead, Berks, SL6 7RJ.

**1.1 Accounting convention**

These accounts have been prepared in accordance with the charity's governing document, the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2016. The charity is a Public Benefit Entity as defined by FRS 102.

The accounts are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £,000.

The comparative figures for 2019 have been restated in respect of the split of income to ensure consistency with the current year classifications.

The accounts have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

**Preparation of consolidated financial statements**

These consolidated financial statements incorporate the financial statements of the Charity and its subsidiary undertaking, NRAS Community Services Limited, made up to 31 December 2020. Intercompany transactions, balances and unrealised gains on transactions between the Charity and its subsidiary are eliminated. Accounting policies of subsidiary undertakings have been changed where necessary to ensure consistency with the policies adopted by the Group. The income of the trading subsidiary is included in the Consolidated Statement of Financial Activities within other trading activities. Expenditure is included in wages and support costs.

**1.2 Going concern**

At the time of approving the accounts, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future, despite the ongoing challenges presented by Covid-19 and its potential impact on income generation in the short-term. This expectation is based on the strong investments and cash position, reflecting a significant amount of unrestricted funds and the financial performance of the Charity since the start of the pandemic. Thus the Trustees' continue to adopt the going concern basis of accounting in preparing the accounts.

**1.3 Charitable funds**

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The cost of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

**1.4 Incoming resources**

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

**1 Accounting policies**

(Continued)

**1.6 Tangible fixed assets and depreciation**

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Improvements to property	20% straight line or lease period if shorter
Website development	25% straight line
Fixtures, fittings & equipment	25% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in net income/(expenditure) for the year.

**1.7 Impairment of fixed assets**

At each reporting end date, the charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

**1.8 Cash and cash equivalents**

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

**1.9 Financial instruments**

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

***Basic financial assets***

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2020

3 Donations and legacies

	Group		Charity	
	2020	2019 As restated	2020	2019 As restated
	£'000	£'000	£'000	£'000
Donations and gifts	698.7	649.1	705.0	664.9
Legacies receivable	139.6	760.4	139.6	760.4
	<u>838.3</u>	<u>1,409.5</u>	<u>844.6</u>	<u>1,425.3</u>
<i>Analysis by fund</i>				
Restricted funds	47.0	59.1	47.0	59.1
Unrestricted funds	<u>791.3</u>	<u>1,350.4</u>	<u>797.6</u>	<u>1,366.2</u>
	<u>838.3</u>	<u>1,409.5</u>	<u>844.6</u>	<u>1,425.3</u>

4 Income from charitable activities

	Group		Charity	
	2020	2019 As restated	2020	2019 As restated
	£'000	£'000	£'000	£'000
Appeals	0.0	3.5	0.0	3.5
Subscriptions	86.1	80.0	86.1	80.0
Lottery income	17.2	16.3	17.2	16.3
Grants	240.5	254.8	240.5	254.8
	<u>343.8</u>	<u>354.6</u>	<u>343.8</u>	<u>354.6</u>
<i>Analysis by fund</i>				
Restricted funds	43.9	40.7	43.9	40.7
Unrestricted funds	<u>299.9</u>	<u>313.9</u>	<u>299.9</u>	<u>313.9</u>
	<u>343.8</u>	<u>354.6</u>	<u>343.8</u>	<u>354.6</u>

5 Other trading activities

	Group		Charity	
	2020	2019 As restated	2020	2019 As restated
	£'000	£'000	£'000	£'000
Merchandising and other trading income	30.9	25.9	30.9	25.9
Trading subsidiary income	<u>6.2</u>	<u>22.3</u>	<u>0.0</u>	<u>0.0</u>
	<u>37.1</u>	<u>48.2</u>	<u>30.9</u>	<u>25.9</u>

6 Investments

	Group		Charity	
	2020	2019	2020	2019
	£'000	£'000	£'000	£'000
Income from listed investments	23.1	28.8	23.1	28.8
Interest receivable	<u>0.1</u>	<u>0.4</u>	<u>0.1</u>	<u>0.4</u>
	<u>23.2</u>	<u>29.2</u>	<u>23.2</u>	<u>29.2</u>

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2020

7 Expenditure on raising funds

	Group and Charity	
	2020 £'000	2019 £'000
Staging fundraising events	20.1	33.8
Staff costs	168.8	144.0
Support costs	48.5	42.6
Governance costs	9.2	8.2
Expenditure on raising funds	<b>246.6</b>	<b>228.6</b>
<i>Analysis by fund</i>		
Restricted funds	0.0	0.0
Unrestricted funds	<b>246.6</b>	<b>228.6</b>
	<b>246.6</b>	<b>228.6</b>

8 Expenditure on charitable activities

Group	Provision of info & support	Digital innovations	Raising awareness	Community support	Supporting our young people	Total
	2020	2020	2020	2020	2020	2020
	£'000	£'000	£'000	£'000	£'000	£'000
Direct costs	34.6	73.4	35.4	0.3	7.4	151.1
Staff costs	222.8	38.7	228.2	78.2	83.6	651.5
Share of support costs (see note 9)	75.3	8.5	65.4	25.6	26.3	201.1
Share of governance costs (see note 9)	14.2	1.6	12.4	4.8	5.0	38.0
	<b>346.9</b>	<b>122.2</b>	<b>341.4</b>	<b>108.9</b>	<b>122.3</b>	<b>1,041.7</b>
<i>Analysis by fund</i>						
Restricted funds	1.1	122.2	23.1	0.0	0.0	146.4
Unrestricted funds	345.8	0.0	318.3	108.9	122.3	895.3
	<b>346.9</b>	<b>122.2</b>	<b>341.4</b>	<b>108.9</b>	<b>122.3</b>	<b>1,041.7</b>
Group	Provision of info & support	Digital innovations	Raising awareness	Community support	Supporting our young people	Total
	2019	2019	2019	2019	2019	2019
	£'000	£'000	£'000	£'000	£'000	£'000
Direct costs	123.0	15.4	31.8	13.8	27.1	211.1
Staff costs	204.1	36.0	94.2	192.0	85.9	612.2
Share of support costs (see note 9)	67.1	0.0	46.5	59.1	28.7	201.4
Share of governance costs (see note 9)	12.9	0.0	8.9	11.3	5.4	38.5
	<b>407.1</b>	<b>51.4</b>	<b>181.4</b>	<b>276.2</b>	<b>147.1</b>	<b>1,063.2</b>
<i>Analysis by fund</i>						
Restricted funds	15.6	51.4	0.0	0.0	0.0	67.0
Unrestricted funds	391.5	0.0	181.4	276.2	147.1	996.2
	<b>407.1</b>	<b>51.4</b>	<b>181.4</b>	<b>276.2</b>	<b>147.1</b>	<b>1,063.2</b>

## 8 Expenditure on charitable activities

Charity	Provision of info & support	Digital innovations	Raising awareness	Community support	Supporting our young people	Total
	2020	2020	2020	2020	2020	2020
	£'000	£'000	£'000	£'000	£'000	£'000
Direct costs	34.6	73.4	35.4	0.3	7.4	151.1
Staff costs	222.8	38.7	228.2	78.2	83.6	651.5
Share of support costs (see note 9)	75.3	8.5	65.4	25.6	26.3	201.1
Share of governance costs (see note 9)	9.6	1.6	12.4	4.8	5.0	33.4
	<b>342.3</b>	<b>122.2</b>	<b>341.4</b>	<b>108.9</b>	<b>122.3</b>	<b>1,037.1</b>
<b>Analysis by fund</b>						
Restricted funds	1.1	122.2	23.1	0.0	0.0	146.4
Unrestricted funds	341.2	0.0	318.3	108.9	122.3	890.7
	<b>342.3</b>	<b>122.2</b>	<b>341.4</b>	<b>108.9</b>	<b>122.3</b>	<b>1,037.1</b>

Charity	Provision of info & support	Digital innovations	Raising awareness	Community support	Supporting our young people	Total
	2019	2019	2019	2019	2019	2019
	As restated	As restated	As restated	As restated	As restated	As restated
	£'000	£'000	£'000	£'000	£'000	£'000
Direct costs	123.0	15.4	31.8	13.8	27.1	211.1
Staff costs	193.0	36.0	94.2	192.0	85.9	601.1
Share of support costs (see note 9)	67.1	0.0	46.5	59.1	28.7	201.4
Share of governance costs (see note 9)	7.9	0.0	8.9	11.3	5.4	33.5
	<b>391.0</b>	<b>51.4</b>	<b>181.4</b>	<b>276.2</b>	<b>147.1</b>	<b>1,047.1</b>
<b>Analysis by fund</b>						
Restricted funds	51.6	15.4	0.0	0.0	0.0	67.0
Unrestricted funds	339.4	36.0	181.4	276.2	147.1	980.1
	<b>391.0</b>	<b>51.4</b>	<b>181.4</b>	<b>276.2</b>	<b>147.1</b>	<b>1,047.1</b>

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
 NOTES TO THE ACCOUNTS  
 FOR THE YEAR ENDED 31 DECEMBER 2020

9 Support costs

Group	Support costs	Governance costs	Total	Support costs	Governance costs	Total
	2020	2020	2020	2019	2019	2019
	£'000	£'000	£'000	£'000	£'000	£'000
Staff costs		23.6	23.6		15.9	15.9
IT	59.1		59.1	45.9		45.9
Office	121.8		121.8	115.3		115.3
Other overheads	49.8		49.8	67.2		67.2
Depreciation & dilapidations	18.9		18.9	15.6		15.6
Insurance		5.8	5.8		5.6	5.6
Professional fees		0.0	0.0		9.3	9.3
Auditors' remuneration:			0.0			0.0
Audit fees		13.0	13.0		15.8	15.8
Other services		4.8	4.8		0.0	0.0
Trustee expenses			0.0		0.1	0.1
	<b>249.6</b>	<b>47.2</b>	<b>296.8</b>	<b>244.0</b>	<b>46.7</b>	<b>290.7</b>
Analysed between						
Fundraising (note 7)	48.5	9.2	57.7	42.6	8.2	50.8
Charitable activities (note 8)	201.1	38.0	239.1	201.4	38.5	239.9
	<b>249.6</b>	<b>47.2</b>	<b>296.8</b>	<b>244.0</b>	<b>46.7</b>	<b>290.7</b>

The above costs were allocated on a headcount basis.

Charity	Support costs	Governance costs	Total	Support costs	Governance costs	Total
	2020	2020	2020	2019	2019	2019
	£'000	£'000	£'000	£'000	£'000	£'000
Staff costs		23.6	23.6		15.9	15.9
IT	59.1		59.1	45.9		45.9
Office	121.8		121.8	115.3		115.3
Other overheads	49.8		49.8	67.2		67.2
Depreciation & dilapidations	18.9		18.9	15.6		15.6
Insurance		5.8	5.8		5.6	5.6
Professional fees			0.0		9.3	9.3
Auditors' remuneration:			0.0			0.0
Audit fees		8.4	8.4		10.8	10.8
Other services		4.8	4.8		0.0	0.0
Trustee expenses			0.0		0.1	0.1
	<b>249.6</b>	<b>42.6</b>	<b>292.2</b>	<b>244.0</b>	<b>41.7</b>	<b>285.7</b>
Analysed between						
Fundraising (note 7)	48.5	9.2	57.7	42.6	8.2	50.8
Charitable activities (note 8)	201.1	33.4	234.5	201.4	33.5	234.9
	<b>249.6</b>	<b>42.6</b>	<b>292.2</b>	<b>244.0</b>	<b>41.7</b>	<b>285.7</b>

The above costs were allocated on a headcount basis.

10 Trustees

None of the Trustees (nor any persons connected with them) received any remuneration during the year, and they were reimbursed a total of £nil travelling expenses (2019: £96).

11 Employees

**Number of employees**

The average monthly number of full-time equivalent employees during the year was:

	2020 Number	2019 Number As restated
All employees - Group and Charity	23	21

**Employment costs**

	Group		Charity	
	2020 £'000	2019 £'000	2020 £'000	2019 £'000
Wages and salaries	761.5	699.6	761.5	688.5
Social security	66.9	56.9	66.9	56.9
Pension costs	15.5	14.6	15.5	14.6
	<u>843.9</u>	<u>771.1</u>	<u>843.9</u>	<u>760.0</u>

The total amount of redundancy payments made by the Company in the year was £nil (2019: £1.1k).

The number of employees who received total employee benefits (excluding employer pension costs) of more than £60,000 is as follows:

	2020 Number	2019 Number
£60,001 - £70,000	1	-

**Remuneration of key management personnel**

The remuneration of key management personnel is as follows:

	2020 £'000	2019 £'000 As restated
Aggregate Compensation	214.5	252.3

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2020**

**12 Net gains/(losses) on investments**

	<b>2020</b>	<b>2019</b>
	<b>£'000</b>	<b>£'000</b>
Revaluation of investments	(0.1)	66.5

**13 Tangible fixed assets - Group and Charity**

	<b>Improvements to property</b>	<b>Website development</b>	<b>Fixtures, fittings &amp; equipment</b>	<b>Total</b>
	<b>£'000</b>	<b>£'000</b>	<b>£'000</b>	<b>£'000</b>
<b>Cost</b>				
At 31 December 2019	61.7	207.7	124.0	393.4
Additions	0.0	66.5	6.1	72.6
<b>At 31 December 2020</b>	<b>61.7</b>	<b>274.2</b>	<b>130.1</b>	<b>466.0</b>
<b>Depreciation</b>				
At 31 December 2019	58.3	164.2	103.9	326.4
Charge for the year	0.7	12.0	6.2	18.9
<b>At 31 December 2020</b>	<b>59.0</b>	<b>176.2</b>	<b>110.1</b>	<b>345.3</b>
<b>Carrying amount</b>				
<b>At 31 December 2020</b>	<b>2.7</b>	<b>98.0</b>	<b>20.0</b>	<b>120.7</b>
<b>At 31 December 2019</b>	<b>3.4</b>	<b>43.5</b>	<b>20.1</b>	<b>67.0</b>

**14 Fixed asset investments - Group and Charity**

	<b>2020</b>	<b>2019</b>
	<b>£'000</b>	<b>£'000</b>
<b>Listed investments</b>		
Market value at 1 January	798.8	703.5
Additions	73.2	28.8
Revaluation	(0.1)	66.5
<b>Market value at 31 December</b>	<b>871.9</b>	<b>798.8</b>

**15 Financial instruments**

	<b>2020</b>	<b>2019</b>
	<b>£'000</b>	<b>£'000</b>
<b>Carrying amount of financial assets</b>		
Instruments measured at amortised cost	70.6	575.6
Instruments measured at fair value through profit or loss	871.9	798.8
<b>Carrying amount of financial liabilities</b>		
Measured at amortised cost	179.3	160.8

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
 NOTES TO THE ACCOUNTS  
 FOR THE YEAR ENDED 31 DECEMBER 2020

16 Debtors

	Group		Charity	
	2020 £'000	2019 £'000	2020 £'000	2019 £'000
<b>Amounts falling due within one year:</b>				
Trade debtors	14.3	22.6	14.3	22.6
Amounts owed by group undertakings	0.0	0.0	6.2	31.2
Other debtors	56.3	553.0	56.3	553.0
Prepayments and accrued income	44.1	43.7	44.1	43.7
	<u>114.7</u>	<u>619.3</u>	<u>120.9</u>	<u>650.5</u>

17 Creditors: amounts falling due within one year

	Group		Charity	
	2020 £'000	2019 £'000	2020 £'000	2019 £'000
Trade creditors	51.9	84.8	51.9	84.8
Other taxes and social security costs	19.1	17.6	19.1	17.6
Other creditors	22.6	21.0	17.8	18.0
Accruals and deferred income	104.8	55.0	101.8	55.0
	<u>198.4</u>	<u>178.4</u>	<u>190.6</u>	<u>175.4</u>

	2020 £'000	2019 £'000
Deferred income included in the financial statements as follows:		
At 1 January	0.0	0.0
Movement during the year	41.1	0.0
At 31 December	<u>41.1</u>	<u>0.0</u>

Income had been deferred in relation to grants received which relate to services that will be delivered in 2021.

18 Retirement benefit schemes

**Defined contribution schemes**

The Charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the Charity in an independently administered fund.

The charge to profit or loss in respect of defined contribution schemes was £15.5k (2019: £14.6k).

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2020

19 Fund reconciliation

The income funds of the Charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

Unrestricted Funds

	Balance at 1 January 2020	Movement in funds			Balance at 31 December 2020
		Incoming resources 2020	Resources expended 2020	Transfer of funds 2020	
	£'000	£'000	£'000	£'000	£'000
Unrestricted	1,670.4	1,095.5	(1,019.7)	(145.8)	1,600.4
Designated - Juvenile Idiopathic Arthritis activities	0.0	56.0	(122.3)	66.3	0.0
	<b>1,670.4</b>	<b>1,151.5</b>	<b>(1,142.0)</b>	<b>(79.5)</b>	<b>1,600.4</b>

	Balance at 1 January 2019	Movement in funds			Balance at 31 December 2019
		Incoming resources 2019	Resources expended 2019	Transfer of funds 2019	
	£'000	£'000	£'000	£'000	£'000
Unrestricted	1,087.0	1,627.4	(977.3)	(66.7)	1,670.4
Designated - Juvenile Idiopathic Arthritis activities	0.0	89.3	(147.1)	57.8	0.0
Designated - Rheum4U events	0.0	8.0	(8.0)	0.0	0.0
Designated - Conference attendance	0.0	8.4	(16.9)	8.5	0.0
Designated - webinar programme	0.0	5.0	(5.1)	0.1	0.0
Designated - video development	0.0	3.6	(3.9)	0.3	0.0
	<b>1,087.0</b>	<b>1,741.7</b>	<b>(1,158.3)</b>	<b>0.0</b>	<b>1,670.4</b>

Restricted Funds

	Balance at 1 January 2020	Movement in funds			Balance at 31 December 2020
		Incoming resources 2020	Resources expended 2020	Transfer of funds 2020	
	£'000	£'000	£'000	£'000	£'000
Development of elearning suite	2.8	15.0	(97.3)	79.5	0.0
Development of online self-management course in Scotland	9.7	19.4	(16.9)	0.0	12.2
Re-development of DAS app	19.3	0.0	(8.0)	0.0	11.3
JIA publications	0.0	9.5	0.0	0.0	9.5
JIA family support day	1.0	0.0	0.0	0.0	1.0
Information video in Hindi	0.0	5.0	0.0	0.0	5.0
Blood Monitoring publication	0.0	10.0	(1.1)	0.0	8.9
Community pharmacy engagement	0.0	32.0	(23.1)	0.0	8.9
	<b>32.8</b>	<b>90.9</b>	<b>(146.4)</b>	<b>79.5</b>	<b>56.8</b>

	Balance at 1 January 2019	Movement in funds			Balance at 31 December 2019
		Incoming resources 2019	Resources expended 2019	Transfer of funds 2019	
	£'000	£'000	£'000	£'000	£'000
Development of elearning suite	0.0	50.0	(47.2)	0.0	2.8
Development of online self-management course in Scotland	0.0	9.7	0.0	0.0	9.7
Re-development of DAS app	0.0	24.1	(4.8)	0.0	19.3
JIA family support day	0.0	1.0	0.0	0.0	1.0
Production of Patient Survey	0.0	15.0	(15.0)	0.0	0.0
	<b>0.0</b>	<b>99.8</b>	<b>(67.0)</b>	<b>0.0</b>	<b>32.8</b>

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2020

**20 Analysis of net assets between funds - Group**

	Restricted £'000	Unrestricted £'000	Total £'000
<b>Fund balances at 31 December 2020 are represented by:</b>			
Tangible fixed assets	0.0	120.7	120.7
Investments	0.0	871.9	871.9
Current assets/(liabilities)	56.8	607.8	664.6
	<u>56.8</u>	<u>1,600.4</u>	<u>1,657.2</u>

**Fund balances at 31 December 2019 are represented by:**

	Restricted £'000	Unrestricted £'000	Total £'000
Tangible fixed assets	0.0	67.0	67.0
Investments	0.0	798.8	798.8
Current assets/(liabilities)	32.8	804.6	837.4
	<u>32.8</u>	<u>1,670.4</u>	<u>1,703.2</u>

**Analysis of net assets between funds - Charity**

	Restricted £'000	Unrestricted £'000	Total £'000
<b>Fund balances at 31 December 2020 are represented by:</b>			
Tangible fixed assets	0.0	120.7	120.7
Investments	0.0	871.9	871.9
Current assets/(liabilities)	56.8	606.2	663.0
	<u>56.8</u>	<u>1,598.8</u>	<u>1,655.6</u>

**Fund balances at 31 December 2019 are represented by:**

	Restricted £'000	Unrestricted £'000	Total £'000
Tangible fixed assets	0.0	67.0	67.0
Investments	0.0	798.8	798.8
Current assets/(liabilities)	32.8	798.3	831.1
	<u>32.8</u>	<u>1,664.1</u>	<u>1,696.9</u>

**21 Commitments under operating leases**

At the reporting end date the group and charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	2020 £'000	2019 £'000
Within one year	101.7	90.2
Between two and five years	116.2	194.9
Over five years	2.9	0.6
	<u>220.8</u>	<u>285.7</u>

**NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
NOTES TO THE ACCOUNTS  
FOR THE YEAR ENDED 31 DECEMBER 2020**

**22 Subsidiary company**

The charity owns the whole of the issued ordinary share capital of NRAS Community Services Ltd (company number: 8953247), a company registered in England. The subsidiary is used for non-primary purpose trading activities.

All activities have been consolidated on a line by line basis in the Statement of financial activities.

The total net profit is gifted to the charity.

A summary of the results of the subsidiary is shown below:

	<b>2020</b>	<b>2019</b>
	<b>£'000</b>	<b>£'000</b>
Turnover	6.1	22.3
Cost of sales		<u>0.0</u>
Gross profit	<u>6.1</u>	<u>22.3</u>
Administrative expenses	<u>(4.6)</u>	<u>(16.1)</u>
Net profit	<u>1.5</u>	<u>6.2</u>
Retained earnings brought forward in subsidiary	6.2	15.8
Gift aid to National Rheumatoid Arthritis Society	<u>(6.2)</u>	<u>(15.8)</u>
Retained earnings carried forward in subsidiary	<u>1.5</u>	<u>6.2</u>
The assets and liabilities were:		
The aggregate of the assets, liabilities and funds was:		
Assets	15.6	40.4
Liabilities	<u>(14.1)</u>	<u>(34.2)</u>
Total net assets	<u>1.5</u>	<u>6.2</u>
Called up share capital	0.0	0.0
Profit and loss reserve	<u>1.5</u>	<u>6.2</u>
	<u>1.5</u>	<u>6.2</u>

**23 Related party transactions**

There were no related party transactions in the year (2019: nil) requiring disclosure.

**24 Capital Commitments**

As at 31 December 2020 the Charity had capital commitments of £nil (2019: £28.8k relating to the development of a new website).

NATIONAL RHEUMATOID ARTHRITIS SOCIETY  
 NOTES TO THE ACCOUNTS  
 FOR THE YEAR ENDED 31 DECEMBER 2020

25 Cash generated from operations

	Group		Charity	
	2020	2019	2020	2019
	£'000	£'000	£'000	£'000
(Loss)/ Surplus for the year	(46.0)	616.2	(41.3)	625.8
Adjustments for:				
Investment income recognised in profit or loss	(23.2)	(29.2)	(23.2)	(29.2)
Fair value gains and losses on investments	0.1	(66.5)	0.1	(66.5)
Gift aid donation from subsidiary			(6.2)	(15.8)
Depreciation and impairment of tangible fixed assets	18.9	15.6	18.9	15.6
Movements in working capital:				
(Increase)/ decrease in debtors	504.6	(564.3)	529.5	(580.5)
Increase/ (decrease) in creditors	20.0	56.0	15.3	57.5
<b>Cash generated from operations</b>	<b>474.4</b>	<b>27.8</b>	<b>493.1</b>	<b>6.9</b>

26 Analysis of changes in net funds

	At start of year	Cash flows	At end of year
	£'000	£'000	£'000
Cash	396.5	351.8	748.3
<b>Total</b>	<b>396.5</b>	<b>351.8</b>	<b>748.3</b>